10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

OR

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ___________ to ___________

Commission file number: 000-54436

COSMOS HEALTH INC.

(Exact name of registrant as specified in its charter)

Nevada	27-0611758
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
141 West Jackson Blvd, Suite 4236 Chicago, Illinois	60604
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number: (312) 536-3102

N/A

(Former name, former address and former three months, if changed since last report)

Title of Each Class	Trading Symbol	Name of Each Exchange On Which Registered
Common Stock, $.001 par value	COSM	The Nasdaq Capital Market

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☐	Smaller reporting company	☒
(Do not check if a smaller reporting company)		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Applicable only to Corporate Issuers:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date: 10,620,670 as of May 16, 2023.

COSMOS HEALTH INC.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited).	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	34
Item 3.	Quantitative and Qualitative Disclosures about Market Risk.	42
Item 4.	Controls and Procedures.	42
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings.	44
Item 1A	Risk Factors	44
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	44
Item 3.	Defaults Upon Senior Securities.	44
Item 4.	Mine Safety Disclosures.	44
Item 5.	Other Information.	44
Item 6.	Exhibits.	45
SIGNATURES		46

2

COSMOS HEALTH INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
	March 31, 2023			December 31, 2022
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	12,037,647		$	20,749,683
Accounts receivable, net		22,561,797			22,761,990
Accounts receivable - related party		2,754,756			2,830,595
Marketable securities		16,433			14,881
Inventory		4,299,538			3,451,868
Loans receivable		388,463			377,038
Loans receivable - related party		505,983			427,920
Prepaid expenses and other current assets		2,936,054			1,967,527
Prepaid expenses and other current assets - related party		5,135,078			3,463,401
TOTAL CURRENT ASSETS		50,635,749			56,044,903
Property and equipment, net		1,821,837			1,817,025
Goodwill and intangible assets, net		694,484			706,914
Loans receivable - long term portion		3,754,587			3,792,034
Loans receivable - related party - long term		8,396,630			3,851,280
Operating lease right-of-use asset		1,115,526			821,069
Financing lease right-of-use asset		389,837			291,762
Other assets		1,207,538			713,634
TOTAL ASSETS	$	68,016,188		$	68,038,621
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	10,897,943		$	11,918,997
Accounts payable and accrued expenses - related party		787,251			205,360
Accrued interest		53,445			275,547
Lines of credit		4,710,314			5,758,737
Convertible notes payable, net of unamortized discount of $0 and $258,938, respectively		-			100,000
Derivative liability - convertible note		-			54,293
Notes payable		781,958			2,158,417
Notes payable - related party		11,089			10,912
Loans payable - related party		13,029			12,821
Taxes payable		457,686			126,855
Operating lease liability, current portion		195,812			167,393
Financing lease liability, current portion		123,267			97,097
Other current liabilities		520,622			862,440
TOTAL CURRENT LIABILITIES		18,552,416			21,748,869
Share settled debt obligation		-			1,554,590
Notes payable - long term portion		2,727,548			2,859,570
Operating lease liability, net of current portion		919,711			653,673
Financing lease liability, net of current portion		279,674			206,407
Other liabilities		1,156,642			1,358,803
TOTAL LIABILITIES		23,635,991			28,381,912
Commitments and Contingencies (see Note 14)		-			-
MEZZANINE EQUITY
Preferred stock, $0.001 par value; 100,000,000 shares authorized:
Series A preferred stock, stated value $1,000 per share, 6,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022; dividends of $372,414		372,414			372,414
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 300,000,000 shares authorized; 10,620,470 and 10,605,412 shares issued and 10,605,172 and 10,589,915 outstanding as of March 31, 2023 and December 31, 2022, respectively		10,621			10,606
Additional paid-in capital		112,302,825			112,205,952
Subscription receivable		(108	)		(4,750,108	)
Treasury stock, 15,497 shares as of March 31, 2023 and December 31, 2022, respectively		(816,707	)		(816,707	)
Accumulated deficit		(66,692,676	)		(66,232,813	)
Accumulated other comprehensive loss		(796,172	)		(1,132,635	)
TOTAL STOCKHOLDERS' EQUITY		44,007,783			39,284,295
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY	$	68,016,188		$	68,038,621
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

COSMOS HEALTH INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
	Three Months Ended March 31,
	2023			2022
REVENUE	$	12,349,777		$	13,071,800
COST OF GOODS SOLD		11,392,700			11,179,868
GROSS PROFIT		957,077			1,891,932
OPERATING EXPENSES
General and administrative expenses		2,089,014			868,639
Salaries and wages		949,451			521,471
Sales and marketing expenses		467,263			146,949
Depreciation and amortization expense		102,521			112,622
TOTAL OPERATING EXPENSES		3,608,249			1,649,681
GAIN (LOSS) FROM OPERATIONS		(2,651,172	)		242,251
OTHER INCOME (EXPENSE)
Other expense, net		5,743			(54,812	)
Interest expense		(134,373	)		(584,176	)
Interest income		183,416			64,827
Non-cash interest expense		-			(260,527	)
Gain on equity investments, net		1,293			1,678
Gain on extinguishment of debt		1,908,513			1,004,124
Change in fair value of derivative liability		3,384			15,001
Foreign currency transaction gain (loss), net		196,035			(159,352	)
TOTAL OTHER INCOME, NET		2,164,011			26,763
INCOME (LOSS) BEFORE INCOME TAXES		(487,161	)		269,014
INCOME TAX BENEFIT (EXPENSE)		27,298			(65,667	)
NET INCOME (LOSS)		(459,863	)		203,347
Deemed dividend on issuance of warrants		-			(5,788,493	)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS		(459,863	)		(5,585,146	)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustment, net		336,463			(405,229	)
TOTAL COMPREHENSIVE LOSS	$	(123,400	)	$	(5,990,375	)
BASIC NET LOSS PER SHARE	$	(0.04	)	$	(7.86	)
DILUTED NET LOSS PER SHARE	$	(0.04	)	$	(7.86	)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
Basic		10,615,075			710,221
Diluted		10,615,075			710,221
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

COSMOS HEALTH INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY AND MEZZANINE EQUITY (Unaudited)
																							Accumulated
	Preferred Stock				Common Stock				Additional						Treasury Stock								Other			Total
	No. of Shares		Value		No. of Shares		Value		Paid-in Capital			Subscription Receivable			No. of Shares		Value			Accumulated Deficit			Comprehensive Loss			Stockholders' Equity
Balance at January 1, 2022		-	$	-		701,780	$	702	$	39,692,595		$	-			15,497	$	(816,707	)	$	(34,345,506	)	$	(151,621	)	$	4,379,463
Foreign currency translation adjustment, net		-		-		-		-		-			-			-		-			-			(405,229	)		(405,229	)
Issuance of Series A preferred stock, net of issuance costs of $547,700		6,000		5,452,300		-		-		-			-			-		-			-			-			-
Conversion of notes payable into shares of common stock		-		-		9,520		10		973,410			-			-		-			-			-			973,420
Cashless exercise of warrants		-		-		33,179		33		(829	)		-			-		-			-			-			-
Net income		-		-		-		-		-			-			-		-			203,347			-			203,347
Balance at March 31, 2022		6,000	$	5,452,300		744,479		745		40,665,176			-			15,497	$	(816,707	)	$	(34,142,159	)	$	(556,850	)	$	5,151,001
																							Accumulated
	Preferred Stock				Common Stock				Additional						Treasury Stock								Other			Total
	No. of Shares		Value		No. of Shares		Value		Paid-in Capital			Subscription Receivable			No. of Shares		Value			Accumulated Deficit			Comprehensive Loss			Stockholders' Equity
Balance at January 1, 2023		-	$	372,414		10,605,412	$	10,606	$	112,205,952		$	(4,750,108	)		15,497	$	(816,707	)	$	(66,232,813	)	$	(1,132,635	)	$	39,284,295
Foreign currency translation adjustment, net		-		-		-		-		-			-			-		-			-			336,463			336,463
Proceeds from sale of common stock		-		-		-		-		-			4,750,000			-		-			-			-			4,750,000
Shares issued in lieu of cash		-		-		15,258		15		96,873			-			-		-			-			-			96,888
Net loss		-		-		-		-		-			-			-		-			(459,863	)		-			(459,863	)
Balance at March 31, 2023		-	$	372,414		10,620,670	$	10,621	$	112,302,825		$	(108	)		15,497	$	(816,707	)	$	(66,692,676	)	$	(796,172	)	$	44,007,783
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

COSMOS HEALTH INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
	Three Months Ended March 31,
	2023			2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss)	$	(459,863	)	$	203,347
Adjustments to Reconcile Net Income to Net Cash Used In Operating Activities:
Depreciation and amortization expense		71,811			93,042
Amortization of finance right-of-use assets		30,710			19,580
Lease expense		55,354			54,124
Amortization of debt discounts and accretion of debt		-			260,527
Bad debt expense		181,321			-
Shares issued in lieu of cash		96,888			-
Interest imputed on finance leases		6,219			3,507
Deferred income taxes		2,829			62,594
Gain on extinguishment of debt		(1,908,513	)		(1,004,124	)
Change in fair value of the derivative liability		(3,384	)		(15,001	)
Gain on net change in fair value of equity investments		(1,293	)		(1,678	)
Changes in assets and liabilities:
Accounts receivable		385,809			226,934
Accounts receivable - related party		131,531			(10,967	)
Inventory		(776,554	)		(934,400	)
Prepaid expenses and other current assets		(1,461,343	)		141,119
Prepaid expenses and other current assets - related party		(1,597,170	)		(1,183,403	)
Accounts payable and accrued expenses		(1,154,718	)		300,913
Accounts payable and accrued expenses - related party		581,176			(370,694	)
Accrued interest		(223,534	)		20,356
Taxes payable		324,243			(107,462	)
Operating lease liabilities		(55,538	)		(54,241	)
Other current liabilities		(348,828	)		(23,438	)
Other liabilities		(221,326	)		(17,911	)
NET CASH USED IN OPERATING ACTIVITIES		(6,344,173	)		(2,337,276	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from loan receivable		92,603			91,661
Issuance on loan receivable - related party		(4,553,030	)		-
Purchase of property and equipment		(26,028	)		(4,438	)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES		(4,486,455	)		87,223
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of convertible note payable		(100,000	)		-
Payment of note payable		(1,245,022	)		(2,263,471	)
Payment of related party loan		-			(22,432	)
Proceeds from related party loan		-			460,034
Payment of lines of credit		(5,452,321	)		(6,244,162	)
Proceeds from lines of credit		4,325,744			5,779,114
Proceeds from issuance of Series A Preferred Stock		-			5,452,300
Proceeds from the issuance of common stock		4,750,000			-
Payments of finance lease liability		(35,596	)		(22,622	)
Payments of financing fees		-			(224,320	)
NET CASH PROVIDED BY FINANCING ACTIVITIES		2,242,805			2,914,441
Effect of exchange rate changes on cash		(124,213	)		59,552
NET CHANGE IN CASH AND CASH EQUIVALENTS		(8,712,036	)		723,940
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		20,749,683			286,487
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	12,037,647		$	1,010,427
Supplemental Disclosure of Cash Flow Information
Cash paid during the year:
Interest	$	588,051		$	281,889
Income tax	$	-		$	-
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Conversion of notes payable to common stock	$	-		$	973,420
Deemed dividend on warrants upon conversion of convertible debt	$	-		$	5,788,493
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

NOTE 1 – BASIS OF PRESENTATION

The terms “COSM,” “we,” “the Company,” “Group” and “us” as used in this report refer to Cosmos Health, Inc. The accompanying unaudited condensed consolidated balance sheet as of March 31, 2023 and unaudited condensed consolidated statements of operations and comprehensive income for the three months ended March 31, 2023 have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management of COSM, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023, or any other period. These unaudited consolidated financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (“Form 10-K”). The accompanying condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited financial statements filed in our Form 10-K and is included for comparison purposes in the accompanying balance sheet.

NOTE 2 – ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN

Cosmos Health Inc. and its subsidiaries are an international healthcare group headquartered in Chicago, Illinois. The group is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation”. The Company is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the group is involved in the healthcare distribution sector through its subsidiaries in Greece and the UK, serving retail pharmacies and wholesale distributors. The Company is strategically focusing on the research and development (“R&D”) of novel patented nutraceuticals (Intellectual Property) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. The Company has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. The Company has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK.

The Company was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009, and on November 29, 2022, we changed our name to Cosmos Health Inc. Through its acquisition of Amplerissimo Ltd, on September 27, 2013, the Company changed its principal activities into trading of products, providing representation, and provision of consulting services to various sectors. On August 1, 2014, the Company formed SkyPharm S.A., a Greek Company (“SkyPharm”), a subsidiary that focuses on the trading, sourcing and export of nutraceutical and pharmaceutical products. In February 2017, the Company acquired Decahedron Ltd., a UK Company (“Decahedron”) which is a fully licensed second-generation wholesaler specializing in imports and exports of generics and OTC pharmaceutical products within the EEA and distributor of Sky Premium Life nutraceutical products in the UK. On December 19, 2018, the Company acquired Cosmofarm, a pharmaceutical wholesaler specializing in the distribution and export of pharmaceutical products through its extensive pharmacies network.

On March 17, 2023, the Company announced that it had entered into a definitive agreement to acquire ZipDoctor Inc., a telehealth company for a total sum of $150,000 in cash.  The Sale and Purchase Agreement (“SPA”) was signed on March 17, 2023, and the transaction closed on April 3, 2023 (see Note 17).

7

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Summary of Significant Accounting Policies

Basis of Financial Statement Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP.

Principles of Consolidation

Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated.

Transactions in and Translations of Foreign Currency

The functional currency for the Greek subsidiaries of the Company (Cosmofarm SA and SkyPharm SA) is EURO (€) and for the UK subsidiary (Decahedron Ltd) is GBP (£). As a result, the financial statements of the subsidiaries have been transferred from the local currency into US dollars using (i) year-end exchange rates for balance sheet accounts, and (ii) average exchange rates for the reporting period for all income statements accounts. Foreign currency translations gains and losses are reported as a separate component of the condensed consolidated statements of changes in stockholders’ equity and mezzanine equity.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The Effects of COVID-19

Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur, and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

The Effects of War in the Ukraine

On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. We do not conduct any commercial transactions with either Ukraine or Russia and the Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. Such political issues and conflicts could have a material adverse effect on our results of operations and financial condition if they escalate in areas in which we do business. In addition, changes in and adverse actions by governments in foreign markets in which we do business could have a material adverse effect on our results of operations and financial condition.

8

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of March 31, 2023 and December 31, 2022, there were $6,995,287 and $0 held in Treasury bills with a maturity of less than 3 months.

The Company maintains bank accounts in the United States denominated in U.S. Dollars, in Greece denominated in Euros, U.S. Dollars and Great Britain Pounds (British Pounds Sterling), and in Bulgaria denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling).

Account Receivable, net

Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables’ portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. As of March 31, 2023 and December 31, 2022, the Company’s allowance for doubtful accounts was $7,614,237 and $7,309,311, respectively.

Tax Receivable

The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of March 31, 2023 and December 31, 2022, the Company had a VAT net receivable balance of $243,424 and a net payable balance of $79,373 respectively, recorded in the condensed consolidated balance sheet as prepaid expenses and other current assets and accounts payable and accrued expenses, respectively.

Inventory

Inventory is stated at the lower-of-cost or net realizable value using the weighted average FIFO method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment.

The Company writes down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met.

Property and Equipment, net

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows:

	Estimated Useful Life
Leasehold improvements and technical works	Lesser of lease term or 40 years
Vehicles	6 years
Machinery	20 years
Furniture, fixtures and equipment	5–10 years
Computers and software	3-5 years

9

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Depreciation expense was $65,629 and $84,884 for the three months ended March 31, 2023 and 2022, respectively.

Goodwill and Intangibles, net

The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. First, under step 0, we determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount. Following, if step 0 fails, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit.

On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill.

Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for its pharmaceuticals and nutraceuticals products license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of March 31, 2023, no revision to the remaining amortization period of the intangible assets was made.

10

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Amortization expense was $21,058 and $8,158 for the three months ended March 31, 2023 and 2022, respectively.

Impairment of Long-Lived Assets

In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.

Equity Method Investment

For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company will record its share in the earnings of the investee and will include it within the condensed consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value. See Note 3, for additional detail.

Investments in Equity Securities

Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for use in current operations are reported as a component of current assets in the accompanying condensed consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying condensed consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment.

As of March 31, 2023, investments consisted of (i) 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp and (ii) 16,666 shares which traded at a closing price of $0.49 per share or value of $8,099 of National Bank of Greece. Additionally, the Company has $8,333 in equity securities of Pancreta Bank, which are revalued annually.  

Fair Value Measurement

The Company applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

11

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

The following tables presents assets that are measured and recognized at fair value as of March 31, 2023 and December 31, 2022, on a recurring basis:

	March 31, 2023						Total Carrying
	Level 1		Level 2		Level 3		Value
Marketable securities – Pancretan Bank	$	8,334		-		-	$	8,334
Marketable securities – National Bank of Greece		8,099		-		-		8,099
	$	16,433					$	16,433

	December 31, 2022						Total Carrying
	Level 1		Level 2		Level 3		Value
Marketable securities – Pancretan Bank	$	8,200		-		-	$	8,200
Marketable securities – National Bank of Greece		6,681		-		-		6,681
	$	14,881					$	14,881

In addition, ASC 825-10-25, Fair Value Option, (“ASC 825-10-25”), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.

Derivative Instruments

Derivative financial instruments are recorded in the accompanying condensed consolidated balance sheets at fair value in accordance with ASC 815. When the Company enters into a financial instrument such as a debt or equity agreement (the “host contract”), the Company assesses whether the economic characteristics of any embedded features are clearly and closely related to the primary economic characteristics of the remainder of the host contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the host contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument, then the embedded feature is bifurcated from the host contract and accounted for as a derivative instrument. The estimated fair value of the derivative feature is recorded in the accompanying condensed consolidated balance sheets separately from the carrying value of the host contract. Subsequent changes in the estimated fair value of derivatives are recorded as a gain or loss in the Company’s condensed consolidated statements of operations and comprehensive loss.

Customer Advances

The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company’s products. The Company records these receipts as customer advances until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer advances balance and credit the Company’s revenues.

Revenue Recognition

In accordance with ASC 606, Revenue from Contracts with Customers, the Company uses a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, including the constraint on variable consideration, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon transfer of the product to the customer.

12

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Commencing from January 1, 2023, and pursuant to the agreement with Medihelm, the exclusive distributor of the Company’s own proprietary line of nutraceuticals, the Company considers the transaction price to be variable and records an estimate of the transaction price, subject to the constraint for variable consideration. The Company is basing the change in transaction price with the exclusive distributor through assessment of significant overdue receivables from the exclusive distributor, which the Company reassessed during the 3-month period ended March 31, 2023. Essentially, the Company applies the “expected value” model under ASC 606-10-32-5 and has applied specific constraints to revenue due from the customer at the end of each reporting period. Following the application of the “expected value” model the Company deferred an amount of $112,515 and recorded it against the sales to Medihelm for the three-month period ended March 31, 2023. The Company does not consider that sales to any other customer include a variable component as of March 31, 2023.

Stock-based Compensation

The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (“ASC 718”) and Staff Accounting Bulletin No. 107 (“SAB 107”) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.

The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, “Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.”

Foreign Currency Translation and Transactions

Assets and liabilities of all foreign operations are translated at period-end rates of exchange, and amounts included in the accompanying condensed statements of operations and comprehensive income (loss) are translated at the average rates of exchange for the period. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ equity (deficit) until the entity is sold or substantially liquidated.

Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss).

Income Taxes

The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 19% in the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership.

We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets.

13

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Retirement and Termination Benefits

Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee’s work experience and renumeration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability.

Basic and Diluted Net Loss per Common Share

Basic income per share is calculated by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding.

The following table summarizes potential common shares that were excluded as their effect is anti-dilutive:

	March 31, 2023		March 31, 2022
Warrants		4,194,236		117,976
Options		-		1,480
Convertible Notes		-		29,602
Total		4,194,236		149,058

Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented.

14

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed consolidated financial statements. 

NOTE 3 – EQUITY METHOD INVESTMENTS

Distribution and Equity Agreement

On March 19, 2018, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon Global Inc. (“Marathon”), a company incorporated in the Province of Ontario, Canada. Marathon was formed to be a global supplier of cannabis, cannabidiol (CBD) and/or any cannabis extract products, extracts, ancillaries and derivatives (collectively, the “Products”). The Company was appointed the exclusive distributor of the Products initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. The Company has no present intention to distribute any Products under this Agreement in the United States or otherwise participate in cannabis operations in the United States. The Company intended to await further clarification from the U.S. Government on cannabis regulation prior to determining whether to enter the domestic market.

The Distribution and Equity Acquisition Agreement was to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five (5) years of the agreement. On March 20, 2023, the Company sent a termination notice to Marathon, which became effective on April 19, 2023 as a result of Marathon’s failure to satisfy these conditions.  The transaction closed on May 22, 2018 after the due diligence period, following which the Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it failed to meet certain performance milestones. The Company was entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. The Company was also given the right to nominate one director to the Marathon board of directors.

The Company had accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). On March 20, 2023, the Company’s legal counsel provided notice to Marathon Global Inc, that the Company terminated the Equity agreement dated on March 19, 2018, pursuant to Section 3.2. Accordingly, the Company recorded a gain on extinguishment of debt of $1,554,590 due to the write-off of the share settled debt obligation, for the period ended March 31, 2023.

Since Marathon was a newly formed entity with no assets and no activity, the Company attributed no value to the 5 million shares in Marathon which was received as consideration for the distribution services. As described in Note 3, the Company exchanged the Marathon shares in May and July 2018.

CosmoFarmacy LP

In September 2019, the Company entered into an agreement with an unaffiliated third party to incorporate CosmoFarmacy L.P. for the purpose of providing strategic management consulting services and the retail trade of pharmaceutical products, and OTC to pharmacies. CosmoFarmacy was incorporated with a 30-year term through May 31, 2049. The unaffiliated third party is the general partner (the “GP”) of the limited partnership and is responsible for management and decision-making associated with CosmoFarmacy. The initial share capital was set to EUR 150,000 ($163,080) which was later increased to EUR 500,000 ($543,600). The GP contributed the pharmacy license (the “License”) valued at EUR 350,000 (30-year term) to operate the business of CosmoFarmacy in exchange for a 70% equity ownership. The Company is a limited partner and contributed cash of EUR 150,000 ($163,080) for the remaining 30% equity ownership. CosmoFarmacy is not publicly traded and the Company’s investment has been recorded using the equity method of accounting. The value of the investment as of March 31, 2023 and December 31, 2022, was $163,080 and $160,470, respectively, and is included in “Other assets” on the Company’s condensed consolidated balance sheets. 

15

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

NOTE 4 – PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	March 31, 2023			December 31, 2022
Leasehold improvements	$	512,843		$	502,882
Vehicles		109,732			107,976
Furniture, fixtures and equipment		1,997,337			1,945,207
Computers and software		146,041			138,783
		2,765,953			2,694,848
Less: Accumulated depreciation and amortization		(944,116	)		(877,823	)
Total	$	1,821,837		$	1,817,025

NOTE 5 – GOODWILL AND INTANGIBLE ASSETS

Intangible assets consist of the following at:

	March 31, 2023			December 31, 2022
License	$	652,853		$	643,204
Trade name / mark		36,997			36,997
Customer base		176,793			176,793
		866,642			856,994
Less: Accumulated amortization		(221,856	)		(199,777	)
Subtotal		644,787			657,217
Goodwill		49,697			49,697
Total	$	694,484		$	706,914

At March 31, 2023, the estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal years is as follows:

Year	Amount
2023	$	71,056
2024		79,719
2025		74,868
2026		44,361
2027		44,361
Thereafter		330,422
Total amortization	$	644,787

NOTE 6 – LOAN RECEIVABLE

On October 30, 2021, the Company entered into an agreement for a ten-year loan with Medihelm SA to memorialize €4,284,521 ($4,849,221) in prepayments the Company had made. The prepayments to Medihelm SA had been made in accordance with the parallel export business, through which Medihelm supplied and would supply SkyPharm SA with branded pharmaceuticals. This business is no longer in place for the Company and thus the Company entered into this agreement with Medihelm SA in order for the outstanding amount to be settled. Interest is calculated at a rate of 5.5% per annum on a 360-day basis. Under the terms of the agreement, the Company is to receive 120 equal payments over the term of the loan. As of December 31, 2022, the Company had a short-term receivable balance of $377,038 and a long-term receivable balance of $3,792,034 under this loan. During the three months ended March 31, 2023, the Company received €86,305 ($93,831) in principal payments such that as of March 31, 2023, the Company had a short-term receivable balance of $388,463 and a long-term receivable balance of $3,754,587 under this loan. The Company also received €45,212 ($49,154) in interest payments during the three months ended March 31, 2023.

16

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

NOTE 7 – INCOME TAXES

The Company is incorporated in the United States of America and is subject to United States federal taxation. No provisions for income taxes have been made as the Company had no U.S. taxable income for the three months ended March 31, 2023 and 2022.

The Company’s Greece subsidiaries are governed by the income tax laws of Greece. The corporate tax rate in Greece is 22% on income reported in the statutory financial statements after appropriate tax adjustments.

The Company’s United Kingdom subsidiaries are governed by the income tax laws of the United Kingdom. The corporate tax rate in the United Kingdom is 19% on income reported in the statutory financial statements after appropriate tax adjustments.

As of March 31, 2023 and 2022, the Company’s effective tax rate differs from the U.S. federal statutory tax rate primarily due to a valuation allowance recorded against net deferred tax assets in in the United States and the United Kingdom.

We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred ax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. As of March 31, 2023 and December 31, 2022, the Company has maintained a valuation allowance against all net deferred tax assets in the United States, Greece, and the UK.

For the three months ended March 31, 2023, and 2022, the Company has recorded tax benefit (expense) in any jurisdiction where it is subject to income tax, in the amount of ($27,298) and $65,667, respectively, on the condensed consolidated statement of operation and comprehensive loss.

NOTE 8 – CAPITAL STRUCTURE

Preferred Stock

The Company is authorized to issue 100 million shares of preferred stock, of which 6,000,000 are designated as Series A convertible preferred stock. The preferred stock has a liquidation preference over the common stock and is non-voting. As of March 31, 2023 and December 31, 2022, all Series A convertible preferred stock had been converted and no preferred shares were issued and outstanding.

Major Rights & Preferences of Series A Preferred Stock

On and effective October 4, 2021, the Company amended and restated its articles of incorporation (the “Amended and Restated Articles”) and filed a certificate of designation (the “COD”) for its Series A Preferred Stock (the “Series A Preferred Stock”) with the State of Nevada. The Amended and Restated Articles allow the Company’s Board of Directors the authority to authorize the issuance of preferred stock from time to time in one or more classes or series by resolution. On February 23, 2022, the Company filed Correction No. 1 to the COD. On July 28, 2022, the Company filed an Amendment to the COD with the State of Nevada to allow a holder to waive application of the Beneficial Ownership Limitation with respect to the conversion of Series A Preferred Stock.

17

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

The Series A Preferred Stock was initially convertible into the Company’s common stock as determined by dividing the number of shares of Series A Preferred Stock to be converted by the lower of (i) $75.00 or (ii) 80% of the average volume weighted average price for the Company’s common stock for the five (5) trading days immediately following the effectiveness of the registration statement concerning the shares (the “Conversion Price”). On June 14, 2022, the Conversion Price was reset to $15.54 per share.

Each holder was entitled to receive dividends in shares of Series A Preferred Stock or cash determined based on the stated value of each Series A Preferred Stock at the dividend rate of 8.0% per year. As of March 31, 2023 and December 31, 2022, the cumulative accrued dividend has been recorded as mezzanine equity in the amount of $372,414. The Company has not issued shares of Series A Preferred Stock or cash for the accrued dividends as of March 31, 2023.

On February 28, 2022, the Company entered into a securities purchase agreement, or the Purchase Agreement, with certain investors and an insider for a private placement of the Company’s securities (the “Private Placement”).

The Private Placement consisted of the sale of 6,000 shares of the Company’s Series A Convertible Preferred Stock, or the Series A Shares, at a price of $1,000 per share, and 80,000 warrants to purchase shares of common stock, or the Warrants, for aggregate gross proceeds of approximately $6 million. The Warrants were initially exercisable to purchase shares of common stock at $82.50 per share, or 110% of the Series A Shares initial conversion price and will expire five and one-half years following the initial exercise date of the Warrants. The Company determined that the 80,000 warrants were additional value being distributed to the preferred stockholders and presented the warrants’ fair value of $5,788,493 as a deemed dividend on issuance of warrants in the condensed consolidated statements of operations and comprehensive loss. The warrants were valued using the Black-Scholes option pricing model with the following terms: a) exercise price of $82.50, b) common stock fair value of $85.50, c) volatility of 118%, d) discount rate of 1.71%, e) term of 5.50 years and f) dividend rate of 0%.

The closing of the Private Placement occurred on February 28, 2022. As a condition to the closing of the sale, the Company’s common stock received conditional approval for listing and trading on the Nasdaq Capital Market and commenced trading on February 28, 2022, under the trading symbol, COSM. Concurrent with the issuance of the Series A Shares, the Company executed a registration rights agreement (the “Registration Rights Agreement”) to register the resale of the shares of common stock issuable upon conversion of the Series A Shares and the shares of common stock issuable upon exercise of the warrants issued in connection with the Series A Shares. The Company was required to file its initial registration statement within 45 days following February 28, 2022. The Effectiveness Date was required to be 60 days after February 28, 2022, or 75 days following the SEC’s full review, and any additional registration statements that may be required are to be filed within 20 days following the date required by the SEC. The Company failed to timely file its initial registration statement and thus paid each holder 2% of the subscription amount in cash.

Treasury stock

As of March 31, 2023 and December 31, 2022, the Company held 15,497 shares at a cost of $816,707. Shares of our common stock that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. No repurchases took place within the 3-month period ended March 31, 2023 and 2022.

On January 24, 2023 the Company announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $3 million of its common stock. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. No repurchases took place within the 3-month period ended March 31, 2023.

18

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Mezzanine Equity

The Series A Shares were recorded at its initial net carrying value in the amount of $5,452,300. The Series A Shares were recorded as mezzanine equity in accordance with ASC 480 as the Company was potentially obligated to issue a variable number of shares at a fixed price known at inception and there was no maximum number of shares that could potentially be issued upon conversion. In this instance, cash settlement would have been presumed. Immediately upon effectiveness of the registration statement registering for resale of all the common stock issuable under the Series A Shares, all outstanding Series A Shares were automatically converted into common stock.

As of December 31, 2022, 6,000 of the Series A Shares had been converted into 386,588 shares of common stock in accordance with the terms of the agreements and thus an amount of $5,452,300 was reclassified from mezzanine equity to common stock and additional paid-in capital, in the aggregate.  

Common Stock

The Company is authorized to issue 300 million shares of common stock. As of March 31, 2023 and December 31, 2022, the Company had 10,620,470 and 10,605,412 shares of our common stock issued, respectively, and 10,605,172 and 10,589,915 shares outstanding, respectively.

Reverse split

On December 15, 2022 the Company announced a reverse stock split with a ratio of 1-for-25 (one-for-twenty five) effective at the opening of the business day on Friday, December 16, 2022. The reverse stock split was authorized at the Company’s Annual General Meeting (“AGM”) on December 2, 2022 and was approved by the Company’s Board of Directors on December 15, 2022.

Issuance of common stock

During the 3-month period ended March 31, 2023 the Company issued 15,258 to a consultant for services rendered. The shares were valued and expensed on the date of issuance and are separately presented in the condensed consolidated statement of changes in stockholders’ equity and mezzanine as “Shares issued in lieu of cash”.

Debt Conversions

During the period ended March 31, 2022, the Company issued 9,520 shares of common stock upon the conversion of $1,190,000 of notes payable. The Company recorded $973,420 as a capital contribution and an increase in equity related to the conversion of the $1,190,000 reduced by $216,580 recorded as a gain upon extinguishment of debt upon modification. The $216,580 gain upon extinguishment was determined using the fair value of the Company of $102.25 per share at the extinguishment commitment date.

Exercise of Warrants

During the three months ended March 31, 2022, the Company issued 33,179 shares of common stock upon the cashless exercise of 109,952 warrant shares.

No options warrants or other potentially dilutive securities have been issued during the three months ended March 31, 2023.

19

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

NOTE 9 – RELATED PARTY TRANSACTIONS

Doc Pharma S.A.

Prepaid expenses and other current assets – related party

As of March 31, 2023, and December 31, 2022, the Company had a prepaid balance of $4,940,863 and $3,320,345 to Doc Pharma S.A. related to purchases of inventory.

Accounts payable and accrued expenses - related party

As of March 31, 2023, and December 31, 2022, the Company had an accounts payable balance of $8,882 and $201,991.

Accounts receivable - related party

Additionally, the Company had a receivable balance of $1,886,890 and $2,070,570 from Doc Pharma S.A as of March 31, 2023, and December 31, 2022, respectively.

Sales and Purchases

During the three months ended March 31, 2023 and 2022, the Company purchased a total of $450,911 and $687,382 of products from Doc Pharma S.A., respectively. During the three months ended March 31, 2023 and 2022 the Company had $627 and $383,688 revenue from Doc Pharma S.A., respectively.

Other Agreements

On October 10, 2020, the Company entered into a contract manufacturer outsourcing (“CMO”) agreement with Doc Pharma whereby Doc Pharma is responsible for the development and manufacturing of pharmaceutical products and nutritional supplements according to the Company’s specifications based on strict pharmaceutical standards and good manufacturing practice (“GMP”) protocols as the National Organization for Medicines requires. The Company has the exclusive ownership rights for trading and distribution of its own branded nutritional supplements named “Sky Premium Life^®”. The duration of the agreement is for 5 years however either party may terminate the agreement at any time giving six-months advance notice. Doc Pharma is exclusively responsible for supplying the raw materials and packaging required to manufacture the final product. However, they are not responsible for potential delays that may arise, concerning their import. Doc Pharma is obliged to store the raw and packaging materials. The delivery of raw and packaging materials should be purchased at least 30 and 25 days, respectively, before the delivery date of the final product. The Manufacturer solely delivers the finished product to the Company. There is a minimum order quantity (“MoQ”) of 1,000 pieces per product code. Both parties have agreed that the Company will deposit 60% of the total cost upon agreement and assignment and 40% of the total cost including VAT charge upon the delivery date. The prices are indicative and are subject to amendments if the cost of the raw material or the production cost change.

For the three months ended March 31, 2023 and 2022, the Company has purchased €347,461 ($401,786) and €461,453 ($517,566), respectively, in inventory related to this agreement.

On May 17, 2021, Doc Pharma and the Company entered into a Research and Development (“R&D”) agreement whereby Doc Pharma will be responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life^®. These products will be sold in Greece and abroad. The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought in total as of December 31, 2022, 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost. No additional licenses were purchased during the 3-month period ended March 31, 2023. The agreement will be terminated on December 31, 2025.  

Loans receivable - related party

The balance of prepaid expenses due Doc Pharma SA as of December 31, 2022, had increased to €7,103,706 ($7,599,545), which was mainly attributable to the prepayments SkyPharm SA made in accordance with the CMO agreement and the extensive orders and sales of the SPL products the Company expects to achieve within 2023, mainly through its Amazon channels in the UK, Singapore, Canada and other countries. However, as the benefit from a significant portion of the prepaid balance would not have been realized within a 12-month period, the Company opted to secure a portion of the outstanding prepaid balance through a loan agreement. SkyPharm S.A. (the “Lender”) entered into a loan agreement with Doc Pharma S.A. (the “Borrower”) for €4,000,000 ($4,279,200), all of which was financed through the outstanding prepaid balance. The duration of the loan will be for a 10-year period up to December 1, 2032 (the “Maturity Date”). The loan will bear a fixed interest rate of 5.5% payable on a monthly basis and will be repayable in 120 equal instalments of €33,333.33 ($35,660). The loan may be prepaid anytime during its in full or partially based on the Company’s product requirements and other factors, without Doc Pharma incurring any prepayment penalty. As of March 31, 2023 and December 31, 2022, the loan had a current portion of €410,400 ($446,187) and €400,000 ($427,720) and a non-current portion of €3,589,600 ($3,902,613), and €3,600,000 ($3,851,280) respectively, which is classified as loans receivable – related party as of March 31, 2023. For the 3-month period ended March 31, 2023 and the Company has recorded interest income of €55,000 ($59,796) relating to this loan which had not been paid as of March 31, 2023.

20

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Doc Pharma S.A is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma S.A. in the past.

Cana Holdings Laboratories Holding Limited 

Loans receivable - related party - long term

On February 28, 2023 (Issue Date) the Company signed a Secured Promissory Note with Cana Laboratories Holding (Cyprus) Limited (the “Holder”), whereby the Holder borrowed the sum of €4,100,000 ($4,457,520) from the Company. Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (4.77% as of March 31, 2023). The maturity date (“Maturity Date”) of this Note shall be five (5) years from the Issue Date. The Principal Amount, as well as all accrued interest shall be due and payable on the Maturity Date. During the three months ended March 31, 2023, the Company recorded interest income of €34,015 ($36,497).

Cana is considered a related party, since the Company has signed a binding letter of intent and an SPA for the acquisition of Cana. The acquisition is expected to be completed within 2023.

Panagiotis Kozaris

Prepaid expenses and other current assets - related party

From time-to-time the Company purchases back shares that Panagiotis Kozaris owns and records them as treasury shares. The Company pays Panagiotis Kozaris in advance for the shares owned and obtains the shares upon execution of a cumulative stock-purchase agreement (“SPA”). During the 3-month period ended March 31, 2023 and March 31, 2022, the Company paid Panagiotis Kozaris an additional sum of $51,159 and $0 respectively for shares owned, however, no SPA for these funds has been executed as of March 31, 2023. The Company intends to execute a cumulative SPA for these amounts during 2023. The total balances owed of $194,215 and $143,056 are included in prepaid expenses and other current assets – related party, on the accompanying condensed consolidated balance sheets as of March 31, 2023 and December 31, 2022, respectively.

Panagiotis Kozaris is considered a related party due to the fact that he is a former General operational manager and current employee of Cosmofarm SA.

Maria Kozari

Accounts receivable - related party

During 2021, the Company, through its subsidiary, Cosmofarm SA, commenced a partnership with a pharmacy called “Pharmacy & More”, owned by Maria Kozari. The transactions with the respective pharmacy were in Cosmofarm’s normal course of business, however, a more flexible credit policy was allowed as the pharmacy was new and needed to be established in the market. During the 3-month periods ended March 31, 2023 and 2022 the Company’s net sales to Pharmacy & More amounted to $118,987 and $113,621 respectively. As of March 31, 2023 and December 31, 2022 the Company’s outstanding receivable balance due from the pharmacy amounted to $867,866 (€798,258) and $760,025 (€710,436), respectively, and are included in accounts receivable - related party, on the accompanying condensed consolidated balance sheets.

Maria Kozari is considered a related party to the Company due to the fact that she is the daughter of Panagiotis Kozaris, a former Operational General Manager and current employee of Cosmofarm SA.

Notes Payable – Related Party 

21

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

A summary of the Company’s related party notes payable activity as of and for the three and twelve month periods ended March 31, 2023 and December 31, 2022 is presented below:

	March 31, 2023		December 31, 2022
Beginning balance	$	10,912	$	464,264
Payments		-		(472,920	)
Foreign currency translation		177		(19,568	)
Ending balance	$	11,089	$	10,912

Grigorios Siokas

On December 20, 2018, the €1,500,000 ($1,718,400) note payable, originally borrowed pursuant to a Loan Agreement with a third-party lender, dated March 16, 2018, was transferred to Grigorios Siokas. The note bore an interest rate of 4.7% per annum, originally matured on March 18, 2019 pursuant to the original agreement which was extended to December 31, 2021, and again to December 31, 2023. During the year ended December 31, 2022, the Note was paid in full and as of March 31, 2023 the Company had an outstanding balance of $0. As of March 31, 2023 and December 31, 2022 the Company had accrued interest of €22,891 ($24,887) and €192,891 ($206,355) outstanding related to this loan, classified under accrued interest, in the Company’s condensed consolidated balance sheets.

Grigorios Siokas is the Company’s CEO and principal shareholder.

Dimitrios Goulielmos

On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. As of March 31, 2023 and December 31, 2022, the Company had a principal balance of €10,200 ($11,089) and €10,200 ($10,912), respectively.

Dimitrios Goulielmos is a current director and former CEO of the Company.

The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2023, the Company recorded a loss of $177.

Loans Payable – Related Party

A summary of the Company’s related party loans payable during the three months ended March 31, 2023, and the year ended December 31, 2022 is presented below:

	March 31, 2023		December 31, 2022
Beginning balance	$	12,821	$	1,293,472
Proceeds		-		3,635,756
Payments		-		(4,851,678	)
Foreign currency translation		208		(64,729	)
Ending balance	$	13,029	$	12,821

Grigorios Siokas

From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of December 31, 2022, the Company had an outstanding principal balance under these loans of $12,821 in loans payable to Grigorios Siokas. As of March 31, 2023 the Company had an outstanding principal balance of $13,029.

22

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2023 the Company recorded a loss of $208.

Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.

NOTE 10 – LINES OF CREDIT

A summary of the Company’s lines of credit as of March 31, 2023 and December 31, 2022 is presented below:

	March 31, 2023		December 31, 2022
National	$	2,383,647	$	3,103,605
Alpha		803,142		991,492
Pancreta		1,093,420		1,232,128
EGF		430,105		431,512
Ending balance	$	4,710,314	$	5,758,737

The line of credit with National Bank of Greece is renewed annually with current interest rates of 6.00%, 4.35% (“COSME 2” facility), and 4.35% plus the 6-month Euribor plus any contributions currently in force by law on certain lines of credit (“COSME 1” facility).

The maximum borrowing allowed for the 6% line of credit was $3,234,420 and $3,182,655 as of March 31, 2023 and December 31, 2022, respectively. The outstanding balance of the facility was $1,471,908 and $2,118,952, as of March 31, 2023 and December 31, 2022, respectively.

The maximum borrowing allowed for the COSME 1 and COSME 2 lines of credit, was $1,087,200 and $1,069,800 as of March 31, 2023 and December 31, 2022, respectively. The outstanding balance of the facilities was $911,739 and $984,653 as of March 31, 2023 and December 31, 2022, respectively. 

The line of credit with Alpha Bank of Greece is renewed annually with a current interest rate of 6.00%. The maximum borrowing allowed was $1,087,200 and $1,069,800 as of March 31, 2023 and December 31, 2022, respectively. The outstanding balance of the facility was $803,142 and $991,429, as of March 31, 2023 and December 31, 2022, respectively.

The Company entered into a line of credit with Pancreta Bank on February 23, 2021. The line of credit is renewed annually with a current interest rate of 6.10%. The maximum borrowing allowed as of March 31, 2023 and December 31, 2022 was $1,511,208 and $1,487,022, respectively. The outstanding balance of the facility as of March 31, 2023 and December 31, 2022 was $1,093,420 and $1,232,128, respectively.

The Company entered into a line of credit with EGF on June 6, 2022. The line of credit is renewed annually with a current interest rate of 4.49%. The maximum borrowing allowed as of March 31, 2023 and December 31, 2022 was $434,880 and $427,920, respectively. The outstanding balance of the facility as of March 31, 2023 and December 31, 2022 was $430,105 and $431,512, respectively.

Under the agreements, the Company is required to maintain certain financial ratios and covenants. As of March 31, 2023 and December 31, 2022, the Company was in compliance with these ratios and covenants.

The above lines of credit are guaranteed and backed by customer receivable checks. They are a type of factoring, where the postponed customer checks are assigned by the Company to the bank, in order to be financed at a pre-agreed rate.

23

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Interest expense for the three-months ended March 31, 2023 and 2022, was $19,435 and $17,175, respectively.

NOTE 11 – CONVERTIBLE DEBT

A summary of the Company’s convertible debt activity as of and for the 3 and 12 months ended March 31, 2023 and December 31, 2022 is presented below:

	March 31, 2023			December 31, 2022
Beginning balance convertible notes	$	100,000		$	640,000
Payments		(100,000	)		(525,000	)
Conversion to common stock		-			(15,000	)
Convertible notes payable	$	-		$	100,000

December 21, 2020 Securities Purchase Agreement

On December 21, 2020 the Company entered into a convertible promissory note with Platinum Point Capital, LLC (the “Holder”, “Lender” or “Platinum”) pursuant to a Securities Purchase Agreement (the “SPA”).

The Company issued the $540,000 Note in exchange for $500,000 in cash and included a $40,000 Original Issue Discount (“OID”) and paid $3,000 in financing costs. The principal amount together with interest at the rate of eight percent (8.0%) per annum, compounded annually (the “Interest Rate”), will be paid to the Lenders on or before the Maturity Date (December 31, 2021 or as defined below). Accrued interest shall be calculated on the basis of a 360-day year for the actual number of days elapsed. In the event that on or before the Maturity Date, the Note either (i) had not been converted or have not been otherwise satisfied in full or (ii) an Event of Default (as defined in the SPA) occurs, then the applicable rate of interest on the outstanding amount of the Note since inception shall be the Interest Rate plus eighteen percent (18.0%), the Default Interest. Unless previously converted, the principal and accrued interest on the Note is due and payable in cash (USD) upon the earlier of (i) December 31, 2021, (ii) a Change of Control (as defined in the SPA) or (iii), an Event of Default (collectively, the “Maturity Date”).

On May 1, 2022 the Company issued 1,574 shares of common stock to convert the outstanding principal and accrued interest balance of $26,515 to equity. Following the conversion, the outstanding balance of the above Note is $0. Upon conversion, the 1,574 shares were issued at a fair value of $38,144 which was recorded as equity. Accordingly, upon conversion, the Company reduced its derivative liability by $11,629.

The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a derivative liability which is accounted for separately. The Company determined a derivative liability exists and determined that the embedded derivative was valued at $456,570 which was recorded as a debt discount, and together with the original issue discount and transaction expenses of $43,000, in the aggregate of $499,570, is being amortized over the life of the loan. As of December 31, 2022 the full amount of the debt discount has been amortized. Therefore, as of March 31, 2023 and December 31, 2022, the fair value of the derivative liability was $0. For the three months ended March 31, 2023 and 2022, the Company recorded a loss on the change in fair value of the derivative of $0 and a gain of $1,873, respectively.

January 7, 2021 Subscription Agreement

On January 7, 2021 (the “Issue Date”), the Company entered into a subscription agreement with an unaffiliated third party, whereby the Company issued for a purchase price of $100,000 in principal amount, a convertible promissory note. The note bore an interest rate of 8% per annum and originally matured on the earlier of (i) consummation of the Company listing its common shares on the NEO Stock Exchange or (ii) October 31, 2021.

24

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

However, the listing to NEO Stock Exchange did not occur. As of December 31, 2022, the Company had a principal balance of $100,000 and had accrued $13,740 in interest expense. During the three months ended March 31, 2023, the Company paid the balance in full.

The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a derivative liability which is accounted for separately. The Company measured the embedded derivative valued at $62,619 which was recorded as a debt discount and additional paid-in capital and was being amortized over the life of the loan. As of December 31, 2022, the debt discount had been fully amortized. As of March 31, 2023 and December 31, 2022, the fair value of the derivative liability was $0 and $54,293, respectively. For the three months ended March 31, 2023 and 2022, the Company recorded a loss of $3,384 and a gain of $13,128, respectively, from the change in fair value of derivative liability as other income in the condensed consolidated statements of operations and comprehensive loss.

The Company considered both the note payable and conversion feature separately and upon settlement. The Company re-valued the conversion feature to fair value and applied extinguishment accounting as the debt has now been settled. Because the conversion feature is extinguished upon settling the note, the value of the conversion feature goes though debt extinguishment debt and the Company recorded a gain on settlement of debt. During the three months ended March 31, 2023, the Company recorded a gain on extinguishment of debt of $50,909.

Convertible Promissory Note and Securities Purchase Agreement

On September 17, 2021 (the “Issue Date”), the Company entered into a convertible promissory note and securities purchase agreement with an unaffiliated third party.

The Company issued the convertible promissory note for a purchase price of $525,000 in principal amount for cash proceeds of $500,000. The note was issued with an original issue discount (“OID”) of $25,000, bears an interest rate of 10% per annum and matures on the earlier of (i) the consummation of the Company listing its common shares on the Nasdaq Stock Market or (ii) September 17, 2022.

Upon the consummation of our Nasdaq listing in 2022, the total principal and accrued interest outstanding on the note would convert into shares of the Company’s common stock at a 30% discount to the prices of the common shares sold in the financing to be conducted in conjunction with our Nasdaq listing, subject to a conversion floor of $75.00. However, the Company, upon agreement with the third party, did not convert the note and fully repaid it in cash on October 21, 2022.

As of December 31, 2022, the Company repaid the remaining outstanding balance of the note and thus its outstanding balance as of the end of the period was $0. For the three months ended March 31, 2023 and 2022, the Company recorded amortization of debt discount in the amount of $0 and $127,916, respectively, which is included in non-cash interest expense on the accompanying condensed statements of operations and comprehensive loss.

Derivative Liabilities

The table below provides a summary of the changes in fair value, including net transfers in and/or out of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2023:

	Amount
Balance on January 1, 2023	$	54,293
Reduction of derivative related to conversions		(50,909	)
Change in fair value of derivative liabilities		(3,384	)
Balance on March 31, 2023	$	-

25

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

The fair value of the derivative conversion features and warrant liabilities as of December 31, 2022 was calculated using a Monte-Carlo option model valued with the following assumptions:

	December 31,
	2022
Dividend yield		0	%
Expected volatility	87.9%-157.2
Risk free interest rate	1.46%-3.75
Contractual terms (in years)	1.25 - .75

NOTE 12 – DEBT

A roll forward of the Company’s third-party debt for the three months ended March 31, 2023 is presented below:

March 31, 2023	Trade Facility			Third Party			COVID Loans			Total
Beginning balance 12/31/22	$	3,305,532		$	1,505,078		$	207,377		$	5,017,987
Payments		(1,153,365	)		(86,561	)		(5,096	)		(1,245,022	)
Debt forgiveness		(306,637	)		-			-			(306,637	)
Foreign currency translation		29,890			11,409			1,879			43,178
Ending balance 3/31/23		1,875,420			1,429,926			204,160			3,509,506
Notes payable - long-term		(1,549,260	)		(1,002,288	)		(176,000	)		(2,727,548	)
Notes payable - short-term	$	326,160		$	427,638		$	28,160		$	781,958

Our outstanding debt as of March 31, 2023, is repayable as follows:
	March 31,  2023
2023	$	802,622
2024		806,824
2025		1,613,928
2026		174,947
2027 and thereafter		111,185
Total debt		3,509,506
Less: notes payable–- current portion		(781,958	)
Notes payable–- long term portion	$	2,727,548

26

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Loan Facility Agreement

On August 4, 2021, the Company entered into an exchange agreement for the existing loan facility agreement with Synthesis Peer-to-Peer Income Fund, whereby the Company agreed to the following:

• Issue on August 4, 2021, 12,852 shares of common stock to settle $1,606,500 (€1,350,000) of debt. The Company recorded a gain on settlement of $292,383 upon the issuance of the 12,852 shares; and

• Agreed to issue no more than 9,520 shares of common stock upon approval of the listing of the Company’s common stock on Nasdaq to settle $1,190,000 (€1,000,000) of debt. The Company issued these shares on February 28, 2022. Upon issuance of the 9,520 shares of common stock, the Company recorded a gain on extinguishment of debt in the amount of $216,580 determined using the fair value of the Company’s common stock at the commitment date of $102.25 per share.

The Company incurred non-cash interest expense of $6,642 during the period ended December 31, 2022 concerning the debt extinguishment. The principal debt balance was paid in full during the year ended December 31, 2022. As of March 31, 2023 and December 31, 2022, the outstanding principal balance on the debt was $0, and had accrued interest expense of $18,527 and $12,853, respectively.

Trade Facility Agreements

On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “TFF”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”) as amended on November 16, 2017, and May 16, 2018.

On October 17, 2018, the Company entered into a further amended agreement with Synthesis whereby the current balance on the TFF as of October 1, 2018, which was €4,866,910 ($5,629,555) and related accrued interest of €453,094 ($524,094) would be split into two principal balances of Euro €2,000,000 ($2,316,000), (the "EURO Loan") and USD $4,000,000, the "USD Loan". Interest on both the EURO Loan and USD Loan commenced on October 1, 2018, at 6% per annum plus one-month Euribor (2.49% as of March 31, 2023), and 6% plus one-month LIBOR (4.77% as of date of March 31, 2023), respectively.

On December 30, 2020, the Company transferred the EURO Loan to a new third-party lender. The terms remained the same except interest accrues at 5.5% per annum plus one-month Euribor (2.49% as of March 31, 2023). The principal was scheduled to be repaid in a total of five quarterly installments beginning October 31, 2021 of €50,000 ($54,360) each with a final repayment of €1,800,000 ($1,956,960) Euro payable on October 31, 2022.

On March 3, 2022, the Company entered into a modification agreement to extend the maturity date to January 10, 2023 and payments under the USD Loan. During June 2022, the Company agreed with the Lender to postpone the repayment of an installment of $500,000 due on June 30, 2022 (based on the modification agreement signed on March 3, 2022) until January 2023. During September 2022, the Company agreed with the Lender to postpone the repayment of the outstanding balance on the USD Loan of $3,950,000, plus unpaid accrued interest until January 2023. The Company capitalized fees paid upon modification of €200,000 ($221,060) that are being amortized over the life of the loan. The Company incurred non-cash interest expense of $23,820 during the three-month period ended March 31, 2022 concerning the above capitalized fees.

During the year ended December 31, 2022, the Company repaid €175,000 ($187,215) of the EURO Loan and $2,593,363 of the USD Loan such that as of December 31, 2022, the Company had principal balances of €1,775,000 ($1,898,895) and $1,406,637 under the agreements, respectively. As of March 31, 2022, the Company had accrued $81,813 in interest expense related to these agreements. 

On December 21, 2022 the USD Loan was assigned to GIB Fund Solutions ICAV (the “Fund”). On January 31, 2023, the Company paid $1,100,000 to the Fund under a full and final settlement agreement for the USD Loan, recording a gain on extinguishment of debt of $306,637 relating to the waiver of the unpaid balance. Additionally, the Company repaid €50,000 ($54,360) of the EURO Loan during the 3-month period ended March 31, 2023. As of March 31, 2023 the Company had an outstanding principal balance of €1,725,000 ($1,875,420), of which $1,549,260 is classified as notes payable-long term on the condensed consolidated balance sheets. As of March 31, 2023, the Company had accrued $14,380 in interest expense related to these agreements.

On December 22, 2022, Skypharm SA signed an agreement for the extension of the payments and an increase in interest rate due under the EURO loan, that was extended to be repaid with a balloon payment now due on October 31, 2025. This extension was agreed upon in writing on December 22, 2022 with a retroactive modification date to October 31, 2022 (the original maturity date). 

27

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Third Party Debt

On November 16, 2015, the Company entered into a Loan Agreement with Panagiotis Drakopoulos, the Company’s former Director and former Chief Executive Officer, pursuant to which the Company borrowed €40,000 ($42,832) as a note payable from Mr. Drakopoulos. The note bore an interest rate of 6% per annum and was due and payable in full on November 15, 2016. As of December 31, 2022, the Company had an outstanding principal balance of €8,000 ($8,558) and accrued interest of €6,797 ($7,271). During the three months ended March 31, 2023, the Company paid the outstanding balance of €8,000. Therefore, as of March 31, 2023, the balance due is $0. Mr Drakopoulos is not considered a related party since he is no longer employed by the Company and currently holds no equity position in the Company.

May 18, 2020, July 3, 2020, and August 4, 2020 Senior Promissory Notes

Modification of May 18, 2020, July 3, 2020, and August 4, 2020 Senior Promissory Notes

On February 23, 2022, the Company entered into modification agreements to extend the due dates of the May 18 Note, July 3 Note, and August 4 Note to June 30, 2023 of $9,000,000, in the aggregate. The Company paid restructuring fees totaling $506,087 upon modification. The Company determined the modification should be recorded as debt extinguishment in accordance with ASC 470 because the present value of the remaining cash flows under the terms of the new debt instrument is at least 10% different from the present value of the remaining cash flows under the terms of the original instrument. The Company recorded the new debt at fair value in the amount of $7,706,369 and a gain upon extinguishment in the amount of $787,544. During the year ended December 31, 2022, the Company repaid the aggregate principal balance of $7,000,000 and the aggregate accrued interest related to these notes in full. During the three months ended March 31, 2022 the Company recorded non-cash interest expense in the amount of $89,275 for the amortization of debt issuance costs.

June 23, 2020 Debt Agreement

On June 23, 2020, the Company’s subsidiary, Cosmofarm, entered into an agreement with the “National Bank of Greece SA” (the “Bank”) to borrow a maximum of €500,000 ($611,500). The note has a maturity date of sixty (60) months from the date of the first disbursement, which includes a grace period of nine months. The total amount of the initial proceeds was paid in 3 equal monthly installments. The note is interest bearing from the date of receipt and is payable every three (3) months at an interest rate of 3.06% plus 3-month Euribor  (2.78% as of March 31, 2023). The outstanding balance was €294,118 ($319,765) and €323,529 ($346,112) on March 31, 2023 and December 31, 2022, respectively of which $191,859 and $220,253, is classified as Notes payable - long-term portion respectively, on the accompanying condensed consolidated balance sheets. During the three months ended March 31, 2023, the Company repaid €29,412 ($31,976) of the principal balance.

November 19, 2020 Debt Agreement

On November 19, 2020, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($611,500). The note matures on November 18, 2025 and bears an annual interest rate, based on a 360-day year, of 3.3% plus .6% plus 6-month Euribor when Euribor is positive. The principal is to be repaid in 18 quarterly installments of €27,778 ($30,210).  During the year ended December 31, 2022, the Company repaid €111,111 ($118,867) of the principal and as of December 31, 2022, the Company had accrued interest of $8,069 related to this note and a principal balance of €333,333 ($356,600), of which $237,733 is classified as Notes payable – long term portion on the accompanying condensed consolidated balance sheet. During the three months ended March 31, 2023, the Company repaid €27,778 ($30,200) of the principal and as of March 31, 2023, the Company has accrued interest of €2,516 ($2,735) related to this note and a principal balance of €305,556 ($332,200), of which $211,400 is classified as Notes payable – long term portion on the accompanying condensed consolidated balance sheet.

July 30, 2021 Debt Agreement

On July 30, 2021, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($578,850). The note matures on August 5, 2026 and bears an annual interest rate that applies to 60% of the principal of the note that is based on a 365-day year, of 5.84% plus 3-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a nine-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 18 quarterly installments of €27,778 commencing three months from the end of the grace period. During the year ended December 31, 2022, the Company repaid €77,985 ($83,428) of the principal balance. As of December 31, 2022, the Company had accrued interest of €2,509 ($2,728) and a principal balance of €422,016 ($451,472), of which $336,788 is classified as notes payable – long term portion on the accompanying condensed consolidated balance sheet. During the three months ended March 31, 2023, the Company repaid €26,451 ($28,758) of the principal. As of March 31, 2023, the Company has accrued interest of €4,136 ($4,947) and principal of €395,564 ($430,057), of which $312,520 is classified as Notes payable – long term portion on the accompanying condensed consolidated balance sheet.

28

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

June 9, 2022 Debt Agreement

On June 9, 2022 the Company entered into an agreement with a third-party lender in the principal amount of €320,000 ($335,008), the “Note”. The Note matures on June 16, 2027 and bears an annual interest rate of 3.89% plus an additional rate of 0.60%, plus the 3-month Euribor (2.78% as of March 31, 2023). Pursuant to the agreement, there is a twelve-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 17 equal quarterly installments of €18,824 commencing on June 30, 2023. As of March 31, 2023 and December 31, 2022 the Company has accrued interest of €3,532 ($3,840) and €7,707 ($8,379), respectively, and an outstanding balance of €320,000 ($347,904), of which $286,509 and $281,924, respectively, is classified as Notes payable – long term portion on the accompanying condensed consolidated balance sheets.

August 29, 2022 Promissory Note

On August 29, 2022, the Company entered into a promissory note for the principal amount of $166,667. The Company received $150,000 in cash and recorded $16,667 as an original issue discount upon issuance. The promissory note matures on the earlier of (a) December 27, 2022, or (b) the date the Company completes a debt or equity financing of at least $1,000,000. The debt carried an annual interest rate of 12% which was due upon maturity. As of December 31, 2022, the Company had repaid the principal balance in full and had a balance of $5,041 in accrued interest related to this note. The Company repaid the outstanding interest during the 3-month period ended March 31, 2023 and thus the balance of both principal and interest as of March 31, 2023 is $0.

COVID-19 Loans

On May 12, 2020, the Company’s subsidiary, SkyPharm, was granted and on May 22, 2020 received a €300,000 ($366,900) loan from the Greek government. The loan will be repaid in 40 equal monthly installments beginning on July 29, 2022. As a condition to the loan, the Company was required to retain the same number of employees until October 31, 2020. As of December 31, 2022, the principal balance was $150,441. During the three months ended March 31, 2023, the Company repaid €4,688 ($5,096) of the principal balance.  The outstanding balance as of March 31, 2023 is €135,938 ($147,791).

On June 24, 2020, the Company received a loan £50,000 ($68,310) from the United Kingdom government. The loan has a ten-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement, which was on July 10, 2020. The Company may prepay this loan without penalty at any time. As of December 31, 2022, the principal balance was £47,144 ($56,936). As of March 31, 2023, the principal balance was £45,573 ($56,369).

29

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

None of the above loans were made by any related parties.

NOTE 13 – LEASES

The Company has various operating and finance lease agreements with terms up to 10 years, for various types of property and equipment (such as office space and vehicles) etc. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised.

The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet.

The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the average interest rate of our long-term debt on the date of inception.

Operating Leases

The Company’s weighted-average remaining lease term relating to its operating leases is 5.23 years, with a weighted-average discount rate of 6.74%.

The Company incurred lease expense, due to amortization of operating lease right-of-use assets, of $55,354 and $54,124 which was included in “General and administrative expenses,” for the three months ended March 31, 2023 and 2022, respectively.

The following table presents information about the amount and timing of cash flows arising from the Company’s operating leases as of March 31, 2023:

Maturity of Operating Lease Liability:
2023	$	197,540
2024		264,035
2025		190,379
2026		153,712
Thereafter		581,964
Total undiscounted operating lease payments	$	1,387,630
Less: Imputed interest		(272,107	)
Present value of operating lease liabilities		1,115,523

30

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Finance leases

The Company’s weighted-average remaining lease term relating to its finance leases is 3.34 years, with a weighted-average discount rate of 6.74%, based on the interest rate implicit in the lease.

The following table presents information about the amount and timing of cash flows arising from the Company’s finance leases as of March 31, 2023:

Maturity of Finance Lease Liability
2023	$	112,406
2024		133,861
2025		103,586
2026		77,014
Thereafter		23,474
Total undiscounted finance lease payments	$	450,341
Less: Imputed interest		(47,400	)
Present value of finance lease liabilities	$	402,941

The Company incurred interest expense on its finance leases of $6,219 and $3,507 which was included in “Interest expense”, on the accompanying condensed statements of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, respectively. The Company incurred amortization expense on its finance leases of $30,710 and $19,580, which was included in “Depreciation and amortization expense”, on the accompanying condensed statements of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, respectively. The total cash used for the Company’s finance leases for the three months ended March 31, 2023 and March 31, 2022 amounted to $35,596 and $22,622 respectively and is solely related to lease payments.

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Legal Matters

From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of March 31, 2023, the following litigation matters were pending. None of the below is expected to have a material financial or operational impact.

Solgar Inc, a competitor of the Company, sued SkyPharm SA for product homogeneity regarding the nutraceutical line “Sky Premium Life”. As a result, Solgar requested the prohibition for SkyPharm to manufacture, import and sell, market or in any way possess and distribute, including internet sales and advertise in any way in the Greek market of “Sky Premium Life” due to homogeneity with Solgar’s products. Solgar Inc. has further requested to be awarded compensation for non-pecuniary damage amounting to €20,000 ($21,744). The case was heard on January 28, 2022, and the decision numbered 8842/2022 of the court of Thessaloniki was issued, which, accepted our claims and dismissed the Solgar’s Inc. lawsuit.

31

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

On July 22, 2015, the National Medicines Agency approved the license of wholesale sale of pharmaceutical products under the name SkyPharm SA with set validity at five years and an expiration date of July 22, 2020. Subsequently, SkyPharm SA on June 15, 2020, legally and timely submitted the application for renewal of the wholesale license of pharmaceutical products to the National Medicines Agency. The National Medicines Agency did not respond, therefore the Company asked for an immediate decision on the renewal. Two months after the filing of no. 3459 / 15.01.2021 letter and almost nine months after the no. 627615.06.2020 company application for the renewal, the National Medicines Agency replied by rejecting the renewal request on March 9, 2021 (ref. 62769 / 20-25.02.2021). In addition, document No. 127351-16.12.2021 of EOF (Greek National Medicines Organization) to SkyPharm states that after an inspection of EOF at the premises of Doc Pharma, we did not have a wholesale license in violation of article 106 par. 1b and par. 1c of the ministerial decision D.YG3a / GP.32221 / 29-4-2019. The National Medicines Agency has not yet provided update on the implications of the renewal’s rejection.

There has been a payment request by the Greek court, which relates to a fine arising from Cosmofarm’s SA tax audit for financial year 2014. The law with no. 483/16.12.2020 was used by the court against Cosmofarm SA (the “defendant”). The defendant appealed against the decision using the law with no.11541/09.03.2021. This appeal was dismissed after 120 days from its submission to the court. Additionally, there had been an obligation for payment of additional tax and fines related to this matter in the amount of €91,652 ($99,644), which the defendant has already settled. However, the defendant has claimed back the respective amount through appeal. As of March 31, 2023, the trial is still pending.

Advisory Agreements

On July 1, 2021, the Company entered into a two-year advisory agreement with a third party (the “Consultant”) for advisory and consulting services related to the Company’s intention to become listed on Nasdaq. Peter Goldstein, a then director of the Company is a principal of the Consultant. As consideration for services rendered, and successful Nasdaq listing, the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023.

Research and Development Agreements

On June 26, 2022, the Company signed a research and development (R&D) agreement with a third party, through which the Company assigns to the third party the development of new products and services in the field of health, focusing on the human intestinal microbiome. The cost of the projects amount to EUR 820,000 ($891,504) which is allocated to certain phases. The amount will be due and payable upon completion of the corresponding phases. The Company records the corresponding R&D expense based on the project’s progress, which is actually invoiced by the third party in the relevant period. No such costs were incurred for the 3-month period ended March 31, 2023 or 2022.

NOTE 15 – WARRANTS

Omnibus Equity Incentive Plan

On September 19, 2022 the Company held a Board of Directors meeting, whereas, the Board of Directors had elected to adopt an Omnibus Equity Incentive Plan (the “Plan”), that includes reserving 200,000 shares of common stock eligible for issuance under the Plan to be registered on a Form S-8 Registration Statement with the SEC. The Plan is designed to enable the flexibility to grant equity awards to the Company’s officers, employees, non-employee directors and consultants and to ensure that it can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. According to the Proxy Statement filed with the SEC on October 20, 2022 the Plan received final approval by the Company’s stockholders at the Annual Meeting of Stockholders held on December 2, 2022.

32

COSMOS HEALTH INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2023

Warrants 

As of March 31, 2023, there were 4,194,236 warrants classified within equity outstanding and 4,194,236 warrants exercisable with 4,180,902 warrants having expiration dates from May 2023 through December 2027 and 13,334 warrants with no expiration date.

A summary of the Company’s warrant activity during the three months ended March 31, 2023 is presented below:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
Warrants	Shares		Price		Term		Value
Balance outstanding, January 1, 2023		4,194,236	$	8.31		5.04	$	2,562,600
Balance outstanding, March 31, 2023		4,194,236	$	8.31		4.80	$	913,209
Exercisable, March 31, 2023		4,194,236	$	8.31		4.80	$	913,209

NOTE 16 – DISAGGREGATION OF REVENUE

ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc.). ASC 606-10-55-89 explains that the extent to which an entity’s revenue is disaggregated depends on the facts and circumstances that pertain to the entity’s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue.

The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue.

The following table presents our revenue disaggregated by country for the three months ended:

	March 31,		March 31,
Country	2023		2022
Greece		11,914,231		13,009,038
Cyprus		33,315
UK		402,231		51,426
Croatia		-		11,336
Total	$	12,349,777	$	13,071,800

NOTE 17 – SUBSEQUENT EVENTS

Acquisition of a Telehealth Company

On March 17, 2023, the Company announced that it has entered into a definitive agreement to acquire ZipDoctor Inc., a telehealth company for a total sum of $150,000, settled in cash. The Sale and Purchase Agreement (“SPA”) was signed on March 17, 2023, and the transaction closed on April 3, 2023.

Purchase of Building

On May 3, 2023, the Company acquired the entire property which houses the operations of its wholly owned subsidiary CosmoFarm Pharmaceuticals ("CosmoFarm"). The property comprises a 3-story building, that is 2,700 square meters (or approximately 29,063 square feet) in size. The purchase price was €966,000 (or approximately $1,068,000).

Conclusion of Stock Purchase Agreement

On May 8, 2023, the Company entered into a Stock Purchase Agreement with the owners of one hundred (100%) percent of the equity (the “Shares”) of Pharmaceutical Laboratories Cana S.A. (“Cana Holdings”).  The Purchase Price of the Shares is €800,000 ($869,760) and 46,377 shares of Cosmos restricted common stock at an issuance price of $17.25 per share or $800,000 for a total purchase price of $1,669,760.

Cana Holdings is a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.

As previously described on February 28, 2023, the Company issued a €4,100,000 ($4,497,017) five-year senior secured promissory note, classified as loans receivable - related party on the accompanying condensed consolidated balance sheet, to Cana Holdings.  The closing of this transaction is conditioned upon: (i) the satisfactory completion of due diligence; (ii) delivery of auditors’ financial statements of Cana Holdings as of December 31, 2022; (iii) receipt by the Company of all required approvals, covenants and waivers; (iv) indebtedness of Cana Holdings shall not exceed €1,000,000 ($1,087,200) (exclusive of the Note); (v) payment of the Purchase Price and delivery of the Shares; (vi) no material adverse changes in the business of Cana Holdings; and (vii) customary closing conditions.

33

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Available Information

The following discussion should be read in conjunction with our interim Condensed Consolidated Financial Statements and the related notes and other financial information appearing elsewhere in this report as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Form 10-K for the year ended December 31, 2022 (“Form 10-K”) and this Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.

We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.

Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Overview

Summary

We are an international healthcare company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices. The Company uses a differentiated operating model based on a lean, nimble and decentralized structure, with an emphasis on acquisitions of established companies and our ability to maintain better pharmaceutical assets than others. This operating model and the execution of our corporate strategy are designed to enable the Company to achieve sustainable growth and create added value for our shareholders. In particular, we look to enhance our pharmaceutical and over-the-counter product lines by acquiring or licensing rights to additional products and regularly evaluate selective company acquisition opportunities. The Company, through its subsidiaries, is operating within the pharmaceutical industry and in order to compete successfully in the healthcare industry, must demonstrate that its products offer medical benefits as well as cost advantages. Currently, most of the products that the Company is trading, compete with other products already in the market in the same therapeutic category, and are subject to potential competition from new products that competitors may introduce in the future.

We continue to rapidly expand our distribution network worldwide and open new markets for our proprietary line of branded pharmaceuticals, nutraceuticals, and nutraceuticals through our distribution channels and e-commerce marketplace. We use our extensive network with direct access to Europe’s primary sales channels for pharmaceuticals and nutraceuticals, which includes over 160 pharmaceutical wholesale distributors in Europe’s largest markets, over 40,000 pharmacies in Europe and 1,500 pharmacies in Greece. We achieve stable supply of pharmaceuticals from DocPharma, a related party, which enhances our ability to scale our expansion. We receive full priority in the production of nutraceuticals and volumes. Our full production in Greece ensures a decisive production-cost advantage whilst we secure additional discounts by leveraging our purchasing scale.

Our focus on investing in technology enhances yield cost savings and economies of scale the safety, distribution and warehousing efficiency and reliability, as a result of 0% error selection rate and acceleration order fulfillment.

34

Revenue sources

The Company operates in nutraceuticals industry, distribution of pharmaceuticals and healthcare distribution.

Pharmaceuticals

We are engaged in the promotion, distribution and sale of licensed branded generics and OTC products throughout Europe by our subsidiaries in Greece and UK. Our capital efficient business model is based on infrastructure, efficiency and scale. We believe that there is a significant growth on opportunities through product additions and geographic expansion.

Healthcare Distribution

We conduct direct distribution and sales of pharmaceuticals, medical devices, branded generics and OTC products. Our automated and GDP licensed distribution facilities ensure all medications reach their destination daily on an efficient and secure way. Our network exceeds over 1,500 pharmacies in Greece. We have created an upgraded and high-end distribution center in Greece due to our Robotic systems and integrated automations (“ROWA” robotics).

Nutraceutical

We have created and developed our own proprietary branded nutraceutical products, named “Sky Premium Life®” which was launched in 2018 and “Mediterranation®” which was launched in 2022. Utilizing unique formulations, and specialized extraction processes which follow strict pharmaceutical standards, our proprietary lines of nutraceuticals aim for excellence. We have a full portfolio of fast-moving and specialty formulas with more than 80 product codes including vitamins, minerals and other herbal extracts. Our nutraceutical products are manufactured exclusively by Doc Pharma, a related party of the Company. Our nutraceutical products have penetrated several markets within 2022 and 2023 through digital channels such as Amazon and Tmall. We focus on nutraceutical products because we foresee it as a market with high grow opportunities due to its large market size and margin contribution as the demand for nutraceutical products is increasing globally.

Regulations and Licenses

Our subsidiary, Decahedron, was granted the license for the wholesale of medicinal products for human use in February 2021 pursuant to the regulation of 18 of The Human Medicines Regulations 2012 (SI 2012/1916). It fulfills the guidelines of the Wholesale Distribution Authorisation (Human). Finally, our subsidiary, Cosmofarm S.A., was granted the license for the wholesale of pharmaceutical products for human use on February 2019 pursuant to the EU directive of (2013/C 343/01). It fulfils the Guidelines of the Good Distribution Practices of medical products for human use. All licenses were granted based on inspections and are valid unless current inspections occur which will revise their status.

35

Risks

Supply chain disruption is a growing concern for the European pharmaceutical industry as it increasingly looks to cut costs by relying on ‘emerging markets’, where standards can be lower in terms of compliance, ethics and health and safety.

Hikes in the price of medicine and their impact on the sustainability of the healthcare systems are garnering more and more attention. European regulators are willing to play their part in safeguarding continued access to safe and effective medicines. Regulators can speed up the approval of branded pharmaceuticals and biosimilars to boost competition and drive down prices.

Cuts in healthcare spending keep occurring since the financial crises of the late of 2000s. Europe’s slow recovery has been uneven, with austerity and economic uncertainty, especially in the EU’s poorer member states, such as Greece.

Distribution and Trade Agreements

On July 1, 2021 the Company’s subsidiary SkyPharm SA, entered into an exclusive distribution agreement with a company based in Germany the “Distributor A”, whereas SkyPharm appointed Distributor A to be the responsible Partner for the distribution, promotion, trade marketing, logistics and sale of the nutraceuticals manufactured and supplied by SkyPharm (Sky Premium Life®), in the territories of Austria and Germany. Distributor A places purchase orders with SkyPharm at the company’s address and the purchase order is necessary to initiate any shipment.

On July 7, 2021 SkyPharm SA signed a trade agreement with a company specializing in e-commerce mall advice and operation, henceforward referred as “Distributor B”. Based on the agreement, SkyPharm will sell its own branded products Sky Premium Life ® to final consumers through the e-commerce store opened by Distributor B on Tmall International MALL and Distributor B will provide platform operation services to SkyPharm. The services provided by Distributor B will include mall construction, mall operation and network promotion, along with collection, settlement, customer service, logistics and distribution.

On November 25, 2021 SkyPharm SA signed a trade agreement with a wholesaler which operates in the storage, distribution, trading and promotion of pharmaceutical products) henceforward referred as “Distributor C”. Based on the agreement Distributor C is appointed as the exclusive representative for the promotion & distribution of our proprietary nutraceutical products Sky Premium Life®, in Greece.

During July 2021, the Company’s subsidiary Decahedron Ltd, created a distribution page on Amazon UK, through which it sells, advertises and promotes our own proprietary branded nutraceutical product line “Sky Premium Life®, directly to final consumers.

On September 22, 2022, the Company entered into a distribution agreement with a third party in order to become the distributor of Monkeypox Virus Real-Time PCR Detection Kits. Cosmos will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the test kits across Europe on a non-exclusive basis.

Acquisitions and Co-Ventures

On September 28, 2022, the Company the Company entered into a non-binding letter of intent (“LOI”) agreement to wholly acquire ZipDoctor Inc., a company that possesses a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists. The current parent company of the acquiree will continue to manage all its aspects of the day-to-day operations, including product development, marketing, and operational support.

On March 17, 2023, the Company announced that it has entered into a definitive agreement to acquire ZipDoctor Inc. for a total sum of $150,000. The Sale and Purchase Agreement (“SPA”) was signed on March 17, 2023, and the transaction closed on April 3, 2023.

On May 8, 2023, the Company entered into a Stock Purchase Agreement with the owners of one hundred (100%) percent of the equity (the “Shares”) of Pharmaceutical Laboratories Cana S.A. (“Cana Holdings”).  The purchase price for the shares for each of two Sellers is €800,000 and 46,377 shares of Cosmos restricted common stock at an issuance price of $17.25 per share or $800,000.

Cana Holdings is a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.

As previously announced on February 28, 2023, the Company issued a five-year senior secured promissory note (the “Note”) in the principal amount of €4,100,000 to Cana Holdings.  The closing of this transaction is conditioned upon: (i) the satisfactory completion of due diligence; (ii) delivery of auditors’ financial statements of Cana Holdings as of December 31, 2022; (iii) receipt by the Company of all required approvals, covenants and waivers; (iv) indebtedness of Cana Holdings shall not exceed €1,000,000 (exclusive of the Note); (v) payment of the Purchase Price and delivery of the Shares; (vi) no material adverse changes in the business of Cana Holdings; and (vii) customary closing conditions.

On October 27, 2022, the Company signed an LOI with a holding company engaged in the development, marketing, manufacturing, acquisition, operation, and sale of a broad spectrum of nutritional and related products to enter into a co-venture relationship pursuant to a definitive distribution agreement to develop commercial opportunities relating to the marketing, distribution, and sale of nutraceutical products on a world-wide basis. This LOI is non-binding and subject to good faith negotiation, preparation, and execution of a definitive agreement mutually satisfactory to both parties.

36

Results of Operations

Three Months Period Ended March 31, 2023 and 2022

Revenue

The Company had revenue of $12,349,777 and $13,071,800 (a decrease of 5.52%) for the three months ended March 31, 2023 and 2022, respectively. The Company had a net loss of $459,863 on revenue of $12,349,777 versus a net loss of $5,585,146 on revenue of $13,071,800 for the three months ended March 31, 2023 and 2022, respectively.  The Company’s revenue remained relatively stable, although the effect of the foreign exchange rates was negative for the three-month period ended March 31, 2023 compared to the three-month period ended March 31, 2022.

Cost of Goods Sold

The Company had costs of goods sold of $11,392,700 versus $11,179,868 (an increase of 1.9%) for the three months ended March 31, 2023 and 2022, respectively. Cost of goods sold remained stable, which is in accordance with the revenues movement for the 3-month period ended March 31, 2023 and March 31, 2022.

Our future revenue growth is expected to continue to be affected by various factors such as industry growth trends, including drug utilization, the introduction of new innovative brand therapies, the likely increase in the number of branded pharmaceutical products that will be available over the next few years’ price increases and price deflation, general economic conditions, including the effects of the current conflict in the Ukraine, the coronavirus in the United Kingdom and the member states of European Union, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third party reimbursement rates to our customers, and changes in government rules and regulations.

Gross Profit

The Company had gross profit of $957,077 versus $1,891,932 (a decrease of 49.41%) for the three months ended March 31, 2023 and 2022, respectively. The decrease in gross profit for the three-month period is attributable to the decreased and discounted sales of SkyPharm’s nutritional supplements, pursuant to an effort of substantially decrease the receivable balances. Since nutraceuticals is a high margin revenue stream, this contributed to the decreased gross profit for the period.

Operating Expenses

The Company had general and administrative costs of $2,089,014 and $868,639 salaries and wages expenses of $949,451 and $521,471, sales and marketing expenses of $467,263 and $146,949 and depreciation and amortization expense of $102,521 and $112,622 for a net operating loss of $2,651,172 and a net operating gain of $242,251 (an increase of 112.85% in Operating Expenses) for the three months ended March 31, 2023 and 2022, respectively. The increase in operating expenses is primarily attributed to management’s compensation and increased advertising costs during the three-month period ended March 31, 2023.

Other Income (Expense)

The Company had interest expense related to notes payable of $134,373 versus $584,176 and non-cash interest expense related to the amortization of debt discount of $0 versus $260,527 for the three months ended March 31, 2023 and 2022, respectively. The decrease in interest expense is attributable to the significant debt repayments that took place within December 2022. Moreover, a gain on equity investments of $1,293 versus $1,678 and a change in fair value of derivative liability of $3,384 versus $15,001 due to agreements on convertible debentures were recorded during the three-month periods ended March 31, 2023 and 2022. The net foreign currency gain amounted to $196,035 versus a loss of $159,352 and interest income amounted to $183,416 versus $64,827 for the three months ended March 31, 2023 and 2022, respectively. The change to foreign currency gain is derived from the positive movement of the foreign exchange rates and the increase in interest income is attributable to the Company’s treasury bills and loans receivable balances, that were not in place as of March 31, 2022. Additionally, a gain on debt extinguishment relating to the write-off of a share settled debt obligation and the forgiveness of a Note’s payable balance of $1,908,513 versus a gain of $1,004,124 were recorded for the three months ended March 31, 2023 and 2022. Finally, the Company’s other income was $5,743 versus other expense of $54,812 for the three months ended March 31, 2023 and 2022, respectively.

37

Unrealized Foreign Currency losses

The Company had an unrealized foreign currency gain of $336,463 versus loss of $405,229, attributable to the positive movement of the exchange rates during the three-month period ended March 31, 2023 and a net comprehensive loss of $123,400 versus a loss of $5,990,375 for the three months ended March 31, 2023 and 2022, respectively, which mainly derives from the deemed dividends on the issuance of warrants of $5,788,493 recorded during the three-month period ended March 31, 2022.

Liquidity and Capital Resources

As of March 31, 2023, the Company had working capital of $32,083,333 compared to $34,296,034 as of December 31, 2022.

The Company had cash and cash equivalents of $12,037,647 versus $20,749,683 as of March 31, 2023 and December 2022, respectively. The Company had net cash used in operating activities of $6,344,173 and $2,337,276 for the three months ended March 31, 2023 and 2022, respectively. The Company has devoted substantially all of its cash resources to expand through organic business growth and has incurred significant general and administrative expenses in order to enable the financing and growth of its business and operations.

The Company had net cash used in investing activities of $4,486,455 and net cash provided by investing activities of $87,223 during the three months ended March 31, 2023 and 2022, respectively. For the three months ended March 31, 2023 the net cash used in investing activities was mainly attributable to the outflow of the loan receivable to a related party.

The Company had net cash provided by financing activities of $2,242,805 versus $2,914,441 during the three months ended March 31, 2023 and 2022, respectively.

For the period ended March 31, 2023, the Company received proceeds from lines of credit of $4,325,744 and payments of lines of credit of $5,452,321, for a net decrease on the line of credit of $1,126,577.

We anticipate using cash in our bank account as of March 31, 2023, cash generated from debt or equity financing, from investing activities or from management loans, to the extent that funds are available to do so to conduct our business in the upcoming year. Management is not obligated to provide these or any other funds. If we fail to meet these requirements, we may lose the qualification for quotation and our securities would no longer trade on Nasdaq market. Further, as a consequence we would fail to satisfy our reporting obligations with the Securities and Exchange Commission (“SEC”), and investors would then own stock in a company that does not provide the disclosure available in quarterly and annual reports filed with the SEC and investors may have increased difficulty in selling their stock as we will be non-reporting.

38

Plan of Operation in the Next Twelve Months

Specifically, our plan of operations for the next 12 months is as follows:

We assess the foreseeable development of the Company as being positive. Over the medium term we expect to further expand our market shares. However, during the course of further organizational optimization there may be associated extraordinary additional costs.

Our plan for our own branded nutraceuticals is to enlarge our portfolio up to 150 SKUs by the end of 2023 including more basic line formulas to cover more customer needs of any age, advanced formulations, formulas based on herbs and further clinical studies with research and development for further products. Our plan for geographic expansion in distributing and market penetration in EU, Asia, USA, and Canada is based on exclusive distributors, wholesalers, ecommerce, development of franchising model, alliances and acquisitions of nutraceutical companies.

In addition, our plan for branded generics and OTC products is geographic expansion across the world, especially in the EU and UK, as well as in third world countries with fast registration, and developed markets with liberalized OTC policies for online pharmacies and supermarkets. We also intend to enhance our exclusive distribution rights with a growing basis of cooperating partners while purchasing generics’, biosimilar drugs and OTC licenses. We also intend to enhance our product expectance by registered copyrights and trademarks in all OTC drugs. In addition, we remain committed to strategic research and development across each business unit with a particular focus on assets with inherently lower risk. Our plan for our healthcare distribution is to expand in the Greek territory, enlarge our customer portfolio and integrate an established sales network of pharmacies through the use of B2B and B2C ecommerce platforms and exclusive distributors. We are also aiming at increasing the exports of branded pharmaceuticals as we focus on higher profit margins categories (OTC and VMS), deliver 3PL services to pharma companies, put in force loyalty programs, provide added value services to pharmacies and emergency deliveries to VIP customers. The Company will evaluate and, where appropriate, execute on opportunities to expand its network of pharmacies and products in areas that it believes will offer above average growth characteristics and attractive margins.

The Company is growing its business through organic growth, market penetration, geographic expansion and acquisitions which would add value to its business and its Shareholders. The Company is also committed to pursuing various forms of business development; this can include trading, alliances, joint ventures and dispositions. Moreover, it hopes to continue to build on its portfolio of pharmaceutical products and expand its OTC and nutraceutical product portfolio. Thus, the Company believes that it is developing a sound sales distribution network specializing in its own branded nutraceutical products.

The Company’s main objective is expanding the business operations of its subsidiaries. The Company views its business development activity as an enabler of its strategies, and it seeks to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic, and financial approach to evaluating business development opportunities. Under these principles the Company assesses businesses and assets as part of its regular, ongoing portfolio review process and continues to consider trading development activities for its businesses. The Company’s objective is the optimization of operating expenses across all entities without compromising the quality of the Company’s services and products.

Changes in the behavior and spending patterns of purchasers of pharmaceutical and healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of doctor visits, and foregoing healthcare insurance coverage, may impact the Company’s business.

The pharmaceutical sector offers a large growth potential within the European pharmaceutical market, if service, price and quality are strictly directed towards the customer requirements. The Company will continue to encounter competition in the market by product, service, reliability, and a high level of quality. On the procurement side, the Company can access a wide range of supply possibilities. To minimize business risks, the Company diversifies its sources of supply all over Europe. It secures its high-quality demands through careful supplier qualification and selection, as well as active suppliers’ system management.

39

While the Company intends to pursue these milestones, there may be circumstances where for valid business reasons or due to factors beyond the control of the Company (e.g., the COVID-19 pandemic), a reallocation of efforts may be necessary or advisable. Although the Company does not currently anticipate that the COVID-19 pandemic will cause material delays in the timelines or estimates set out above, due to the evolving nature of COVID-19 and its impacts, these timelines and estimates may require adjustment in the future.

The Company intends to spend the funds available to strengthen working capital, inventories, intangible assets, acquisitions, research and development, sales and marketing expenses. Due to the uncertain nature of the industry in which the Company operates, projects may be frequently reviewed and reassessed. Accordingly, while it is currently intended by management that the available funds will be expended as set forth above, actual expenditures may in fact differ from these amounts and allocations.

Off Balance Sheet Arrangements

As of March 31, 2023, there were no off-balance sheet arrangements.

Critical Accounting Policies

In December 2001, the SEC requested that all registrants list their most “critical accounting polices” under the Management’s Discussion and Analysis section. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.

Revenue Recognition: The Company adopted Topic 606 Revenue from Contracts with Customers on January 1, 2018. As a result, it has changed its accounting policy for revenue recognition as detailed in Note 2.

Foreign Currency. Assets and liabilities of all foreign operations are translated at period-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the period. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in net (loss) earnings.

Income Taxes. The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes, ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company is liable for income taxes in Greece and the United Kingdom. The corporate income tax rate is 22% in Greece (tax losses are carried forward for five years effective January 1, 2013) and 19% in United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership.

We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets.

40

We recognize the impact of an uncertain tax position in our financial statements if, in management’s judgment, the position is not more-likely-than-not sustainable upon audit based on the position’s technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position is necessary. We operate and are subject to audit in multiple taxing jurisdictions.

We record interest and penalties related to income taxes as a component of interest and other expense as incurred, respectively.

Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740 “Accounting for Income Taxes” as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in this financial statement because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

The Company has net operating loss carry-forwards in our parent, Cosmos Health Inc., which are applicable to future taxable income in the United States (if any). Additionally, the Company has income tax liabilities in the United Kingdom. The income tax assets and liabilities are not able to be netted. We therefore reserve the income tax assets applicable to the United States but recognize the income tax liabilities in Greece and the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership.

Accounts Receivable and Allowance for Doubtful Accounts

The Company follows ASC 310 to estimate the allowance for doubtful accounts. Pursuant to FASB ASC paragraph 310-10-35-9, losses from uncollectible receivables shall be accrued when both of the following conditions are met: (a) information available before the financial statements are issued or are available to be issued (as discussed in Section 855-10-25) indicates that it is probable that an asset has been impaired at the date of the financial statements, and (b) the amount of the loss can be reasonably estimated. Those conditions may be considered in relation to individual receivables or in relation to groups of similar types of receivables. If the conditions are met, accrual shall be made even though the receivables that are uncollectible may not be identifiable. The Company reviews individually each trade receivable for collectability and performs on-going credit evaluations of its customers and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by the review of their current credit information; and determines the allowance for doubtful accounts based on historical write-off experience, customer specific facts and general economic conditions that may affect a client’s ability to pay. Bad debt expense is included in general and administrative expenses, if any.

Inventory Reserves

Our merchandise inventories are made up of finished goods and are valued at the lower of cost or market using the weighted-average cost method. Average cost includes the direct purchase price, net of vendor allowances and cash discounts, of merchandise inventory. We record valuation reserves on an annual basis for merchandise damage and defective returns, merchandise items with slow-moving or obsolescence exposure and merchandise that has a carrying value that exceeds market value. These reserves are estimates of a reduction in value to reflect inventory valuation at the lower of cost or market. The reserve for merchandise returns is based upon the determination of the historical net realizable value of products sold from our returned goods inventory or returned to vendors for credit. Our reserve for merchandise returns includes amounts for returned product on-hand as well as for new merchandise on-hand that we estimate will ultimately become returned goods inventory after being sold based on historical return rates.

41

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable. A smaller reporting company is not required to provide the information required by this Item.

Item 4. Controls and Procedures. 

Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act) that are designed to ensure that information required to be disclosed in the Company’s Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the Principal Executive Officer and the Principal Financial Officer have concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were partially effective. The Management is committed to remediate the material weaknesses identified in the Form 10K, which include lack of segregation of duties and lack of internal controls structure review. As part of this commitment, the Management has assigned to finance personnel responsibilities on key processes in order to examine and improve operating practices, perform extensive financial control and financial risk management processes, as well as to define and develop new policies and controls in order to improve the accuracy of the disclosures. In addition, the Internal Auditors of the Company are in the process of developing further procedures to ensure the effectiveness of internal controls and the accuracy and completeness of financial reporting. The Company will evaluate the controls and procedures on a quarterly basis and judge what weaknesses to be remediated based on materiality and circumstances.

42

Changes in Internal Controls Over Financial Reporting

During the most recently completed fiscal year, there has been no change in our internal control over financial reporting that has materially affected or is reasonably likely to materially affect it. 

Our Audit Committee is in process of evaluating our existing controls and procedures, while communicating with the Management on quarterly basis.

Audit Committee

We have a separately-designated standing audit committee, which is appointed by the Board of Directors of Cosmos Health Inc. On April 28, 2022, Dr Anastasios Aslidis was elected to serve on the Board of Directors and was appointed as a chair of the Audit Committee, replacing Mr Peter Goldstein, who submitted his resignation on the same date. Our three independent directors, Anastasios Aslidis, John Hoidas and Demetrios Demetriades serve on the Audit Committee. The primary function of the committee is to assist the Board of Directors in overseeing (1) the financial reporting and accounting processes of the Company, and (2) the financial statements audits of the Company. The Committee also prepares a written report to be included in the annual proxy statement of the Company pursuant to the applicable rules and regulations of the “SEC”. In furtherance of these purposes, the Committee shall maintain direct communication among the Company’s independent auditors and the Board of Directors. The independent auditors and any other registered public accounting firm engaged in preparing or issuing an audit report or performing other audit review or attest services for the Company shall report directly to the Committee and are ultimately accountable to the Committee and the Board of Directors.

In discharging its oversight role, the Committee is authorized to investigate any matter brought to its attention with full access to all books, records, facilities and personnel of the Company. The Committee shall have the sole authority to retain at the Company’s expense outside legal, accounting or other advisors to advise the Committee and to receive appropriate funding, as determined by the Committee, from the Company for the payment of the compensation of such advisors and for the payment of ordinary administrative expenses of the Committee that are necessary to carry out its duties. The Committee may request any officer or employee of the Company or the Company’s outside counsel or independent auditors to attend a meeting of the Committee or to meet with any member of, or advisors to, the Committee. The Committee may also meet with the Company’s investment bankers or financial analysts who follow the Company.

The Committee shall meet no less frequently than four times per year, with additional meetings as circumstances warrant. The Committee shall also meet periodically with management, the internal auditors, if any, and the independent auditors in separate executive sessions. The Committee shall record the minutes of all such meetings and shall submit the minutes of its meetings to, or discuss the matters deliberated at each meeting with, the Board of Directors. The Company’s chief financial or accounting officer shall function as the management liaison officer to the Committee.

43

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

There have been no changes since the filing of the Company’s Form 10-K for the year ended December 31, 2022.

Item 1A. Risk Factors

The Company is not required to provide the information called for in this item due to its status as a Smaller Reporting Company. You should refer to the other information set forth in this report, including the information set forth in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as in our consolidated financial statements and the related notes. Our business prospects, financial condition or results of operations could be adversely affected by any of these risks.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None. Previously reported on Form 8-K.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

44

Item 6. Exhibits.

(a) Exhibits.

Exhibit No.	Document Description
31.1*	Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document**
101.SCH	XBRL Taxonomy Extension Schema Document**
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document**
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document**
101.LAB	XBRL Taxonomy Extension Label Linkbase Document**
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document**

_____________

*

This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

**

XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

45

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Cosmos Health Inc.
Date: May 16, 2023	By:	/s/ Grigorios Siokas
		Grigorios Siokas
		Chief Executive Officer
		(Principal Executive Officer)

Date: May 16, 2023	By:	/s/ Georgios Terzis
		Georgios Terzis
		Chief Financial Officer
		(Principal Financial Officer, And Principal Accounting Officer)

46

EXHIBIT INDEX

Exhibit No.	Document Description
31.1*	Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document**
101.SCH	XBRL Taxonomy Extension Schema Document**
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document**
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document**
101.LAB	XBRL Taxonomy Extension Label Linkbase Document**
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document**
Exhibit 101	Interactive data files formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Cash Flows, and (iv) the Notes to the Consolidated Financial Statements.**

___________

*

This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

**

XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

47

EX-31.1

EXHIBIT 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Grigorios Siokas, the Chief Executive Officer of Cosmos Health, Inc., certify that:

1.	I have reviewed this report on Form 10-Q of Cosmos Health Inc. for the quarter ended March 31, 2023;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an quarterly report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Cosmos Health Inc.
Date: May 16, 2023	By:	/s/ Grigorios Siokas
		Grigorios Siokas, Chief Executive Officer
		(Principal Executive Officer)

EX-31.2

EXHIBIT 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Georgios Terzis, the Chief Financial Officer of Cosmos Health, Inc., certify that:

1.	I have reviewed this report on Form 10-Q of Cosmos Health Inc., for the quarter ended March 31, 2023;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an quarterly report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	Cosmos Health Inc.
Date: May 16, 2023	By:	/s/ Georgios Terzis
		Georgios Terzis, Chief Financial Officer
		(Chief Financial Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned hereby certifies that the Quarterly Report on Form 10-Q for the period ended March 31, 2023 of Cosmos Health Inc. (the “Company”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Cosmos Health Inc.
Date: May 16, 2023	By:	/s/ Grigorios Siokas
		Grigorios Siokas
		Principal Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Cosmos Health Inc. and will be retained by Cosmos Health Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned hereby certifies that the Quarterly Report on Form 10-Q for the period ended March 31, 2023 of Cosmos Health Inc. (the “Company”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	Cosmos Health Inc.
Date: May 16, 2023	By:	/s/ Georgios Terzis
		Georgios Terzis
		Principal Financial Officer and Principal Accounting Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Cosmos Health Inc. and will be retained by Cosmos Health Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 16, 2023
Cover [Abstract]
Entity Registrant Name	COSMOS HEALTH INC.
Entity Central Index Key	0001474167
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		10,620,670
Document Quarterly Report	true
Entity File Number	000-54436
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	27-0611758
Entity Interactive Data Current	Yes
Entity Address Address Line 2	Suite 4236
Entity Address Address Line 1	141 West Jackson Blvd
Entity Address City Or Town	Chicago
Entity Address State Or Province	IL
Entity Address Postal Zip Code	60604
City Area Code	312
Local Phone Number	536-3102
Security 12b Title	Common Stock, $.001 par value
Trading Symbol	COSM
Security Exchange Name	NASDAQ
Document Transition Report	false

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 12,037,647	$ 20,749,683
Accounts receivable, net	22,561,797	22,761,990
Accounts receivable - related party	2,754,756	2,830,595
Marketable securities	16,433	14,881
Inventory	4,299,538	3,451,868
Loans receivable	388,463	377,038
Loans receivable - related party	505,983	427,920
Prepaid expenses and other current assets	2,936,054	1,967,527
Prepaid expenses and other current assets - related party	5,135,078	3,463,401
TOTAL CURRENT ASSETS	50,635,749	56,044,903
Property and equipment, net	1,821,837	1,817,025
Goodwill and intangible assets, net	694,484	706,914
Loans receivable - long term portion	3,754,587	3,792,034
Loans receivable - related party - long term	8,396,630	3,851,280
Operating lease right-of-use asset	1,115,526	821,069
Financing lease right-of-use asset	389,837	291,762
Other assets	1,207,538	713,634
TOTAL ASSETS	68,016,188	68,038,621
CURRENT LIABILITIES:
Accounts payable and accrued expenses	10,897,943	11,918,997
Accounts payable and accrued expenses - related party	787,251	205,360
Accrued interest	53,445	275,547
Lines of credit	4,710,314	5,758,737
Convertible notes payable, net of unamortized discount of $0 and $258,938, respectively	0	100,000
Derivative liability - convertible note	0	54,293
Notes payable	781,958	2,158,417
Notes payable - related party	11,089	10,912
Loans payable - related party	13,029	12,821
Taxes payable	457,686	126,855
Operating lease liability, current portion	195,812	167,393
Financing lease liability, current portion	123,267	97,097
Other current liabilities	520,622	862,440
TOTAL CURRENT LIABILITIES	18,552,416	21,748,869
Share settled debt obligation	0	1,554,590
Notes payable - long term portion	2,727,548	2,859,570
Operating lease liability, net of current portion	919,711	653,673
Financing lease liability, net of current portion	279,674	206,407
Other liabilities	1,156,642	1,358,803
TOTAL LIABILITIES	23,635,991	28,381,912
Commitments and Contingencies (see Note 14)	0	0
MEZZANINE EQUITY
Series A preferred stock, stated value $1,000 per share, 6,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022; dividends of $372,414	372,414	372,414
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 300,000,000 shares authorized; 10,620,470 and 10,605,412 shares issued and 10,605,172 and 10,589,915 outstanding as of March 31, 2023 and December 31, 2022, respectively	10,621	10,606
Additional paid-in capital	112,302,825	112,205,952
Subscription receivable	(108)	(4,750,108)
Treasury stock, 15,497 shares as of March 31, 2023 and December 31, 2022, respectively	(816,707)	(816,707)
Accumulated deficit	(66,692,676)	(66,232,813)
Accumulated other comprehensive loss	(796,172)	(1,132,635)
TOTAL STOCKHOLDERS' EQUITY	44,007,783	39,284,295
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY	$ 68,016,188	$ 68,038,621

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Convertible notes payable, net of unamortized discount	$ 0	$ 258,938
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	10,620,470	10,605,412
Common stock, shares outstanding	10,605,172	10,589,915
Treasury stock	15,497	15,497
Series A Preferred Stock [Member]
Preferred stock, shares par value	$ 1,000	$ 1,000
Preferred stock, shares authorized	6,000,000	6,000,000
Preferred Stock, Share Issued	0	0
Preferred Stock,Shares Outstanding	0	0
Preferred dividends, value	$ 372,414	$ 372,414

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited)
REVENUE	$ 12,349,777	$ 13,071,800
COST OF GOODS SOLD	11,392,700	11,179,868
GROSS PROFIT	957,077	1,891,932
OPERATING EXPENSES
General and administrative expenses	2,089,014	868,639
Salaries and wages	949,451	521,471
Sales and marketing expenses	467,263	146,949
Depreciation and amortization expense	102,521	112,622
TOTAL OPERATING EXPENSES	3,608,249	1,649,681
GAIN (LOSS) FROM OPERATIONS	(2,651,172)	242,251
OTHER INCOME (EXPENSE)
Other expense, net	5,743	(54,812)
Interest expense	(134,373)	(584,176)
Interest income	183,416	64,827
Non-cash interest expense	0	(260,527)
Gain on equity investments, net	1,293	1,678
Gain on extinguishment of debt	1,908,513	1,004,124
Change in fair value of derivative liability	3,384	15,001
Foreign currency transaction gain (loss), net	196,035	(159,352)
TOTAL OTHER INCOME, NET	2,164,011	26,763
INCOME (LOSS) BEFORE INCOME TAXES	(487,161)	269,014
INCOME TAX BENEFIT (EXPENSE)	27,298	(65,667)
NET INCOME (LOSS)	(459,863)	203,347
Deemed dividend on issuance of warrants	0	(5,788,493)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(459,863)	(5,585,146)
OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustment, net	336,463	(405,229)
TOTAL COMPREHENSIVE LOSS	$ (123,400)	$ (5,990,375)
BASIC NET LOSS PER SHARE	$ (0.04)	$ (7.86)
DILUTED NET LOSS PER SHARE	$ (0.04)	$ (7.86)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
Basic	10,615,075	710,221
Diluted	10,615,075	710,221

XML

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY (Unaudited) - USD ($)	Total	Preferred Stock	Common Stock	Treasury Stock	Additional Paid-In Capital	Subscription Receivable	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Balance, shares at Dec. 31, 2021			701,780	15,497
Balance, amount at Dec. 31, 2021	$ 4,379,463	$ 0	$ 702	$ (816,707)	$ 39,692,595	$ 0	$ (34,345,506)	$ (151,621)
Foreign currency translation adjustment, net	(405,229)	$ 0	0	0	0	0	0	(405,229)
Issuance of Series A preferred stock, net of issuance costs of $547,700, shares		6,000
Issuance of Series A preferred stock, net of issuance costs of $547,700, amount	0	$ 5,452,300	$ 0	0	0	0	0	0
Conversion of notes payable into shares of common stock, shares			9,520
Conversion of notes payable into shares of common stock, amount	973,420	0	$ 10	0	973,410	0	0	0
Cashless exercise of warrants, shares			33,179
Cashless exercise of warrants, amount	0	0	$ 33	0	(829)	0	0	0
Net income	203,347	$ 0	$ 0	$ 0	0	0	203,347	0
Balance, shares at Mar. 31, 2022		6,000	744,479	15,497
Balance, amount at Mar. 31, 2022	5,151,001	$ 5,452,300	$ 745	$ (816,707)	40,665,176	0	(34,142,159)	(556,850)
Balance, shares at Dec. 31, 2022			10,605,412	15,497
Balance, amount at Dec. 31, 2022	39,284,295	372,414	$ 10,606	$ (816,707)	112,205,952	(4,750,108)	(66,232,813)	(1,132,635)
Foreign currency translation adjustment, net	336,463	0	0	0	0	0	0	336,463
Net income	(459,863)	0	0	0	0	0	(459,863)	0
Proceeds from sale of common stock	4,750,000	0	$ 0	0	0	4,750,000	0	0
Shares issued in lieu of cash, shares			15,258
Shares issued in lieu of cash, amount	96,888	0	$ 15	$ 0	96,873	0	0	0
Balance, shares at Mar. 31, 2023			10,620,670	15,497
Balance, amount at Mar. 31, 2023	$ 44,007,783	$ 372,414	$ 10,621	$ (816,707)	$ 112,302,825	$ (108)	$ (66,692,676)	$ (796,172)

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss)	$ (459,863)	$ 203,347
Adjustments to Reconcile Net Income to Net Cash Used In Operating Activities:
Depreciation and amortization expense	71,811	93,042
Amortization of finance right-of-use assets	30,710	19,580
Lease expense	55,354	54,124
Amortization of debt discounts and accretion of debt	0	260,527
Bad debt expense	181,321	0
Shares issued in lieu of cash	96,888	0
Interest imputed on finance leases	6,219	3,507
Deferred income taxes	2,829	62,594
Gain on extinguishment of debt	(1,908,513)	(1,004,124)
Change in fair value of the derivative liability	(3,384)	(15,001)
Gain on net change in fair value of equity investments	(1,293)	(1,678)
Changes in assets and liabilities:
Accounts receivable	385,809	226,934
Accounts receivable - related party	131,531	(10,967)
Inventory	(776,554)	(934,400)
Prepaid expenses and other current assets	(1,461,343)	141,119
Prepaid expenses and other current assets - related party	(1,597,170)	(1,183,403)
Accounts payable and accrued expenses	(1,154,718)	300,913
Accounts payable and accrued expenses - related party	581,176	(370,694)
Accrued interest	(223,534)	20,356
Taxes payable	324,243	(107,462)
Operating lease liabilities	(55,538)	(54,241)
Other current liabilities	(348,828)	(23,438)
Other liabilities	(221,326)	(17,911)
NET CASH USED IN OPERATING ACTIVITIES	(6,344,173)	(2,337,276)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from loan receivable	92,603	91,661
Issuance on loan receivable - related party	(4,553,030)	0
Purchase of property and equipment	(26,028)	(4,438)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	(4,486,455)	87,223
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of convertible note payable	(100,000)	0
Payment of note payable	(1,245,022)	(2,263,471)
Payment of related party loan	0	(22,432)
Proceeds from related party loan	0	460,034
Payment of lines of credit	(5,452,321)	(6,244,162)
Proceeds from lines of credit	4,325,744	5,779,114
Proceeds from issuance of Series A Preferred Stock	0	5,452,300
Proceeds from the issuance of common stock	4,750,000	0
Payments of finance lease liability	(35,596)	(22,622)
Payments of financing fees	0	(224,320)
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,242,805	2,914,441
Effect of exchange rate changes on cash	(124,213)	59,552
NET CHANGE IN CASH AND CASH EQUIVALENTS	(8,712,036)	723,940
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	20,749,683	286,487
CASH AND CASH EQUIVALENTS AT END OF PERIOD	12,037,647	1,010,427
Supplemental Disclosure of Cash Flow Information
Interest	588,051	281,889
Income tax	0	0
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Conversion of notes payable to common stock	0	973,420
Deemed dividend on warrants upon conversion of convertible debt	$ 0	$ 5,788,493

XML

BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2023

BASIS OF PRESENTATION

BASIS OF PRESENTATION

NOTE 1 – BASIS OF PRESENTATION

The terms “COSM,” “we,” “the Company,” “Group” and “us” as used in this report refer to Cosmos Health, Inc. The accompanying unaudited condensed consolidated balance sheet as of March 31, 2023 and unaudited condensed consolidated statements of operations and comprehensive income for the three months ended March 31, 2023 have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management of COSM, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023, or any other period. These unaudited consolidated financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (“Form 10-K”). The accompanying condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited financial statements filed in our Form 10-K and is included for comparison purposes in the accompanying balance sheet.

XML

ORGANIZATION NATURE OF BUSINESS AND GOING CONCERN

3 Months Ended

Mar. 31, 2023

ORGANIZATION NATURE OF BUSINESS AND GOING CONCERN

ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN

NOTE 2 – ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN

Cosmos Health Inc. and its subsidiaries are an international healthcare group headquartered in Chicago, Illinois. The group is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation”. The Company is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the group is involved in the healthcare distribution sector through its subsidiaries in Greece and the UK, serving retail pharmacies and wholesale distributors. The Company is strategically focusing on the research and development (“R&D”) of novel patented nutraceuticals (Intellectual Property) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. The Company has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. The Company has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK.

The Company was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009, and on November 29, 2022, we changed our name to Cosmos Health Inc. Through its acquisition of Amplerissimo Ltd, on September 27, 2013, the Company changed its principal activities into trading of products, providing representation, and provision of consulting services to various sectors. On August 1, 2014, the Company formed SkyPharm S.A., a Greek Company (“SkyPharm”), a subsidiary that focuses on the trading, sourcing and export of nutraceutical and pharmaceutical products. In February 2017, the Company acquired Decahedron Ltd., a UK Company (“Decahedron”) which is a fully licensed second-generation wholesaler specializing in imports and exports of generics and OTC pharmaceutical products within the EEA and distributor of Sky Premium Life nutraceutical products in the UK. On December 19, 2018, the Company acquired Cosmofarm, a pharmaceutical wholesaler specializing in the distribution and export of pharmaceutical products through its extensive pharmacies network.

On March 17, 2023, the Company announced that it had entered into a definitive agreement to acquire ZipDoctor Inc., a telehealth company for a total sum of $150,000 in cash.  The Sale and Purchase Agreement (“SPA”) was signed on March 17, 2023, and the transaction closed on April 3, 2023 (see Note 17).

Summary of Significant Accounting Policies

Basis of Financial Statement Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP.

Principles of Consolidation

Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated.

Transactions in and Translations of Foreign Currency

The functional currency for the Greek subsidiaries of the Company (Cosmofarm SA and SkyPharm SA) is EURO (€) and for the UK subsidiary (Decahedron Ltd) is GBP (£). As a result, the financial statements of the subsidiaries have been transferred from the local currency into US dollars using (i) year-end exchange rates for balance sheet accounts, and (ii) average exchange rates for the reporting period for all income statements accounts. Foreign currency translations gains and losses are reported as a separate component of the condensed consolidated statements of changes in stockholders’ equity and mezzanine equity.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The Effects of COVID-19

Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur, and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

The Effects of War in the Ukraine

On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. We do not conduct any commercial transactions with either Ukraine or Russia and the Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. Such political issues and conflicts could have a material adverse effect on our results of operations and financial condition if they escalate in areas in which we do business. In addition, changes in and adverse actions by governments in foreign markets in which we do business could have a material adverse effect on our results of operations and financial condition.

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of March 31, 2023 and December 31, 2022, there were $6,995,287 and $0 held in Treasury bills with a maturity of less than 3 months.

The Company maintains bank accounts in the United States denominated in U.S. Dollars, in Greece denominated in Euros, U.S. Dollars and Great Britain Pounds (British Pounds Sterling), and in Bulgaria denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling).

Account Receivable, net

Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables’ portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. As of March 31, 2023 and December 31, 2022, the Company’s allowance for doubtful accounts was $7,614,237 and $7,309,311, respectively.

Tax Receivable

The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of March 31, 2023 and December 31, 2022, the Company had a VAT net receivable balance of $243,424 and a net payable balance of $79,373 respectively, recorded in the condensed consolidated balance sheet as prepaid expenses and other current assets and accounts payable and accrued expenses, respectively.

Inventory

Inventory is stated at the lower-of-cost or net realizable value using the weighted average FIFO method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment.

The Company writes down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met.

Property and Equipment, net

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows:

	Estimated Useful Life
Leasehold improvements and technical works	Lesser of lease term or 40 years
Vehicles	6 years
Machinery	20 years
Furniture, fixtures and equipment	5–10 years
Computers and software	3-5 years

Depreciation expense was $65,629 and $84,884 for the three months ended March 31, 2023 and 2022, respectively.

Goodwill and Intangibles, net

The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. First, under step 0, we determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount. Following, if step 0 fails, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit.

On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill.

Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for its pharmaceuticals and nutraceuticals products license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of March 31, 2023, no revision to the remaining amortization period of the intangible assets was made.

Amortization expense was $21,058 and $8,158 for the three months ended March 31, 2023 and 2022, respectively.

Impairment of Long-Lived Assets

In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.

Equity Method Investment

For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company will record its share in the earnings of the investee and will include it within the condensed consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value. See Note 3, for additional detail.

Investments in Equity Securities

Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for use in current operations are reported as a component of current assets in the accompanying condensed consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying condensed consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment.

As of March 31, 2023, investments consisted of (i) 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp and (ii) 16,666 shares which traded at a closing price of $0.49 per share or value of $8,099 of National Bank of Greece. Additionally, the Company has $8,333 in equity securities of Pancreta Bank, which are revalued annually.  

Fair Value Measurement

The Company applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

The following tables presents assets that are measured and recognized at fair value as of March 31, 2023 and December 31, 2022, on a recurring basis:

	March 31, 2023						Total Carrying
	Level 1		Level 2		Level 3		Value
Marketable securities – Pancretan Bank	$	8,334		-		-	$	8,334
Marketable securities – National Bank of Greece		8,099		-		-		8,099
	$	16,433					$	16,433

	December 31, 2022						Total Carrying
	Level 1		Level 2		Level 3		Value
Marketable securities – Pancretan Bank	$	8,200		-		-	$	8,200
Marketable securities – National Bank of Greece		6,681		-		-		6,681
	$	14,881					$	14,881

In addition, ASC 825-10-25, Fair Value Option, (“ASC 825-10-25”), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.

Derivative Instruments

Derivative financial instruments are recorded in the accompanying condensed consolidated balance sheets at fair value in accordance with ASC 815. When the Company enters into a financial instrument such as a debt or equity agreement (the “host contract”), the Company assesses whether the economic characteristics of any embedded features are clearly and closely related to the primary economic characteristics of the remainder of the host contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the host contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument, then the embedded feature is bifurcated from the host contract and accounted for as a derivative instrument. The estimated fair value of the derivative feature is recorded in the accompanying condensed consolidated balance sheets separately from the carrying value of the host contract. Subsequent changes in the estimated fair value of derivatives are recorded as a gain or loss in the Company’s condensed consolidated statements of operations and comprehensive loss.

Customer Advances

The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company’s products. The Company records these receipts as customer advances until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer advances balance and credit the Company’s revenues.

Revenue Recognition

In accordance with ASC 606, Revenue from Contracts with Customers, the Company uses a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, including the constraint on variable consideration, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon transfer of the product to the customer.

Commencing from January 1, 2023, and pursuant to the agreement with Medihelm, the exclusive distributor of the Company’s own proprietary line of nutraceuticals, the Company considers the transaction price to be variable and records an estimate of the transaction price, subject to the constraint for variable consideration. The Company is basing the change in transaction price with the exclusive distributor through assessment of significant overdue receivables from the exclusive distributor, which the Company reassessed during the 3-month period ended March 31, 2023. Essentially, the Company applies the “expected value” model under ASC 606-10-32-5 and has applied specific constraints to revenue due from the customer at the end of each reporting period. Following the application of the “expected value” model the Company deferred an amount of $112,515 and recorded it against the sales to Medihelm for the three-month period ended March 31, 2023. The Company does not consider that sales to any other customer include a variable component as of March 31, 2023.

Stock-based Compensation

The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (“ASC 718”) and Staff Accounting Bulletin No. 107 (“SAB 107”) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.

The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, “Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.”

Foreign Currency Translation and Transactions

Assets and liabilities of all foreign operations are translated at period-end rates of exchange, and amounts included in the accompanying condensed statements of operations and comprehensive income (loss) are translated at the average rates of exchange for the period. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ equity (deficit) until the entity is sold or substantially liquidated.

Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss).

Income Taxes

The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 19% in the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership.

We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets.

Retirement and Termination Benefits

Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee’s work experience and renumeration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability.

Basic and Diluted Net Loss per Common Share

Basic income per share is calculated by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding.

The following table summarizes potential common shares that were excluded as their effect is anti-dilutive:

	March 31, 2023		March 31, 2022
Warrants		4,194,236		117,976
Options		-		1,480
Convertible Notes		-		29,602
Total		4,194,236		149,058

Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed consolidated financial statements. 

XML

EQUITY METHOD INVESTMENTS

3 Months Ended

Mar. 31, 2023

EQUITY METHOD INVESTMENTS

EQUITY METHOD INVESTMENTS

NOTE 3 – EQUITY METHOD INVESTMENTS

Distribution and Equity Agreement

On March 19, 2018, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon Global Inc. (“Marathon”), a company incorporated in the Province of Ontario, Canada. Marathon was formed to be a global supplier of cannabis, cannabidiol (CBD) and/or any cannabis extract products, extracts, ancillaries and derivatives (collectively, the “Products”). The Company was appointed the exclusive distributor of the Products initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. The Company has no present intention to distribute any Products under this Agreement in the United States or otherwise participate in cannabis operations in the United States. The Company intended to await further clarification from the U.S. Government on cannabis regulation prior to determining whether to enter the domestic market.

The Distribution and Equity Acquisition Agreement was to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five (5) years of the agreement. On March 20, 2023, the Company sent a termination notice to Marathon, which became effective on April 19, 2023 as a result of Marathon’s failure to satisfy these conditions.  The transaction closed on May 22, 2018 after the due diligence period, following which the Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it failed to meet certain performance milestones. The Company was entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. The Company was also given the right to nominate one director to the Marathon board of directors.

The Company had accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). On March 20, 2023, the Company’s legal counsel provided notice to Marathon Global Inc, that the Company terminated the Equity agreement dated on March 19, 2018, pursuant to Section 3.2. Accordingly, the Company recorded a gain on extinguishment of debt of $1,554,590 due to the write-off of the share settled debt obligation, for the period ended March 31, 2023.

Since Marathon was a newly formed entity with no assets and no activity, the Company attributed no value to the 5 million shares in Marathon which was received as consideration for the distribution services. As described in Note 3, the Company exchanged the Marathon shares in May and July 2018.

CosmoFarmacy LP

In September 2019, the Company entered into an agreement with an unaffiliated third party to incorporate CosmoFarmacy L.P. for the purpose of providing strategic management consulting services and the retail trade of pharmaceutical products, and OTC to pharmacies. CosmoFarmacy was incorporated with a 30-year term through May 31, 2049. The unaffiliated third party is the general partner (the “GP”) of the limited partnership and is responsible for management and decision-making associated with CosmoFarmacy. The initial share capital was set to EUR 150,000 ($163,080) which was later increased to EUR 500,000 ($543,600). The GP contributed the pharmacy license (the “License”) valued at EUR 350,000 (30-year term) to operate the business of CosmoFarmacy in exchange for a 70% equity ownership. The Company is a limited partner and contributed cash of EUR 150,000 ($163,080) for the remaining 30% equity ownership. CosmoFarmacy is not publicly traded and the Company’s investment has been recorded using the equity method of accounting. The value of the investment as of March 31, 2023 and December 31, 2022, was $163,080 and $160,470, respectively, and is included in “Other assets” on the Company’s condensed consolidated balance sheets. 

XML

PROPERTY AND EQUIPMENT

3 Months Ended

Mar. 31, 2023

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT

NOTE 4 – PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	March 31, 2023			December 31, 2022
Leasehold improvements	$	512,843		$	502,882
Vehicles		109,732			107,976
Furniture, fixtures and equipment		1,997,337			1,945,207
Computers and software		146,041			138,783
		2,765,953			2,694,848
Less: Accumulated depreciation and amortization		(944,116	)		(877,823	)
Total	$	1,821,837		$	1,817,025

XML

GOODWILL AND INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2023

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS

NOTE 5 – GOODWILL AND INTANGIBLE ASSETS

Intangible assets consist of the following at:

	March 31, 2023			December 31, 2022
License	$	652,853		$	643,204
Trade name / mark		36,997			36,997
Customer base		176,793			176,793
		866,642			856,994
Less: Accumulated amortization		(221,856	)		(199,777	)
Subtotal		644,787			657,217
Goodwill		49,697			49,697
Total	$	694,484		$	706,914

At March 31, 2023, the estimated aggregate amortization expense for intangible assets subject to amortization for each of the five succeeding fiscal years is as follows:

Year	Amount
2023	$	71,056
2024		79,719
2025		74,868
2026		44,361
2027		44,361
Thereafter		330,422
Total amortization	$	644,787

XML

LOAN RECEIVABLE

3 Months Ended

Mar. 31, 2023

LOAN RECEIVABLE

LOAN RECEIVABLE

NOTE 6 – LOAN RECEIVABLE

On October 30, 2021, the Company entered into an agreement for a ten-year loan with Medihelm SA to memorialize €4,284,521 ($4,849,221) in prepayments the Company had made. The prepayments to Medihelm SA had been made in accordance with the parallel export business, through which Medihelm supplied and would supply SkyPharm SA with branded pharmaceuticals. This business is no longer in place for the Company and thus the Company entered into this agreement with Medihelm SA in order for the outstanding amount to be settled. Interest is calculated at a rate of 5.5% per annum on a 360-day basis. Under the terms of the agreement, the Company is to receive 120 equal payments over the term of the loan. As of December 31, 2022, the Company had a short-term receivable balance of $377,038 and a long-term receivable balance of $3,792,034 under this loan. During the three months ended March 31, 2023, the Company received €86,305 ($93,831) in principal payments such that as of March 31, 2023, the Company had a short-term receivable balance of $388,463 and a long-term receivable balance of $3,754,587 under this loan. The Company also received €45,212 ($49,154) in interest payments during the three months ended March 31, 2023.

XML

INCOME TAXES

3 Months Ended

Mar. 31, 2023

INCOME TAXES

INCOME TAXES

NOTE 7 – INCOME TAXES

The Company is incorporated in the United States of America and is subject to United States federal taxation. No provisions for income taxes have been made as the Company had no U.S. taxable income for the three months ended March 31, 2023 and 2022.

The Company’s Greece subsidiaries are governed by the income tax laws of Greece. The corporate tax rate in Greece is 22% on income reported in the statutory financial statements after appropriate tax adjustments.

The Company’s United Kingdom subsidiaries are governed by the income tax laws of the United Kingdom. The corporate tax rate in the United Kingdom is 19% on income reported in the statutory financial statements after appropriate tax adjustments.

As of March 31, 2023 and 2022, the Company’s effective tax rate differs from the U.S. federal statutory tax rate primarily due to a valuation allowance recorded against net deferred tax assets in in the United States and the United Kingdom.

We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred ax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. As of March 31, 2023 and December 31, 2022, the Company has maintained a valuation allowance against all net deferred tax assets in the United States, Greece, and the UK.

For the three months ended March 31, 2023, and 2022, the Company has recorded tax benefit (expense) in any jurisdiction where it is subject to income tax, in the amount of ($27,298) and $65,667, respectively, on the condensed consolidated statement of operation and comprehensive loss.

XML

CAPITAL STRUCTURE

3 Months Ended

Mar. 31, 2023

CAPITAL STRUCTURE

CAPITAL STRUCTURE

NOTE 8 – CAPITAL STRUCTURE

Preferred Stock

The Company is authorized to issue 100 million shares of preferred stock, of which 6,000,000 are designated as Series A convertible preferred stock. The preferred stock has a liquidation preference over the common stock and is non-voting. As of March 31, 2023 and December 31, 2022, all Series A convertible preferred stock had been converted and no preferred shares were issued and outstanding.

Major Rights & Preferences of Series A Preferred Stock

On and effective October 4, 2021, the Company amended and restated its articles of incorporation (the “Amended and Restated Articles”) and filed a certificate of designation (the “COD”) for its Series A Preferred Stock (the “Series A Preferred Stock”) with the State of Nevada. The Amended and Restated Articles allow the Company’s Board of Directors the authority to authorize the issuance of preferred stock from time to time in one or more classes or series by resolution. On February 23, 2022, the Company filed Correction No. 1 to the COD. On July 28, 2022, the Company filed an Amendment to the COD with the State of Nevada to allow a holder to waive application of the Beneficial Ownership Limitation with respect to the conversion of Series A Preferred Stock.

The Series A Preferred Stock was initially convertible into the Company’s common stock as determined by dividing the number of shares of Series A Preferred Stock to be converted by the lower of (i) $75.00 or (ii) 80% of the average volume weighted average price for the Company’s common stock for the five (5) trading days immediately following the effectiveness of the registration statement concerning the shares (the “Conversion Price”). On June 14, 2022, the Conversion Price was reset to $15.54 per share.

Each holder was entitled to receive dividends in shares of Series A Preferred Stock or cash determined based on the stated value of each Series A Preferred Stock at the dividend rate of 8.0% per year. As of March 31, 2023 and December 31, 2022, the cumulative accrued dividend has been recorded as mezzanine equity in the amount of $372,414. The Company has not issued shares of Series A Preferred Stock or cash for the accrued dividends as of March 31, 2023.

On February 28, 2022, the Company entered into a securities purchase agreement, or the Purchase Agreement, with certain investors and an insider for a private placement of the Company’s securities (the “Private Placement”).

The Private Placement consisted of the sale of 6,000 shares of the Company’s Series A Convertible Preferred Stock, or the Series A Shares, at a price of $1,000 per share, and 80,000 warrants to purchase shares of common stock, or the Warrants, for aggregate gross proceeds of approximately $6 million. The Warrants were initially exercisable to purchase shares of common stock at $82.50 per share, or 110% of the Series A Shares initial conversion price and will expire five and one-half years following the initial exercise date of the Warrants. The Company determined that the 80,000 warrants were additional value being distributed to the preferred stockholders and presented the warrants’ fair value of $5,788,493 as a deemed dividend on issuance of warrants in the condensed consolidated statements of operations and comprehensive loss. The warrants were valued using the Black-Scholes option pricing model with the following terms: a) exercise price of $82.50, b) common stock fair value of $85.50, c) volatility of 118%, d) discount rate of 1.71%, e) term of 5.50 years and f) dividend rate of 0%.

The closing of the Private Placement occurred on February 28, 2022. As a condition to the closing of the sale, the Company’s common stock received conditional approval for listing and trading on the Nasdaq Capital Market and commenced trading on February 28, 2022, under the trading symbol, COSM. Concurrent with the issuance of the Series A Shares, the Company executed a registration rights agreement (the “Registration Rights Agreement”) to register the resale of the shares of common stock issuable upon conversion of the Series A Shares and the shares of common stock issuable upon exercise of the warrants issued in connection with the Series A Shares. The Company was required to file its initial registration statement within 45 days following February 28, 2022. The Effectiveness Date was required to be 60 days after February 28, 2022, or 75 days following the SEC’s full review, and any additional registration statements that may be required are to be filed within 20 days following the date required by the SEC. The Company failed to timely file its initial registration statement and thus paid each holder 2% of the subscription amount in cash.

Treasury stock

As of March 31, 2023 and December 31, 2022, the Company held 15,497 shares at a cost of $816,707. Shares of our common stock that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. No repurchases took place within the 3-month period ended March 31, 2023 and 2022.

On January 24, 2023 the Company announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $3 million of its common stock. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions. No repurchases took place within the 3-month period ended March 31, 2023.

Mezzanine Equity

The Series A Shares were recorded at its initial net carrying value in the amount of $5,452,300. The Series A Shares were recorded as mezzanine equity in accordance with ASC 480 as the Company was potentially obligated to issue a variable number of shares at a fixed price known at inception and there was no maximum number of shares that could potentially be issued upon conversion. In this instance, cash settlement would have been presumed. Immediately upon effectiveness of the registration statement registering for resale of all the common stock issuable under the Series A Shares, all outstanding Series A Shares were automatically converted into common stock.

As of December 31, 2022, 6,000 of the Series A Shares had been converted into 386,588 shares of common stock in accordance with the terms of the agreements and thus an amount of $5,452,300 was reclassified from mezzanine equity to common stock and additional paid-in capital, in the aggregate.  

Common Stock

The Company is authorized to issue 300 million shares of common stock. As of March 31, 2023 and December 31, 2022, the Company had 10,620,470 and 10,605,412 shares of our common stock issued, respectively, and 10,605,172 and 10,589,915 shares outstanding, respectively.

Reverse split

On December 15, 2022 the Company announced a reverse stock split with a ratio of 1-for-25 (one-for-twenty five) effective at the opening of the business day on Friday, December 16, 2022. The reverse stock split was authorized at the Company’s Annual General Meeting (“AGM”) on December 2, 2022 and was approved by the Company’s Board of Directors on December 15, 2022.

Issuance of common stock

During the 3-month period ended March 31, 2023 the Company issued 15,258 to a consultant for services rendered. The shares were valued and expensed on the date of issuance and are separately presented in the condensed consolidated statement of changes in stockholders’ equity and mezzanine as “Shares issued in lieu of cash”.

Debt Conversions

During the period ended March 31, 2022, the Company issued 9,520 shares of common stock upon the conversion of $1,190,000 of notes payable. The Company recorded $973,420 as a capital contribution and an increase in equity related to the conversion of the $1,190,000 reduced by $216,580 recorded as a gain upon extinguishment of debt upon modification. The $216,580 gain upon extinguishment was determined using the fair value of the Company of $102.25 per share at the extinguishment commitment date.

Exercise of Warrants

During the three months ended March 31, 2022, the Company issued 33,179 shares of common stock upon the cashless exercise of 109,952 warrant shares.

No options warrants or other potentially dilutive securities have been issued during the three months ended March 31, 2023.

XML

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2023

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

NOTE 9 – RELATED PARTY TRANSACTIONS

Doc Pharma S.A.

Prepaid expenses and other current assets – related party

As of March 31, 2023, and December 31, 2022, the Company had a prepaid balance of $4,940,863 and $3,320,345 to Doc Pharma S.A. related to purchases of inventory.

Accounts payable and accrued expenses - related party

As of March 31, 2023, and December 31, 2022, the Company had an accounts payable balance of $8,882 and $201,991.

Accounts receivable - related party

Additionally, the Company had a receivable balance of $1,886,890 and $2,070,570 from Doc Pharma S.A as of March 31, 2023, and December 31, 2022, respectively.

Sales and Purchases

During the three months ended March 31, 2023 and 2022, the Company purchased a total of $450,911 and $687,382 of products from Doc Pharma S.A., respectively. During the three months ended March 31, 2023 and 2022 the Company had $627 and $383,688 revenue from Doc Pharma S.A., respectively.

Other Agreements

On October 10, 2020, the Company entered into a contract manufacturer outsourcing (“CMO”) agreement with Doc Pharma whereby Doc Pharma is responsible for the development and manufacturing of pharmaceutical products and nutritional supplements according to the Company’s specifications based on strict pharmaceutical standards and good manufacturing practice (“GMP”) protocols as the National Organization for Medicines requires. The Company has the exclusive ownership rights for trading and distribution of its own branded nutritional supplements named “Sky Premium Life^®”. The duration of the agreement is for 5 years however either party may terminate the agreement at any time giving six-months advance notice. Doc Pharma is exclusively responsible for supplying the raw materials and packaging required to manufacture the final product. However, they are not responsible for potential delays that may arise, concerning their import. Doc Pharma is obliged to store the raw and packaging materials. The delivery of raw and packaging materials should be purchased at least 30 and 25 days, respectively, before the delivery date of the final product. The Manufacturer solely delivers the finished product to the Company. There is a minimum order quantity (“MoQ”) of 1,000 pieces per product code. Both parties have agreed that the Company will deposit 60% of the total cost upon agreement and assignment and 40% of the total cost including VAT charge upon the delivery date. The prices are indicative and are subject to amendments if the cost of the raw material or the production cost change.

For the three months ended March 31, 2023 and 2022, the Company has purchased €347,461 ($401,786) and €461,453 ($517,566), respectively, in inventory related to this agreement.

On May 17, 2021, Doc Pharma and the Company entered into a Research and Development (“R&D”) agreement whereby Doc Pharma will be responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life^®. These products will be sold in Greece and abroad. The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought in total as of December 31, 2022, 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost. No additional licenses were purchased during the 3-month period ended March 31, 2023. The agreement will be terminated on December 31, 2025.  

Loans receivable - related party

The balance of prepaid expenses due Doc Pharma SA as of December 31, 2022, had increased to €7,103,706 ($7,599,545), which was mainly attributable to the prepayments SkyPharm SA made in accordance with the CMO agreement and the extensive orders and sales of the SPL products the Company expects to achieve within 2023, mainly through its Amazon channels in the UK, Singapore, Canada and other countries. However, as the benefit from a significant portion of the prepaid balance would not have been realized within a 12-month period, the Company opted to secure a portion of the outstanding prepaid balance through a loan agreement. SkyPharm S.A. (the “Lender”) entered into a loan agreement with Doc Pharma S.A. (the “Borrower”) for €4,000,000 ($4,279,200), all of which was financed through the outstanding prepaid balance. The duration of the loan will be for a 10-year period up to December 1, 2032 (the “Maturity Date”). The loan will bear a fixed interest rate of 5.5% payable on a monthly basis and will be repayable in 120 equal instalments of €33,333.33 ($35,660). The loan may be prepaid anytime during its in full or partially based on the Company’s product requirements and other factors, without Doc Pharma incurring any prepayment penalty. As of March 31, 2023 and December 31, 2022, the loan had a current portion of €410,400 ($446,187) and €400,000 ($427,720) and a non-current portion of €3,589,600 ($3,902,613), and €3,600,000 ($3,851,280) respectively, which is classified as loans receivable – related party as of March 31, 2023. For the 3-month period ended March 31, 2023 and the Company has recorded interest income of €55,000 ($59,796) relating to this loan which had not been paid as of March 31, 2023.

Doc Pharma S.A is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma S.A. in the past.

Cana Holdings Laboratories Holding Limited 

Loans receivable - related party - long term

On February 28, 2023 (Issue Date) the Company signed a Secured Promissory Note with Cana Laboratories Holding (Cyprus) Limited (the “Holder”), whereby the Holder borrowed the sum of €4,100,000 ($4,457,520) from the Company. Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (4.77% as of March 31, 2023). The maturity date (“Maturity Date”) of this Note shall be five (5) years from the Issue Date. The Principal Amount, as well as all accrued interest shall be due and payable on the Maturity Date. During the three months ended March 31, 2023, the Company recorded interest income of €34,015 ($36,497).

Cana is considered a related party, since the Company has signed a binding letter of intent and an SPA for the acquisition of Cana. The acquisition is expected to be completed within 2023.

Panagiotis Kozaris

Prepaid expenses and other current assets - related party

From time-to-time the Company purchases back shares that Panagiotis Kozaris owns and records them as treasury shares. The Company pays Panagiotis Kozaris in advance for the shares owned and obtains the shares upon execution of a cumulative stock-purchase agreement (“SPA”). During the 3-month period ended March 31, 2023 and March 31, 2022, the Company paid Panagiotis Kozaris an additional sum of $51,159 and $0 respectively for shares owned, however, no SPA for these funds has been executed as of March 31, 2023. The Company intends to execute a cumulative SPA for these amounts during 2023. The total balances owed of $194,215 and $143,056 are included in prepaid expenses and other current assets – related party, on the accompanying condensed consolidated balance sheets as of March 31, 2023 and December 31, 2022, respectively.

Panagiotis Kozaris is considered a related party due to the fact that he is a former General operational manager and current employee of Cosmofarm SA.

Maria Kozari

Accounts receivable - related party

During 2021, the Company, through its subsidiary, Cosmofarm SA, commenced a partnership with a pharmacy called “Pharmacy & More”, owned by Maria Kozari. The transactions with the respective pharmacy were in Cosmofarm’s normal course of business, however, a more flexible credit policy was allowed as the pharmacy was new and needed to be established in the market. During the 3-month periods ended March 31, 2023 and 2022 the Company’s net sales to Pharmacy & More amounted to $118,987 and $113,621 respectively. As of March 31, 2023 and December 31, 2022 the Company’s outstanding receivable balance due from the pharmacy amounted to $867,866 (€798,258) and $760,025 (€710,436), respectively, and are included in accounts receivable - related party, on the accompanying condensed consolidated balance sheets.

Maria Kozari is considered a related party to the Company due to the fact that she is the daughter of Panagiotis Kozaris, a former Operational General Manager and current employee of Cosmofarm SA.

Notes Payable – Related Party 

A summary of the Company’s related party notes payable activity as of and for the three and twelve month periods ended March 31, 2023 and December 31, 2022 is presented below:

	March 31, 2023		December 31, 2022
Beginning balance	$	10,912	$	464,264
Payments		-		(472,920	)
Foreign currency translation		177		(19,568	)
Ending balance	$	11,089	$	10,912

Grigorios Siokas

On December 20, 2018, the €1,500,000 ($1,718,400) note payable, originally borrowed pursuant to a Loan Agreement with a third-party lender, dated March 16, 2018, was transferred to Grigorios Siokas. The note bore an interest rate of 4.7% per annum, originally matured on March 18, 2019 pursuant to the original agreement which was extended to December 31, 2021, and again to December 31, 2023. During the year ended December 31, 2022, the Note was paid in full and as of March 31, 2023 the Company had an outstanding balance of $0. As of March 31, 2023 and December 31, 2022 the Company had accrued interest of €22,891 ($24,887) and €192,891 ($206,355) outstanding related to this loan, classified under accrued interest, in the Company’s condensed consolidated balance sheets.

Grigorios Siokas is the Company’s CEO and principal shareholder.

Dimitrios Goulielmos

On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. As of March 31, 2023 and December 31, 2022, the Company had a principal balance of €10,200 ($11,089) and €10,200 ($10,912), respectively.

Dimitrios Goulielmos is a current director and former CEO of the Company.

The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2023, the Company recorded a loss of $177.

Loans Payable – Related Party

A summary of the Company’s related party loans payable during the three months ended March 31, 2023, and the year ended December 31, 2022 is presented below:

	March 31, 2023		December 31, 2022
Beginning balance	$	12,821	$	1,293,472
Proceeds		-		3,635,756
Payments		-		(4,851,678	)
Foreign currency translation		208		(64,729	)
Ending balance	$	13,029	$	12,821

Grigorios Siokas

From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of December 31, 2022, the Company had an outstanding principal balance under these loans of $12,821 in loans payable to Grigorios Siokas. As of March 31, 2023 the Company had an outstanding principal balance of $13,029.

The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2023 the Company recorded a loss of $208.

Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.

XML

LINES OF CREDIT

3 Months Ended

Mar. 31, 2023

LINES OF CREDIT

LINES OF CREDIT

NOTE 10 – LINES OF CREDIT

A summary of the Company’s lines of credit as of March 31, 2023 and December 31, 2022 is presented below:

	March 31, 2023		December 31, 2022
National	$	2,383,647	$	3,103,605
Alpha		803,142		991,492
Pancreta		1,093,420		1,232,128
EGF		430,105		431,512
Ending balance	$	4,710,314	$	5,758,737

The line of credit with National Bank of Greece is renewed annually with current interest rates of 6.00%, 4.35% (“COSME 2” facility), and 4.35% plus the 6-month Euribor plus any contributions currently in force by law on certain lines of credit (“COSME 1” facility).

The maximum borrowing allowed for the 6% line of credit was $3,234,420 and $3,182,655 as of March 31, 2023 and December 31, 2022, respectively. The outstanding balance of the facility was $1,471,908 and $2,118,952, as of March 31, 2023 and December 31, 2022, respectively.

The maximum borrowing allowed for the COSME 1 and COSME 2 lines of credit, was $1,087,200 and $1,069,800 as of March 31, 2023 and December 31, 2022, respectively. The outstanding balance of the facilities was $911,739 and $984,653 as of March 31, 2023 and December 31, 2022, respectively. 

The line of credit with Alpha Bank of Greece is renewed annually with a current interest rate of 6.00%. The maximum borrowing allowed was $1,087,200 and $1,069,800 as of March 31, 2023 and December 31, 2022, respectively. The outstanding balance of the facility was $803,142 and $991,429, as of March 31, 2023 and December 31, 2022, respectively.

The Company entered into a line of credit with Pancreta Bank on February 23, 2021. The line of credit is renewed annually with a current interest rate of 6.10%. The maximum borrowing allowed as of March 31, 2023 and December 31, 2022 was $1,511,208 and $1,487,022, respectively. The outstanding balance of the facility as of March 31, 2023 and December 31, 2022 was $1,093,420 and $1,232,128, respectively.

The Company entered into a line of credit with EGF on June 6, 2022. The line of credit is renewed annually with a current interest rate of 4.49%. The maximum borrowing allowed as of March 31, 2023 and December 31, 2022 was $434,880 and $427,920, respectively. The outstanding balance of the facility as of March 31, 2023 and December 31, 2022 was $430,105 and $431,512, respectively.

Under the agreements, the Company is required to maintain certain financial ratios and covenants. As of March 31, 2023 and December 31, 2022, the Company was in compliance with these ratios and covenants.

The above lines of credit are guaranteed and backed by customer receivable checks. They are a type of factoring, where the postponed customer checks are assigned by the Company to the bank, in order to be financed at a pre-agreed rate.

Interest expense for the three-months ended March 31, 2023 and 2022, was $19,435 and $17,175, respectively.

XML

CONVERTIBLE DEBT

3 Months Ended

Mar. 31, 2023

CONVERTIBLE DEBT

CONVERTIBLE DEBT

NOTE 11 – CONVERTIBLE DEBT

A summary of the Company’s convertible debt activity as of and for the 3 and 12 months ended March 31, 2023 and December 31, 2022 is presented below:

	March 31, 2023			December 31, 2022
Beginning balance convertible notes	$	100,000		$	640,000
Payments		(100,000	)		(525,000	)
Conversion to common stock		-			(15,000	)
Convertible notes payable	$	-		$	100,000

December 21, 2020 Securities Purchase Agreement

On December 21, 2020 the Company entered into a convertible promissory note with Platinum Point Capital, LLC (the “Holder”, “Lender” or “Platinum”) pursuant to a Securities Purchase Agreement (the “SPA”).

The Company issued the $540,000 Note in exchange for $500,000 in cash and included a $40,000 Original Issue Discount (“OID”) and paid $3,000 in financing costs. The principal amount together with interest at the rate of eight percent (8.0%) per annum, compounded annually (the “Interest Rate”), will be paid to the Lenders on or before the Maturity Date (December 31, 2021 or as defined below). Accrued interest shall be calculated on the basis of a 360-day year for the actual number of days elapsed. In the event that on or before the Maturity Date, the Note either (i) had not been converted or have not been otherwise satisfied in full or (ii) an Event of Default (as defined in the SPA) occurs, then the applicable rate of interest on the outstanding amount of the Note since inception shall be the Interest Rate plus eighteen percent (18.0%), the Default Interest. Unless previously converted, the principal and accrued interest on the Note is due and payable in cash (USD) upon the earlier of (i) December 31, 2021, (ii) a Change of Control (as defined in the SPA) or (iii), an Event of Default (collectively, the “Maturity Date”).

On May 1, 2022 the Company issued 1,574 shares of common stock to convert the outstanding principal and accrued interest balance of $26,515 to equity. Following the conversion, the outstanding balance of the above Note is $0. Upon conversion, the 1,574 shares were issued at a fair value of $38,144 which was recorded as equity. Accordingly, upon conversion, the Company reduced its derivative liability by $11,629.

The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a derivative liability which is accounted for separately. The Company determined a derivative liability exists and determined that the embedded derivative was valued at $456,570 which was recorded as a debt discount, and together with the original issue discount and transaction expenses of $43,000, in the aggregate of $499,570, is being amortized over the life of the loan. As of December 31, 2022 the full amount of the debt discount has been amortized. Therefore, as of March 31, 2023 and December 31, 2022, the fair value of the derivative liability was $0. For the three months ended March 31, 2023 and 2022, the Company recorded a loss on the change in fair value of the derivative of $0 and a gain of $1,873, respectively.

January 7, 2021 Subscription Agreement

On January 7, 2021 (the “Issue Date”), the Company entered into a subscription agreement with an unaffiliated third party, whereby the Company issued for a purchase price of $100,000 in principal amount, a convertible promissory note. The note bore an interest rate of 8% per annum and originally matured on the earlier of (i) consummation of the Company listing its common shares on the NEO Stock Exchange or (ii) October 31, 2021.

However, the listing to NEO Stock Exchange did not occur. As of December 31, 2022, the Company had a principal balance of $100,000 and had accrued $13,740 in interest expense. During the three months ended March 31, 2023, the Company paid the balance in full.

The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a derivative liability which is accounted for separately. The Company measured the embedded derivative valued at $62,619 which was recorded as a debt discount and additional paid-in capital and was being amortized over the life of the loan. As of December 31, 2022, the debt discount had been fully amortized. As of March 31, 2023 and December 31, 2022, the fair value of the derivative liability was $0 and $54,293, respectively. For the three months ended March 31, 2023 and 2022, the Company recorded a loss of $3,384 and a gain of $13,128, respectively, from the change in fair value of derivative liability as other income in the condensed consolidated statements of operations and comprehensive loss.

The Company considered both the note payable and conversion feature separately and upon settlement. The Company re-valued the conversion feature to fair value and applied extinguishment accounting as the debt has now been settled. Because the conversion feature is extinguished upon settling the note, the value of the conversion feature goes though debt extinguishment debt and the Company recorded a gain on settlement of debt. During the three months ended March 31, 2023, the Company recorded a gain on extinguishment of debt of $50,909.

Convertible Promissory Note and Securities Purchase Agreement

On September 17, 2021 (the “Issue Date”), the Company entered into a convertible promissory note and securities purchase agreement with an unaffiliated third party.

The Company issued the convertible promissory note for a purchase price of $525,000 in principal amount for cash proceeds of $500,000. The note was issued with an original issue discount (“OID”) of $25,000, bears an interest rate of 10% per annum and matures on the earlier of (i) the consummation of the Company listing its common shares on the Nasdaq Stock Market or (ii) September 17, 2022.

Upon the consummation of our Nasdaq listing in 2022, the total principal and accrued interest outstanding on the note would convert into shares of the Company’s common stock at a 30% discount to the prices of the common shares sold in the financing to be conducted in conjunction with our Nasdaq listing, subject to a conversion floor of $75.00. However, the Company, upon agreement with the third party, did not convert the note and fully repaid it in cash on October 21, 2022.

As of December 31, 2022, the Company repaid the remaining outstanding balance of the note and thus its outstanding balance as of the end of the period was $0. For the three months ended March 31, 2023 and 2022, the Company recorded amortization of debt discount in the amount of $0 and $127,916, respectively, which is included in non-cash interest expense on the accompanying condensed statements of operations and comprehensive loss.

Derivative Liabilities

The table below provides a summary of the changes in fair value, including net transfers in and/or out of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2023:

	Amount
Balance on January 1, 2023	$	54,293
Reduction of derivative related to conversions		(50,909	)
Change in fair value of derivative liabilities		(3,384	)
Balance on March 31, 2023	$	-

The fair value of the derivative conversion features and warrant liabilities as of December 31, 2022 was calculated using a Monte-Carlo option model valued with the following assumptions:

	December 31,
	2022
Dividend yield		0	%
Expected volatility	87.9%-157.2
Risk free interest rate	1.46%-3.75
Contractual terms (in years)	1.25 - .75

XML

DEBT

3 Months Ended

Mar. 31, 2023

DEBT

DEBT

NOTE 12 – DEBT

A roll forward of the Company’s third-party debt for the three months ended March 31, 2023 is presented below:

March 31, 2023	Trade Facility			Third Party			COVID Loans			Total
Beginning balance 12/31/22	$	3,305,532		$	1,505,078		$	207,377		$	5,017,987
Payments		(1,153,365	)		(86,561	)		(5,096	)		(1,245,022	)
Debt forgiveness		(306,637	)		-			-			(306,637	)
Foreign currency translation		29,890			11,409			1,879			43,178
Ending balance 3/31/23		1,875,420			1,429,926			204,160			3,509,506
Notes payable - long-term		(1,549,260	)		(1,002,288	)		(176,000	)		(2,727,548	)
Notes payable - short-term	$	326,160		$	427,638		$	28,160		$	781,958

Our outstanding debt as of March 31, 2023, is repayable as follows:
	March 31,  2023
2023	$	802,622
2024		806,824
2025		1,613,928
2026		174,947
2027 and thereafter		111,185
Total debt		3,509,506
Less: notes payable–- current portion		(781,958	)
Notes payable–- long term portion	$	2,727,548

Loan Facility Agreement

On August 4, 2021, the Company entered into an exchange agreement for the existing loan facility agreement with Synthesis Peer-to-Peer Income Fund, whereby the Company agreed to the following:

• Issue on August 4, 2021, 12,852 shares of common stock to settle $1,606,500 (€1,350,000) of debt. The Company recorded a gain on settlement of $292,383 upon the issuance of the 12,852 shares; and

• Agreed to issue no more than 9,520 shares of common stock upon approval of the listing of the Company’s common stock on Nasdaq to settle $1,190,000 (€1,000,000) of debt. The Company issued these shares on February 28, 2022. Upon issuance of the 9,520 shares of common stock, the Company recorded a gain on extinguishment of debt in the amount of $216,580 determined using the fair value of the Company’s common stock at the commitment date of $102.25 per share.

The Company incurred non-cash interest expense of $6,642 during the period ended December 31, 2022 concerning the debt extinguishment. The principal debt balance was paid in full during the year ended December 31, 2022. As of March 31, 2023 and December 31, 2022, the outstanding principal balance on the debt was $0, and had accrued interest expense of $18,527 and $12,853, respectively.

Trade Facility Agreements

On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “TFF”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”) as amended on November 16, 2017, and May 16, 2018.

On October 17, 2018, the Company entered into a further amended agreement with Synthesis whereby the current balance on the TFF as of October 1, 2018, which was €4,866,910 ($5,629,555) and related accrued interest of €453,094 ($524,094) would be split into two principal balances of Euro €2,000,000 ($2,316,000), (the "EURO Loan") and USD $4,000,000, the "USD Loan". Interest on both the EURO Loan and USD Loan commenced on October 1, 2018, at 6% per annum plus one-month Euribor (2.49% as of March 31, 2023), and 6% plus one-month LIBOR (4.77% as of date of March 31, 2023), respectively.

On December 30, 2020, the Company transferred the EURO Loan to a new third-party lender. The terms remained the same except interest accrues at 5.5% per annum plus one-month Euribor (2.49% as of March 31, 2023). The principal was scheduled to be repaid in a total of five quarterly installments beginning October 31, 2021 of €50,000 ($54,360) each with a final repayment of €1,800,000 ($1,956,960) Euro payable on October 31, 2022.

On March 3, 2022, the Company entered into a modification agreement to extend the maturity date to January 10, 2023 and payments under the USD Loan. During June 2022, the Company agreed with the Lender to postpone the repayment of an installment of $500,000 due on June 30, 2022 (based on the modification agreement signed on March 3, 2022) until January 2023. During September 2022, the Company agreed with the Lender to postpone the repayment of the outstanding balance on the USD Loan of $3,950,000, plus unpaid accrued interest until January 2023. The Company capitalized fees paid upon modification of €200,000 ($221,060) that are being amortized over the life of the loan. The Company incurred non-cash interest expense of $23,820 during the three-month period ended March 31, 2022 concerning the above capitalized fees.

During the year ended December 31, 2022, the Company repaid €175,000 ($187,215) of the EURO Loan and $2,593,363 of the USD Loan such that as of December 31, 2022, the Company had principal balances of €1,775,000 ($1,898,895) and $1,406,637 under the agreements, respectively. As of March 31, 2022, the Company had accrued $81,813 in interest expense related to these agreements. 

On December 21, 2022 the USD Loan was assigned to GIB Fund Solutions ICAV (the “Fund”). On January 31, 2023, the Company paid $1,100,000 to the Fund under a full and final settlement agreement for the USD Loan, recording a gain on extinguishment of debt of $306,637 relating to the waiver of the unpaid balance. Additionally, the Company repaid €50,000 ($54,360) of the EURO Loan during the 3-month period ended March 31, 2023. As of March 31, 2023 the Company had an outstanding principal balance of €1,725,000 ($1,875,420), of which $1,549,260 is classified as notes payable-long term on the condensed consolidated balance sheets. As of March 31, 2023, the Company had accrued $14,380 in interest expense related to these agreements.

On December 22, 2022, Skypharm SA signed an agreement for the extension of the payments and an increase in interest rate due under the EURO loan, that was extended to be repaid with a balloon payment now due on October 31, 2025. This extension was agreed upon in writing on December 22, 2022 with a retroactive modification date to October 31, 2022 (the original maturity date). 

Third Party Debt

On November 16, 2015, the Company entered into a Loan Agreement with Panagiotis Drakopoulos, the Company’s former Director and former Chief Executive Officer, pursuant to which the Company borrowed €40,000 ($42,832) as a note payable from Mr. Drakopoulos. The note bore an interest rate of 6% per annum and was due and payable in full on November 15, 2016. As of December 31, 2022, the Company had an outstanding principal balance of €8,000 ($8,558) and accrued interest of €6,797 ($7,271). During the three months ended March 31, 2023, the Company paid the outstanding balance of €8,000. Therefore, as of March 31, 2023, the balance due is $0. Mr Drakopoulos is not considered a related party since he is no longer employed by the Company and currently holds no equity position in the Company.

May 18, 2020, July 3, 2020, and August 4, 2020 Senior Promissory Notes

Modification of May 18, 2020, July 3, 2020, and August 4, 2020 Senior Promissory Notes

On February 23, 2022, the Company entered into modification agreements to extend the due dates of the May 18 Note, July 3 Note, and August 4 Note to June 30, 2023 of $9,000,000, in the aggregate. The Company paid restructuring fees totaling $506,087 upon modification. The Company determined the modification should be recorded as debt extinguishment in accordance with ASC 470 because the present value of the remaining cash flows under the terms of the new debt instrument is at least 10% different from the present value of the remaining cash flows under the terms of the original instrument. The Company recorded the new debt at fair value in the amount of $7,706,369 and a gain upon extinguishment in the amount of $787,544. During the year ended December 31, 2022, the Company repaid the aggregate principal balance of $7,000,000 and the aggregate accrued interest related to these notes in full. During the three months ended March 31, 2022 the Company recorded non-cash interest expense in the amount of $89,275 for the amortization of debt issuance costs.

June 23, 2020 Debt Agreement

On June 23, 2020, the Company’s subsidiary, Cosmofarm, entered into an agreement with the “National Bank of Greece SA” (the “Bank”) to borrow a maximum of €500,000 ($611,500). The note has a maturity date of sixty (60) months from the date of the first disbursement, which includes a grace period of nine months. The total amount of the initial proceeds was paid in 3 equal monthly installments. The note is interest bearing from the date of receipt and is payable every three (3) months at an interest rate of 3.06% plus 3-month Euribor  (2.78% as of March 31, 2023). The outstanding balance was €294,118 ($319,765) and €323,529 ($346,112) on March 31, 2023 and December 31, 2022, respectively of which $191,859 and $220,253, is classified as Notes payable - long-term portion respectively, on the accompanying condensed consolidated balance sheets. During the three months ended March 31, 2023, the Company repaid €29,412 ($31,976) of the principal balance.

November 19, 2020 Debt Agreement

On November 19, 2020, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($611,500). The note matures on November 18, 2025 and bears an annual interest rate, based on a 360-day year, of 3.3% plus .6% plus 6-month Euribor when Euribor is positive. The principal is to be repaid in 18 quarterly installments of €27,778 ($30,210).  During the year ended December 31, 2022, the Company repaid €111,111 ($118,867) of the principal and as of December 31, 2022, the Company had accrued interest of $8,069 related to this note and a principal balance of €333,333 ($356,600), of which $237,733 is classified as Notes payable – long term portion on the accompanying condensed consolidated balance sheet. During the three months ended March 31, 2023, the Company repaid €27,778 ($30,200) of the principal and as of March 31, 2023, the Company has accrued interest of €2,516 ($2,735) related to this note and a principal balance of €305,556 ($332,200), of which $211,400 is classified as Notes payable – long term portion on the accompanying condensed consolidated balance sheet.

July 30, 2021 Debt Agreement

On July 30, 2021, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($578,850). The note matures on August 5, 2026 and bears an annual interest rate that applies to 60% of the principal of the note that is based on a 365-day year, of 5.84% plus 3-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a nine-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 18 quarterly installments of €27,778 commencing three months from the end of the grace period. During the year ended December 31, 2022, the Company repaid €77,985 ($83,428) of the principal balance. As of December 31, 2022, the Company had accrued interest of €2,509 ($2,728) and a principal balance of €422,016 ($451,472), of which $336,788 is classified as notes payable – long term portion on the accompanying condensed consolidated balance sheet. During the three months ended March 31, 2023, the Company repaid €26,451 ($28,758) of the principal. As of March 31, 2023, the Company has accrued interest of €4,136 ($4,947) and principal of €395,564 ($430,057), of which $312,520 is classified as Notes payable – long term portion on the accompanying condensed consolidated balance sheet.

June 9, 2022 Debt Agreement

On June 9, 2022 the Company entered into an agreement with a third-party lender in the principal amount of €320,000 ($335,008), the “Note”. The Note matures on June 16, 2027 and bears an annual interest rate of 3.89% plus an additional rate of 0.60%, plus the 3-month Euribor (2.78% as of March 31, 2023). Pursuant to the agreement, there is a twelve-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 17 equal quarterly installments of €18,824 commencing on June 30, 2023. As of March 31, 2023 and December 31, 2022 the Company has accrued interest of €3,532 ($3,840) and €7,707 ($8,379), respectively, and an outstanding balance of €320,000 ($347,904), of which $286,509 and $281,924, respectively, is classified as Notes payable – long term portion on the accompanying condensed consolidated balance sheets.

August 29, 2022 Promissory Note

On August 29, 2022, the Company entered into a promissory note for the principal amount of $166,667. The Company received $150,000 in cash and recorded $16,667 as an original issue discount upon issuance. The promissory note matures on the earlier of (a) December 27, 2022, or (b) the date the Company completes a debt or equity financing of at least $1,000,000. The debt carried an annual interest rate of 12% which was due upon maturity. As of December 31, 2022, the Company had repaid the principal balance in full and had a balance of $5,041 in accrued interest related to this note. The Company repaid the outstanding interest during the 3-month period ended March 31, 2023 and thus the balance of both principal and interest as of March 31, 2023 is $0.

COVID-19 Loans

On May 12, 2020, the Company’s subsidiary, SkyPharm, was granted and on May 22, 2020 received a €300,000 ($366,900) loan from the Greek government. The loan will be repaid in 40 equal monthly installments beginning on July 29, 2022. As a condition to the loan, the Company was required to retain the same number of employees until October 31, 2020. As of December 31, 2022, the principal balance was $150,441. During the three months ended March 31, 2023, the Company repaid €4,688 ($5,096) of the principal balance.  The outstanding balance as of March 31, 2023 is €135,938 ($147,791).

On June 24, 2020, the Company received a loan £50,000 ($68,310) from the United Kingdom government. The loan has a ten-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement, which was on July 10, 2020. The Company may prepay this loan without penalty at any time. As of December 31, 2022, the principal balance was £47,144 ($56,936). As of March 31, 2023, the principal balance was £45,573 ($56,369).

None of the above loans were made by any related parties.

XML

LEASES

3 Months Ended

Mar. 31, 2023

LEASES

LEASES

NOTE 13 – LEASES

The Company has various operating and finance lease agreements with terms up to 10 years, for various types of property and equipment (such as office space and vehicles) etc. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised.

The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet.

The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the average interest rate of our long-term debt on the date of inception.

Operating Leases

The Company’s weighted-average remaining lease term relating to its operating leases is 5.23 years, with a weighted-average discount rate of 6.74%.

The Company incurred lease expense, due to amortization of operating lease right-of-use assets, of $55,354 and $54,124 which was included in “General and administrative expenses,” for the three months ended March 31, 2023 and 2022, respectively.

The following table presents information about the amount and timing of cash flows arising from the Company’s operating leases as of March 31, 2023:

Maturity of Operating Lease Liability:
2023	$	197,540
2024		264,035
2025		190,379
2026		153,712
Thereafter		581,964
Total undiscounted operating lease payments	$	1,387,630
Less: Imputed interest		(272,107	)
Present value of operating lease liabilities		1,115,523

Finance leases

The Company’s weighted-average remaining lease term relating to its finance leases is 3.34 years, with a weighted-average discount rate of 6.74%, based on the interest rate implicit in the lease.

The following table presents information about the amount and timing of cash flows arising from the Company’s finance leases as of March 31, 2023:

Maturity of Finance Lease Liability
2023	$	112,406
2024		133,861
2025		103,586
2026		77,014
Thereafter		23,474
Total undiscounted finance lease payments	$	450,341
Less: Imputed interest		(47,400	)
Present value of finance lease liabilities	$	402,941

The Company incurred interest expense on its finance leases of $6,219 and $3,507 which was included in “Interest expense”, on the accompanying condensed statements of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, respectively. The Company incurred amortization expense on its finance leases of $30,710 and $19,580, which was included in “Depreciation and amortization expense”, on the accompanying condensed statements of operations and comprehensive loss for the three months ended March 31, 2023 and 2022, respectively. The total cash used for the Company’s finance leases for the three months ended March 31, 2023 and March 31, 2022 amounted to $35,596 and $22,622 respectively and is solely related to lease payments.

XML

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2023

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

NOTE 14 – COMMITMENTS AND CONTINGENCIES

Legal Matters

From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of March 31, 2023, the following litigation matters were pending. None of the below is expected to have a material financial or operational impact.

Solgar Inc, a competitor of the Company, sued SkyPharm SA for product homogeneity regarding the nutraceutical line “Sky Premium Life”. As a result, Solgar requested the prohibition for SkyPharm to manufacture, import and sell, market or in any way possess and distribute, including internet sales and advertise in any way in the Greek market of “Sky Premium Life” due to homogeneity with Solgar’s products. Solgar Inc. has further requested to be awarded compensation for non-pecuniary damage amounting to €20,000 ($21,744). The case was heard on January 28, 2022, and the decision numbered 8842/2022 of the court of Thessaloniki was issued, which, accepted our claims and dismissed the Solgar’s Inc. lawsuit.

On July 22, 2015, the National Medicines Agency approved the license of wholesale sale of pharmaceutical products under the name SkyPharm SA with set validity at five years and an expiration date of July 22, 2020. Subsequently, SkyPharm SA on June 15, 2020, legally and timely submitted the application for renewal of the wholesale license of pharmaceutical products to the National Medicines Agency. The National Medicines Agency did not respond, therefore the Company asked for an immediate decision on the renewal. Two months after the filing of no. 3459 / 15.01.2021 letter and almost nine months after the no. 627615.06.2020 company application for the renewal, the National Medicines Agency replied by rejecting the renewal request on March 9, 2021 (ref. 62769 / 20-25.02.2021). In addition, document No. 127351-16.12.2021 of EOF (Greek National Medicines Organization) to SkyPharm states that after an inspection of EOF at the premises of Doc Pharma, we did not have a wholesale license in violation of article 106 par. 1b and par. 1c of the ministerial decision D.YG3a / GP.32221 / 29-4-2019. The National Medicines Agency has not yet provided update on the implications of the renewal’s rejection.

There has been a payment request by the Greek court, which relates to a fine arising from Cosmofarm’s SA tax audit for financial year 2014. The law with no. 483/16.12.2020 was used by the court against Cosmofarm SA (the “defendant”). The defendant appealed against the decision using the law with no.11541/09.03.2021. This appeal was dismissed after 120 days from its submission to the court. Additionally, there had been an obligation for payment of additional tax and fines related to this matter in the amount of €91,652 ($99,644), which the defendant has already settled. However, the defendant has claimed back the respective amount through appeal. As of March 31, 2023, the trial is still pending.

Advisory Agreements

On July 1, 2021, the Company entered into a two-year advisory agreement with a third party (the “Consultant”) for advisory and consulting services related to the Company’s intention to become listed on Nasdaq. Peter Goldstein, a then director of the Company is a principal of the Consultant. As consideration for services rendered, and successful Nasdaq listing, the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023.

Research and Development Agreements

On June 26, 2022, the Company signed a research and development (R&D) agreement with a third party, through which the Company assigns to the third party the development of new products and services in the field of health, focusing on the human intestinal microbiome. The cost of the projects amount to EUR 820,000 ($891,504) which is allocated to certain phases. The amount will be due and payable upon completion of the corresponding phases. The Company records the corresponding R&D expense based on the project’s progress, which is actually invoiced by the third party in the relevant period. No such costs were incurred for the 3-month period ended March 31, 2023 or 2022.

XML

WARRANTS

3 Months Ended

Mar. 31, 2023

WARRANTS

WARRANTS

NOTE 15 – WARRANTS

Omnibus Equity Incentive Plan

On September 19, 2022 the Company held a Board of Directors meeting, whereas, the Board of Directors had elected to adopt an Omnibus Equity Incentive Plan (the “Plan”), that includes reserving 200,000 shares of common stock eligible for issuance under the Plan to be registered on a Form S-8 Registration Statement with the SEC. The Plan is designed to enable the flexibility to grant equity awards to the Company’s officers, employees, non-employee directors and consultants and to ensure that it can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. According to the Proxy Statement filed with the SEC on October 20, 2022 the Plan received final approval by the Company’s stockholders at the Annual Meeting of Stockholders held on December 2, 2022.

Warrants 

As of March 31, 2023, there were 4,194,236 warrants classified within equity outstanding and 4,194,236 warrants exercisable with 4,180,902 warrants having expiration dates from May 2023 through December 2027 and 13,334 warrants with no expiration date.

A summary of the Company’s warrant activity during the three months ended March 31, 2023 is presented below:

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
Warrants	Shares		Price		Term		Value
Balance outstanding, January 1, 2023		4,194,236	$	8.31		5.04	$	2,562,600
Balance outstanding, March 31, 2023		4,194,236	$	8.31		4.80	$	913,209
Exercisable, March 31, 2023		4,194,236	$	8.31		4.80	$	913,209

XML

DISAGGREGATION OF REVENUE

3 Months Ended

Mar. 31, 2023

DISAGGREGATION OF REVENUE

DISAGGREGATION OF REVENUE

NOTE 16 – DISAGGREGATION OF REVENUE

ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc.). ASC 606-10-55-89 explains that the extent to which an entity’s revenue is disaggregated depends on the facts and circumstances that pertain to the entity’s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue.

The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue.

The following table presents our revenue disaggregated by country for the three months ended:

	March 31,		March 31,
Country	2023		2022
Greece		11,914,231		13,009,038
Cyprus		33,315
UK		402,231		51,426
Croatia		-		11,336
Total	$	12,349,777	$	13,071,800

XML

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2023

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

NOTE 17 – SUBSEQUENT EVENTS

Acquisition of a Telehealth Company

On March 17, 2023, the Company announced that it has entered into a definitive agreement to acquire ZipDoctor Inc., a telehealth company for a total sum of $150,000, settled in cash. The Sale and Purchase Agreement (“SPA”) was signed on March 17, 2023, and the transaction closed on April 3, 2023.

Purchase of Building

On May 3, 2023, the Company acquired the entire property which houses the operations of its wholly owned subsidiary CosmoFarm Pharmaceuticals ("CosmoFarm"). The property comprises a 3-story building, that is 2,700 square meters (or approximately 29,063 square feet) in size. The purchase price was €966,000 (or approximately $1,068,000).

Conclusion of Stock Purchase Agreement

On May 8, 2023, the Company entered into a Stock Purchase Agreement with the owners of one hundred (100%) percent of the equity (the “Shares”) of Pharmaceutical Laboratories Cana S.A. (“Cana Holdings”).  The Purchase Price of the Shares is €800,000 ($869,760) and 46,377 shares of Cosmos restricted common stock at an issuance price of $17.25 per share or $800,000 for a total purchase price of $1,669,760.

Cana Holdings is a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.

As previously described on February 28, 2023, the Company issued a €4,100,000 ($4,497,017) five-year senior secured promissory note, classified as loans receivable - related party on the accompanying condensed consolidated balance sheet, to Cana Holdings.  The closing of this transaction is conditioned upon: (i) the satisfactory completion of due diligence; (ii) delivery of auditors’ financial statements of Cana Holdings as of December 31, 2022; (iii) receipt by the Company of all required approvals, covenants and waivers; (iv) indebtedness of Cana Holdings shall not exceed €1,000,000 ($1,087,200) (exclusive of the Note); (v) payment of the Purchase Price and delivery of the Shares; (vi) no material adverse changes in the business of Cana Holdings; and (vii) customary closing conditions.

XML

ORGANIZATION NATURE OF BUSINESS AND GOING CONCERN (Policies)

3 Months Ended

Mar. 31, 2023

ORGANIZATION NATURE OF BUSINESS AND GOING CONCERN

Going Concern

The Company’s consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplates the continuation of the Company as a going concern. For the three months ended March 31, 2023, the Company had revenue of $12,349,777, net loss of $459,863 and net cash used in operations of $6,403,186. Additionally, as of March 31, 2023, the Company had positive working capital of $32,083,333, an accumulated deficit of $66,692,676, and stockholders’ equity of $44,007,783. Concerns exist regarding the Company’s ability to meet its obligations as they become due. The Company is subject to a number of risks to those of smaller commercial companies, including dependence on key individuals and products, the difficulties inherent in the development of a commercial market, the need to obtain additional capital, competition from larger companies, and other pharmaceutical and health care companies. Management evaluated the above conditions which raise substantial doubt about the Company’s ability to continue as a going concern to determine if it can meet its obligations for the subsequent twelve months from the date of this report. Management considered its ability to access future capital, curtail expenses if needed, expand product lines, and acquire new products. Based on the management’s evaluations, it has devised a plan in order to meet its obligations for the next twelve months. Management’s plans include expansion of brand name products to the market, expanding the current product portfolio, and evaluating acquisition targets to expand distribution. Furthermore, the Company intends to vertically integrate the supply chain distribution network and additionally intends to utilize its strong cash position as of March 31, 2023, in order to sufficiently fund its operations. Finally, the Company plans to access the capital markets further in order to raise additional funds through equity offerings. It is management’s conclusion that these plans above, collectively, alleviate the conditions that raised substantial doubt about the Company’s ability to continue as a going concern. Therefore, it is determined that no substantial doubt exists about the Company’s ability to continue as a going concern for a period of twelve months from the date of this filing. Summary of Significant Accounting Policies

Basis of Financial Statement Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP.

Principles of Consolidation

Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated.

Transactions in and Translations of Foreign Currency

The functional currency for the Greek subsidiaries of the Company (Cosmofarm SA and SkyPharm SA) is EURO (€) and for the UK subsidiary (Decahedron Ltd) is GBP (£). As a result, the financial statements of the subsidiaries have been transferred from the local currency into US dollars using (i) year-end exchange rates for balance sheet accounts, and (ii) average exchange rates for the reporting period for all income statements accounts. Foreign currency translations gains and losses are reported as a separate component of the condensed consolidated statements of changes in stockholders’ equity and mezzanine equity.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The Effects of COVID-19

Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur, and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

The Effects of War in the Ukraine

On February 24, 2022, Russian forces launched significant military action against Ukraine. There continues to be sustained conflict and disruption in the region, which is expected to endure for the foreseeable future. We do not conduct any commercial transactions with either Ukraine or Russia and the Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. Such political issues and conflicts could have a material adverse effect on our results of operations and financial condition if they escalate in areas in which we do business. In addition, changes in and adverse actions by governments in foreign markets in which we do business could have a material adverse effect on our results of operations and financial condition.

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of March 31, 2023 and December 31, 2022, there were $6,995,287 and $0 held in Treasury bills with a maturity of less than 3 months.

The Company maintains bank accounts in the United States denominated in U.S. Dollars, in Greece denominated in Euros, U.S. Dollars and Great Britain Pounds (British Pounds Sterling), and in Bulgaria denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling).

Account receivable, net

Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables’ portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. As of March 31, 2023 and December 31, 2022, the Company’s allowance for doubtful accounts was $7,614,237 and $7,309,311, respectively.

Tax Receivables

The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. As of March 31, 2023 and December 31, 2022, the Company had a VAT net receivable balance of $243,424 and a net payable balance of $79,373 respectively, recorded in the condensed consolidated balance sheet as prepaid expenses and other current assets and accounts payable and accrued expenses, respectively.

Inventory

Inventory is stated at the lower-of-cost or net realizable value using the weighted average FIFO method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment.

The Company writes down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met.

Property and Equipment, net

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows:

	Estimated Useful Life
Leasehold improvements and technical works	Lesser of lease term or 40 years
Vehicles	6 years
Machinery	20 years
Furniture, fixtures and equipment	5–10 years
Computers and software	3-5 years

Depreciation expense was $65,629 and $84,884 for the three months ended March 31, 2023 and 2022, respectively.

Goodwill and Intangibles, net

The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. First, under step 0, we determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying amount. Following, if step 0 fails, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit.

On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill.

Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for its pharmaceuticals and nutraceuticals products license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of March 31, 2023, no revision to the remaining amortization period of the intangible assets was made.

Amortization expense was $21,058 and $8,158 for the three months ended March 31, 2023 and 2022, respectively.

Impairment of Long-Lived Assets

In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.

Equity Method Investment

For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company will record its share in the earnings of the investee and will include it within the condensed consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value. See Note 3, for additional detail.

Investments in Equity Securities

Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for use in current operations are reported as a component of current assets in the accompanying condensed consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying condensed consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment.

As of March 31, 2023, investments consisted of (i) 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp and (ii) 16,666 shares which traded at a closing price of $0.49 per share or value of $8,099 of National Bank of Greece. Additionally, the Company has $8,333 in equity securities of Pancreta Bank, which are revalued annually.  

Fair Value Measurement

The Company applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

The following tables presents assets that are measured and recognized at fair value as of March 31, 2023 and December 31, 2022, on a recurring basis:

	March 31, 2023						Total Carrying
	Level 1		Level 2		Level 3		Value
Marketable securities – Pancretan Bank	$	8,334		-		-	$	8,334
Marketable securities – National Bank of Greece		8,099		-		-		8,099
	$	16,433					$	16,433

	December 31, 2022						Total Carrying
	Level 1		Level 2		Level 3		Value
Marketable securities – Pancretan Bank	$	8,200		-		-	$	8,200
Marketable securities – National Bank of Greece		6,681		-		-		6,681
	$	14,881					$	14,881

In addition, ASC 825-10-25, Fair Value Option, (“ASC 825-10-25”), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.

Derivatives Instruments

Derivative financial instruments are recorded in the accompanying condensed consolidated balance sheets at fair value in accordance with ASC 815. When the Company enters into a financial instrument such as a debt or equity agreement (the “host contract”), the Company assesses whether the economic characteristics of any embedded features are clearly and closely related to the primary economic characteristics of the remainder of the host contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the host contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument, then the embedded feature is bifurcated from the host contract and accounted for as a derivative instrument. The estimated fair value of the derivative feature is recorded in the accompanying condensed consolidated balance sheets separately from the carrying value of the host contract. Subsequent changes in the estimated fair value of derivatives are recorded as a gain or loss in the Company’s condensed consolidated statements of operations and comprehensive loss.

Customer Advances

The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company’s products. The Company records these receipts as customer advances until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer advances balance and credit the Company’s revenues.

Revenue Recognition

In accordance with ASC 606, Revenue from Contracts with Customers, the Company uses a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, including the constraint on variable consideration, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon transfer of the product to the customer.

Commencing from January 1, 2023, and pursuant to the agreement with Medihelm, the exclusive distributor of the Company’s own proprietary line of nutraceuticals, the Company considers the transaction price to be variable and records an estimate of the transaction price, subject to the constraint for variable consideration. The Company is basing the change in transaction price with the exclusive distributor through assessment of significant overdue receivables from the exclusive distributor, which the Company reassessed during the 3-month period ended March 31, 2023. Essentially, the Company applies the “expected value” model under ASC 606-10-32-5 and has applied specific constraints to revenue due from the customer at the end of each reporting period. Following the application of the “expected value” model the Company deferred an amount of $112,515 and recorded it against the sales to Medihelm for the three-month period ended March 31, 2023. The Company does not consider that sales to any other customer include a variable component as of March 31, 2023.

Stock-based Compensation

The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (“ASC 718”) and Staff Accounting Bulletin No. 107 (“SAB 107”) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model.

The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, “Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.”

Foreign Currency Translations and Transactions

Assets and liabilities of all foreign operations are translated at period-end rates of exchange, and amounts included in the accompanying condensed statements of operations and comprehensive income (loss) are translated at the average rates of exchange for the period. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ equity (deficit) until the entity is sold or substantially liquidated.

Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss).

Income Taxes

The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 19% in the United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership.

We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets.

Retirement and Termination Benefits

Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee’s work experience and renumeration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability.

Basic and Diluted Net Loss per Common Share

Basic income per share is calculated by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding.

The following table summarizes potential common shares that were excluded as their effect is anti-dilutive:

	March 31, 2023		March 31, 2022
Warrants		4,194,236		117,976
Options		-		1,480
Convertible Notes		-		29,602
Total		4,194,236		149,058

Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed consolidated financial statements. 

XML

ORGANIZATION NATURE OF BUSINESS AND GOING CONCERN (Tables)

3 Months Ended

Mar. 31, 2023

ORGANIZATION NATURE OF BUSINESS AND GOING CONCERN

Schedule of Property and Equipment of usefull life

	Estimated Useful Life
Leasehold improvements and technical works	Lesser of lease term or 40 years
Vehicles	6 years
Machinery	20 years
Furniture, fixtures and equipment	5–10 years
Computers and software	3-5 years

Schedule of Assets Measured and Recognized at Fair Value on a Recurring Basis

	March 31, 2023						Total Carrying
	Level 1		Level 2		Level 3		Value
Marketable securities – Pancretan Bank	$	8,334		-		-	$	8,334
Marketable securities – National Bank of Greece		8,099		-		-		8,099
	$	16,433					$	16,433

	December 31, 2022						Total Carrying
	Level 1		Level 2		Level 3		Value
Marketable securities – Pancretan Bank	$	8,200		-		-	$	8,200
Marketable securities – National Bank of Greece		6,681		-		-		6,681
	$	14,881					$	14,881

Summary of potential common shares

	March 31, 2023		March 31, 2022
Warrants		4,194,236		117,976
Options		-		1,480
Convertible Notes		-		29,602
Total		4,194,236		149,058

XML

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2023

PROPERTY AND EQUIPMENT

Schedule of Property and Equipment

	March 31, 2023			December 31, 2022
Leasehold improvements	$	512,843		$	502,882
Vehicles		109,732			107,976
Furniture, fixtures and equipment		1,997,337			1,945,207
Computers and software		146,041			138,783
		2,765,953			2,694,848
Less: Accumulated depreciation and amortization		(944,116	)		(877,823	)
Total	$	1,821,837		$	1,817,025

XML

GOODWILL AND INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2023

GOODWILL AND INTANGIBLE ASSETS

Schedule of Goodwill and Intangible Assets

	March 31, 2023			December 31, 2022
License	$	652,853		$	643,204
Trade name / mark		36,997			36,997
Customer base		176,793			176,793
		866,642			856,994
Less: Accumulated amortization		(221,856	)		(199,777	)
Subtotal		644,787			657,217
Goodwill		49,697			49,697
Total	$	694,484		$	706,914

Schedule of amortization expense for intangible assets

Year	Amount
2023	$	71,056
2024		79,719
2025		74,868
2026		44,361
2027		44,361
Thereafter		330,422
Total amortization	$	644,787

XML

RELATED PARTY TRANSACTIONS (Tables)

3 Months Ended

Mar. 31, 2023

RELATED PARTY TRANSACTIONS

Schedule of Related Party Notes Payable activity

	March 31, 2023		December 31, 2022
Beginning balance	$	10,912	$	464,264
Payments		-		(472,920	)
Foreign currency translation		177		(19,568	)
Ending balance	$	11,089	$	10,912

Schedule of Related Party Loans Payable

	March 31, 2023		December 31, 2022
Beginning balance	$	12,821	$	1,293,472
Proceeds		-		3,635,756
Payments		-		(4,851,678	)
Foreign currency translation		208		(64,729	)
Ending balance	$	13,029	$	12,821

XML

LINES OF CREDIT (Tables)

3 Months Ended

Mar. 31, 2023

LINES OF CREDIT

Schedule of Lines of Credit

	March 31, 2023		December 31, 2022
National	$	2,383,647	$	3,103,605
Alpha		803,142		991,492
Pancreta		1,093,420		1,232,128
EGF		430,105		431,512
Ending balance	$	4,710,314	$	5,758,737

XML

CONVERTIBLE DEBT (Tables)

3 Months Ended

Mar. 31, 2023

CONVERTIBLE DEBT

Schedule of Convertible Debt Activity

	March 31, 2023			December 31, 2022
Beginning balance convertible notes	$	100,000		$	640,000
Payments		(100,000	)		(525,000	)
Conversion to common stock		-			(15,000	)
Convertible notes payable	$	-		$	100,000

Summary of Derivative Liabilities

	Amount
Balance on January 1, 2023	$	54,293
Reduction of derivative related to conversions		(50,909	)
Change in fair value of derivative liabilities		(3,384	)
Balance on March 31, 2023	$	-

	December 31,
	2022
Dividend yield		0	%
Expected volatility	87.9%-157.2
Risk free interest rate	1.46%-3.75
Contractual terms (in years)	1.25 - .75

XML

DEBT (Tables)

3 Months Ended

Mar. 31, 2023

DEBT

Summary of roll forward of the third party Debt

March 31, 2023	Trade Facility			Third Party			COVID Loans			Total
Beginning balance 12/31/22	$	3,305,532		$	1,505,078		$	207,377		$	5,017,987
Payments		(1,153,365	)		(86,561	)		(5,096	)		(1,245,022	)
Debt forgiveness		(306,637	)		-			-			(306,637	)
Foreign currency translation		29,890			11,409			1,879			43,178
Ending balance 3/31/23		1,875,420			1,429,926			204,160			3,509,506
Notes payable - long-term		(1,549,260	)		(1,002,288	)		(176,000	)		(2,727,548	)
Notes payable - short-term	$	326,160		$	427,638		$	28,160		$	781,958

Summary of Outstanding Debt

Our outstanding debt as of March 31, 2023, is repayable as follows:
	March 31,  2023
2023	$	802,622
2024		806,824
2025		1,613,928
2026		174,947
2027 and thereafter		111,185
Total debt		3,509,506
Less: notes payable–- current portion		(781,958	)
Notes payable–- long term portion	$	2,727,548

XML

LEASES (Tables)

3 Months Ended

Mar. 31, 2023

LEASES

Schedule of maturity of Operating Lease liability

Maturity of Operating Lease Liability:
2023	$	197,540
2024		264,035
2025		190,379
2026		153,712
Thereafter		581,964
Total undiscounted operating lease payments	$	1,387,630
Less: Imputed interest		(272,107	)
Present value of operating lease liabilities		1,115,523

Schedule of maturity of finance lease liability

Maturity of Finance Lease Liability
2023	$	112,406
2024		133,861
2025		103,586
2026		77,014
Thereafter		23,474
Total undiscounted finance lease payments	$	450,341
Less: Imputed interest		(47,400	)
Present value of finance lease liabilities	$	402,941

XML

WARRANTS (Tables)

3 Months Ended

Mar. 31, 2023

WARRANTS

Schedule of warrant Activity

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
Warrants	Shares		Price		Term		Value
Balance outstanding, January 1, 2023		4,194,236	$	8.31		5.04	$	2,562,600
Balance outstanding, March 31, 2023		4,194,236	$	8.31		4.80	$	913,209
Exercisable, March 31, 2023		4,194,236	$	8.31		4.80	$	913,209

XML

DISAGGREGATION OF REVENUE (Tables)

3 Months Ended

Mar. 31, 2023

DISAGGREGATION OF REVENUE

Schedule of Revenue Disaggregation

	March 31,		March 31,
Country	2023		2022
Greece		11,914,231		13,009,038
Cyprus		33,315
UK		402,231		51,426
Croatia		-		11,336
Total	$	12,349,777	$	13,071,800

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	3 Months Ended
	Mar. 31, 2023
Vehicles [Member]
Estimated Useful Life	6 years
Machinery [Member]
Estimated Useful Life	20 years
Furniture, fixtures and equipment [Member] | Minimum [Member]
Estimated Useful Life	5 years
Furniture, fixtures and equipment [Member] | Maximum [Member]
Estimated Useful Life	10 years
Computers and software [Member] | Minimum [Member]
Estimated Useful Life	3 years
Computers and software [Member] | Maximum [Member]
Estimated Useful Life	5 years
Leasehold improvements and technical works [Member]
Estimated useful life, description	Lesser of lease term or 40 years

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Fair value of assets and liabilities	$ 16,433	$ 14,881
Marketable securities - Pancretan Bank [Member]
Fair value of assets and liabilities	8,334	8,200
Marketable securities - National Bank of Greece [Member]
Fair value of assets and liabilities	8,099	6,681
Level 1 [Member]
Fair value of assets and liabilities	16,433	14,881
Level 1 [Member] | Marketable securities - Pancretan Bank [Member]
Fair value of assets and liabilities	8,334	8,200
Level 1 [Member] | Marketable securities - National Bank of Greece [Member]
Fair value of assets and liabilities	8,099	6,681
Level 2 [Member] | Marketable securities - Pancretan Bank [Member]
Fair value of assets and liabilities	0	0
Level 2 [Member] | Marketable securities - National Bank of Greece [Member]
Fair value of assets and liabilities	0	0
Level 3 [Member] | Marketable securities - Pancretan Bank [Member]
Fair value of assets and liabilities	0	0
Level 3 [Member] | Marketable securities - National Bank of Greece [Member]
Fair value of assets and liabilities	$ 0	$ 0

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Potential common shares	4,194,236	149,058
Warrant [Member]
Potential common shares	4,194,236	117,976
Options [Member]
Potential common shares		1,480
Convertible Notes [Member]
Potential common shares		29,602

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 17, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 19, 2018
Revenues		$ 12,349,777	$ 13,071,800
Net Income (Loss)		(459,863)	203,347
Net cash used in operations		(6,344,173)	(2,337,276)
Working capital		32,083,333
Accumulated deficit		(66,692,676)		$ (66,232,813)
Stockholder equity		44,007,783	5,151,001	39,284,295	$ 4,379,463
VAT net receivable and payable balance		243,424		79,373
Allowance for doubtful accounts		7,614,237		7,309,311
Cash on hand		6,995,287		0
Depreciation expense		65,629	84,884
Amortization expense		21,058	8,158
Goodwill		49,697		$ 49,697		$ 49,697
Deferred revenue		$ 112,515
Pharmaceuticals And Nutraceuticals Products License [Member]
Estimated useful life		5 years
Zip Doctor Inc [Member]
Payment in cash	$ 150,000
ICC International Cannabis Corp [Member]
Equity method investment aggregate cost		$ 0
Equity method investment shares acquired, shares		3,000,000
Closing price		$ 0
National Bank of Greece [Member]
Equity method investment aggregate cost		$ 8,099
Equity method investment shares acquired, shares		16,666
Closing price		$ 0.49
Pancreta Bank [Member]
Equity method investment aggregate cost		$ 8,333
Greece [Member]
Revenues		$ 11,914,231	$ 13,009,038
Income tax rate		22.00%
United Kingdom Of England [Member]
Income tax rate		19.00%

XML

EQUITY METHOD INVESTMENTS (Details Narrative)	3 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2023 CAD ($)	Mar. 31, 2023 EUR (€)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2019
Gain on extinguishment of debt	$ 1,908,513			$ 1,004,124
Cosmo Farmacy LP [Member]
Initial share capital | €			€ 150,000
Initial share capital increased | €			500,000
Pharmacy license value | €			€ 350,000
Maturity period of license	30 years	30 years	30 years
Ownership equity						70.00%
Cash contributed to limited partner | €			€ 150,000
Equity ownership remaining						30.00%
Marathon Global Inc [Member] | Distribution and Equity Acquisition Agreement [Member]
Upfront cash received		$ 2,000,000
Fair value of settlement account	$ 1,554,590
Gain on extinguishment of debt	$ 1,554,590
Agreement term	5 years	5 years	5 years
Cash received upon gross sales		$ 2,750,000
Marathon Global Inc [Member] | Distribution and Equity Acquisition Agreement [Member] | Gross Sales One [Member]
Cash received upon gross sales		2,750,000
Gross sales		13,000,000
Marathon Global Inc [Member] | Distribution and Equity Acquisition Agreement [Member] | Gross Sales [Member]
Gross sales		$ 6,500,000
Share Exchange Agreement [Member] | ICC [Member]
Investement	$ 163,080				$ 160,470

XML

PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Property plant and equipment	$ 2,765,953	$ 2,694,848
Less: Accumulated depreciation	(944,116)	(877,823)
Total	1,821,837	1,817,025
Computers and software [Member]
Property plant and equipment	146,041	138,783
Vehicles [Member]
Property plant and equipment	109,732	107,976
Leasehold Improvements [Member]
Property plant and equipment	512,843	502,882
Furniture, fixtures and equipment [Member]
Property plant and equipment	$ 1,997,337	$ 1,945,207

XML

GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022	Dec. 19, 2018
Goodwill and intangible assets, gross	$ 866,642	$ 856,994
Less: Accumulated Amortization	(221,856)	(199,777)
Subtotal	644,787	657,217
Goodwill	49,697	49,697	$ 49,697
Total	694,484	706,914
Customer Base [Member]
Goodwill and intangible assets, gross	176,793	176,793
Trade name / mark [Member]
Goodwill and intangible assets, gross	36,997	36,997
License [Member]
Goodwill and intangible assets, gross	$ 652,853	$ 643,204

XML

GOODWILL AND INTANGIBLE ASSETS (Details 1)	Mar. 31, 2023 USD ($)
GOODWILL AND INTANGIBLE ASSETS
2023	$ 71,056
2024	79,719
2025	74,868
2026	44,361
2027	44,361
Thereafter	330,422
Sum	$ 644,787

XML

LOAN RECEIVABLE (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 30, 2021	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Prepayments of loan	$ 4,849,221
Interest rate	5.50%
Principal payments		$ 93,831
Short-term receivable			$ 388,463	$ 377,038
Long term receivables			$ 3,754,587	$ 3,792,034
Loan receivables term	360 days
Decription of loan payment	the Company is to receive 120 equal payments over the term of the loan
Loans [Member]
Interest payments		$ 49,154

XML

INCOME TAXES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income tax expenses benefit	$ (27,298)	$ 65,667
Greece [Member]
Corporate tax rate	22.00%
United Kingdom [Member]
Corporate tax rate	19.00%

XML

CAPITAL STRUCTURE (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Jan. 24, 2023	Feb. 28, 2022	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Preferred stock, shares authorized			100,000,000	100,000,000
Common stock, share issued			10,620,470	10,605,412
Common stock, share outstanding			10,605,172	10,589,915
Extinguishment of debt			$ 306,637
Debt Conversion [Member]
Shares, Issued					9,520
Conversion of Debt					$ 1,190,000
Capital contribution			973,420
Increase in equity related to the conversion			1,190,000
Extinguishment of debt			$ 216,580
Fair values of extinguishment of debt			$ 102.25
Mezzanine Equity [Member]
Net carrying values of preferred equity			$ 5,452,300
Series A Preferred Stock [Member]
Preferred stock, shares authorized			6,000,000	6,000,000
Description of preferred stock convertible into common stock			Series A Preferred Stock was initially convertible into the Company’s common stock as determined by dividing the number of shares of Series A Preferred Stock to be converted by the lower of (i) $75.00 or (ii) 80% of the average volume weighted average price for the Company’s common stock for the five (5) trading days immediately following the effectiveness of the registration statement concerning the shares (the “Conversion Price”). On June 14, 2022, the Conversion Price was reset to $15.54 per share
Dividend rate, per year			8.00%
Deemed dividend			$ 372,414
Preferred stock, shares issued			0	0
Preferred stock, shares outstnading			0	0
Preferred Stock [Member]
Preferred stock, shares authorized			100,000,000
Preferred stock, shares issued			0	0
Preferred stock, shares outstnading			0	0
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized			6,000,000
Series A Convertible Preferred Stock [Member] | Private Placement [Member]
Sales of shares		6,000
Shares price, per share		$ 1,000
Warrants		80,000
Aggregate gross proceeds warrants		$ 6,000,000
Warrants, Description		The Warrants were initially exercisable to purchase shares of common stock at $82.50 per share, or 110% of the Series A Shares initial conversion price and will expire five and one-half years following the initial exercise date of the Warrants
Additional number of warrant		80,000
Dividends		$ 5,788,493
Warrants Black-Scholes option pricing model , Description		The warrants were valued using the Black-Scholes option pricing model with the following terms: a) exercise price of $82.50, b) common stock fair value of $85.50, c) volatility of 118%, d) discount rate of 1.71%, e) term of 5.50 years and f) dividend rate of 0%.
Treasury Stock [Member]
Number of share held			15,497	15,497
Price of held common share			$ 816,707	$ 816,707
Common stock authorized to purchase	$ 3,000,000
Convertible stock				6,000
Conversion of stock in to common stock				386,588
Conversion of stock value				$ 5,452,300
Issuance of common stock [Member]
Common stock, share issued			15,258
Exercise of Warrants [Member]
Issue shares of common stock			33,179
Cashless exercise warrants			109,952

XML

RELATED PARTY TRANSACTIONS (Details) - Notes Payable - Related Party [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Beginning Balance	$ 10,912	$ 464,264
Payments	0	(472,920)
Foreign currency translation	177	(19,568)
Ending Balance	$ 11,089	$ 10,912

XML

RELATED PARTY TRANSACTIONS (Details 1) - Loans Payable - Related Party [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Beginning Balance	$ 12,821	$ 1,293,472
Proceeds	0	3,635,756
Payments	0	(4,851,678)
Foreign currency translation	208	(64,729)
Ending Balance	$ 13,029	$ 12,821

XML

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended
	Mar. 31, 2023	Feb. 28, 2023	May 17, 2022	Dec. 20, 2018	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Jan. 01, 2022
Interest income					$ 183,416	$ 64,827
Outstanding principal balance	$ 781,958				781,958
Accrued interest	53,445				53,445		$ 275,547
Accounts payable balance	787,251				787,251		205,360
Accounts receivable balance	22,561,797				22,561,797		22,761,990
Revenue					12,349,777	13,071,800
Grigorios Siokas [Member]
Borrowing				$ 1,718,400
Outstanding principal balance	13,029				13,029		12,821
Foreign curreny translation					208
Accrued interest	24,887				24,887		206,355
Interest rate				4.70%
Maturity date				Mar. 18, 2019
Dimitrios Goulielmos [Member]
Outstanding principal balance	11,089				11,089		10,912
Loss	177
Panagiotis Kozaris [Member]
Shares owned					51,159	0
Prepaid expenses	194,215				194,215		143,056
DOC Pharma S.A. [Member]
Interest income					59,796
Prepaid expenses					$ 7,599,545
Interest rate					5.50%
Accounts payable balance	8,882				$ 8,882		201,991
Accounts receivable balance	1,886,890				1,886,890		2,070,570
Prepaid balance	4,940,863				4,940,863		3,320,345	$ 4,279,200
Revenue					$ 627	383,688
Agreement term					5 years
Pieces per product					1,000 pieces
Loan current portion	446,187				$ 446,187		427,720
Loan non-current portion	3,902,613				3,902,613		3,851,280
Inventroy purchase	450,911				450,911		687,382
Description of research and development			Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought in total as of December 31, 2022, 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]
Inventroy purchase	401,786				401,786		517,566
Maria Kozari [Member]
Accounts receivable balance	$ 867,866				867,866		$ 760,025
Net sales					$ 118,987	$ 113,621
Cana Holdings Laboratories Holding Limited [Member]
Secured promissory note		$ 4,457,520
Description related to interest on principal		Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus 1 month LIBOR per annum (4.77% as of March 31, 2023)
Maturity of promissory note		5 years
Interest income		$ 36,497

XML

LINES OF CREDIT (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Subtotal	$ 4,710,314	$ 5,758,737
National [Member]
Subtotal	2,383,647	3,103,605
Alpha [Member]
Subtotal	803,142	991,492
Pancreta [Member]
Subtotal	1,093,420	1,232,128
EGF [Member]
Subtotal	$ 430,105	$ 431,512

XML

LINES OF CREDIT (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Interest Expense	$ 134,373	$ 584,176
Line of Credit [Member]
Interest Expense	19,435	$ 17,175
Line of Credit [Member] | National Bank of Greece Two [Member]
Borrowing	1,087,200		$ 1,069,800
Outstanding debt balance	911,739		984,653
Line of Credit [Member] | Alpha Bank of Greece [Member]
Borrowing	1,087,200		1,069,800
Outstanding debt balance	$ 803,142		991,429
Current interest rate	6.00%
Line of Credit [Member] | Pancreta Bank of Greece [Member]
Borrowing	$ 1,511,208		1,487,022
Outstanding debt balance	$ 1,093,420		1,232,128
Current interest rate	6.10%
National Bank of Greece One [Member] | Line of Credit [Member]
Borrowing	$ 3,234,420		3,182,655
Outstanding debt balance	1,471,908		2,118,952
EGF [Member] | Line of Credit [Member]
Borrowing	434,880		427,920
Outstanding debt balance	$ 430,105		$ 431,512
Current interest rate	4.49%
National Bank of Greece [Member] | Line of Credit [Member]
Current interest rate	4.35%
National Bank of Greece [Member] | Line of Credit [Member] | Cosme [Member]
Current interest rate	4.35%
National Bank of Greece [Member] | Line of Credit [Member] | CosmeOne [Member]
Current interest rate	6.00%

XML

CONVERTIBLE DEBT (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
CONVERTIBLE DEBT
Beginning balance convertible notes	$ 100,000	$ 640,000
Payments	(100,000)	(525,000)
Conversion to common stock	0	(15,000)
Convertible notes payable	$ 0	$ 100,000

XML

CONVERTIBLE DEBT (Details 1)	3 Months Ended
	Mar. 31, 2023 USD ($)
CONVERTIBLE DEBT
Beginning balance	$ 54,293
Reduction of derivative related to conversions	(50,909)
Change in fair value of derivative liabilities	(3,384)
Ending balance	$ 0

XML

CONVERTIBLE DEBT (Details 2)	12 Months Ended
	Dec. 31, 2022
Dividend yield	0.00%
Minimum [Member]
Expected volatility	87.90%
Risk free interest rate	1.46%
Contractual terms (in years)	1 month 7 days
Maximum [Member]
Expected volatility	157.20%
Risk free interest rate	3.75%
Contractual terms (in years)	22 days

XML

CONVERTIBLE DEBT (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	Jan. 31, 2022	Dec. 21, 2020	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	May 01, 2022	Sep. 17, 2021	Jan. 07, 2021
Gain on extinguishment of debt			$ 1,908,513	$ 1,004,124
Convertible notes payable, principal amount			0		$ 100,000
Amortization of debt discount			0	260,527
Derivative liability			$ 0		$ 54,293
Shares issued			10,620,470		10,605,412
Accrued Interest expense			$ 13,740
Securities Purchase Agreement [Member]
Gain on extinguishment of debt			50,909
Convertible notes payable, principal amount			525,000
Gain on change in fair value of derivative liability			3,384	13,128
Accrued interest						$ 26,515
Derivative liability						$ 11,629
Shares issued						1,574
Shares issued at a fair value						$ 38,144
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member]
Amortization of debt discount			62,619
Derivative liability			$ 0		$ 54,293
Additional paid in capital	$ 294,000
Decrease to accumulated deficit	$ 53,248
Debt original issue discount		$ 40,000			25,000		$ 25,000
Financing cost		$ 3,000
Interest rate		8.00%	10.00%
Default interest rate		18.00%						8.00%
Purchase price principal amount								$ 100,000
Note issued		$ 540,000
Cash proceeds from conversion			$ 500,000
Conversion discount to price			30.00%
Note issued upon exchange for cash		500,000
Securities Purchase Agreement [Member] | Institutional investors [Member] | Senior Convertible Note 1 [Member]
Amortization of debt discount			$ 0	127,916
Derivative liability			0		$ 0
Debt discount		456,570
Transaction expenses		43,000
Amortized cost		$ 499,570
Loss on the change in fair value of the derivative			$ 0	$ 1,873

XML

DEBT (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Notes payable - long-term	$ (2,727,548)		$ (2,859,570)
Notes payable- short -term	781,958
Beginning balance loans	5,017,987
Payments	(1,245,022)
Endining balance loan	3,509,506
Debt forgiveness	(306,637)
Foreign currency translation	196,035	$ (159,352)
Foreign currency translation	43,178
Notes payable - short-term	781,958		$ 2,158,417
Third Party [Member]
Notes payable - long-term	(1,002,288)
Beginning balance loans	1,505,078
Payments	(86,561)
Endining balance loan	1,429,926
Debt forgiveness	0
Foreign currency translation	11,409
Notes payable - short-term	427,638
Trade Facility [Member]
Notes payable - long-term	(1,549,260)
Notes payable- short -term	326,160
Beginning balance loans	3,305,532
Payments	(1,153,365)
Endining balance loan	1,875,420
Debt forgiveness	(306,637)
Foreign currency translation	29,890
COVID Loans
Notes payable - long-term	(176,000)
Beginning balance loans	207,377
Payments	(5,096)
Endining balance loan	204,160
Debt forgiveness	0
Foreign currency translation	1,879
Notes payable - short-term	$ 28,160

XML

DEBT (Details 1)	Mar. 31, 2023 USD ($)
DEBT
2023	$ 802,622
2024	806,824
2025	1,613,928
2026	174,947
2027 and thereafter	111,185
Total Debt	3,509,506
Less: notes payable - current portion	(781,958)
Notes payable - long term portion	$ 2,727,548

XML

DEBT (Details Narrative) - USD ($)			1 Months Ended							3 Months Ended		12 Months Ended
	Mar. 03, 2022	May 12, 2020	Dec. 21, 2022	Feb. 23, 2022	Jul. 30, 2021	Nov. 19, 2020	Jun. 24, 2020	Jun. 23, 2020	Nov. 16, 2015	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Aug. 29, 2022	Dec. 31, 2021	Aug. 04, 2021	Dec. 30, 2020	Oct. 17, 2018
Gain on extinguishment of debt										$ 306,637
Note payable long term										2,727,548		$ 2,859,570
Cash interest expense										$ 134,373	$ 584,176
Interest rate description			one-month Euribor (2.49% as of March 31, 2023)							one-month Euribor (2.49% as of March 31, 2023), and 6% plus one-month LIBOR (4.77% as of date of March 31, 2023), respectively
Non cash interest expenses										$ 23,820		6,642
Repayment of installment										$ 500,000
Repayments of debt												187,215
Capitalized fees	$ 221,060
Debt instruments final payament												2,593,363
Debt prinicipal balance under agrreement												1,406,637
Loan principal balance												$ 1,898,895
Debt outstanding amount	$ 3,950,000				$ 578,850
Shares issued										10,620,470		10,605,412
Final repayment										1,956,960
June 23, 2020 [Member] | National Bank of Greece SA [Member]
Repayments of debt										$ 31,976
Debt amount received from related party								$ 611,500
Debt outstanding amount										319,765		$ 346,112
Notes payable long term										$ 191,859		220,253
Maturity date								60 months
August 29, 2022 [Member] | Promissory Notes [Member]
Agreement description										the Company entered into a promissory note for the principal amount of $166,667. The Company received $150,000 in cash and recorded $16,667 as an original issue discount upon issuance. The promissory note matures on the earlier of (a) December 27, 2022, or (b) the date the Company completes a debt or equity financing of at least $1,000,000
Accured interest												5,041
Interest rate													12.00%
Debt Exchange Agreement [Member]
Repayments of debt										$ 30,200		118,867
Agreement description						bears an annual interest rate, based on a 360-day year, of 3.3% plus .6% plus 6-month Euribor when Euribor is positive. The principal is to be repaid in 18 quarterly installments of €27,778 ($30,210).
Debt outstanding amount						$ 611,500
Accrued expenses										18,527		12,853
Accrued interest										2,735		8,069
Notes payable long term										211,400		237,733
Shares issued															12,852
Gain on settlement of debt upon shares issuance															$ 292,383
Common stock shares issuable upon listing on nasdaq															9,520
Settlement of debt, shares issuable upon listing on nasdaq															$ 1,190,000
Settlement of debt															$ 1,606,500
Gain from extinguishment of debt										216,580
Principal amount of existing loan										$ 332,200		356,600
Upon issuance of common stock										9,520
Maturity of note						Nov. 18, 2025
July 30, 2021 Debt Agreement [Member]
Repayments of debt										$ 28,758		83,428
Agreement description					The note matures on August 5, 2026 and bears an annual interest rate that applies to 60% of the principal of the note that is based on a 365-day year, of 5.84% plus 3-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a nine-month grace period
Debt outstanding amount										430,057		451,472
Accured interest										4,947		2,728
Notes payable long term										$ 312,520		336,788
June 9, 2022 Debt Agreement One [Member]
Agreement description										Company entered into an agreement with a third-party lender in the principal amount of €320,000 ($335,008), the “Note”. The Note matures on June 16, 2027 and bears an annual interest rate of 3.89% plus an additional rate of 0.60%, plus the 3-month Euribor (2.78% as of March 31, 2023). Pursuant to the agreement, there is a twelve-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 17 equal quarterly installments of €18,824 commencing on June 30, 2023
Debt outstanding amount										$ 347,904		286,509		$ 4,000,000
Accured interest										3,840		8,379
Notes payable long term												281,924
Synthesis Facility Agreement [Member] | TFF [Member]
Debt outstanding amount																	$ 5,629,555
Accrued expenses																	$ 524,094
Synthesis Facility Agreement [Member] | TFF [Member] | Principal balance 2 [Member]
Stated interest rate																	6.00%
Debt split, balance																	$ 4,000,000
Synthesis Facility Agreement [Member] | TFF [Member] | Principal Balance One [Member]
Debt instrument, accrue interest rate																5.50%
Debt intrument split, principal balance																	$ 231,600
Loan Agreement [Member] | Panagiotis Drakopoulos [Member]
Debt outstanding amount										0		8,558
Accrued expenses												7,271
Short term debt borrowing capacity									$ 42,832
Interest rate									6.00%
Full and Final Settlement Agreement [Member]
Payment of loan			$ 1,100,000
Gain on extinguishment of debt			306,637
Repayment of loan			54,360
Outstanding principal loan balance			1,875,420
Note payable long term			1,549,260
Accrued interest expenses										14,380
Senior Promissory Notes [Member]
Gain on extinguishment of debt				$ 787,544
Aggregate amount of senior promissory notes				9,000,000								$ 7,000,000
Fee payment				506,087
New debt amount fair value				$ 7,706,369
Cash interest expense										89,275
Covid Ninteen [Member]
Loan received from related party		$ 366,900
Debt outstanding amount			150,441							147,791
Debt principal balance										5,096
Covid Ninteen [Member] | United Kingdom Government [Member]
Loan received							$ 68,310
Interest rate							2.50%
Loan prinipal amount			$ 56,936							$ 56,369

XML

LEASES (Details) - Operating Lease [Member]	Mar. 31, 2023 USD ($)
2023	$ 197,540
2024	264,035
2025	190,379
2026	153,712
Thereafter	581,964
Total undiscounted operating lease payments	1,387,630
Less: Imputed interest	(272,107)
Present value of operating lease liabilities	$ 1,115,523

XML

LEASES (Details 1) - Finance Lease [Member]	Mar. 31, 2023 USD ($)
2023	$ 112,406
2024	133,861
2025	103,586
2026	77,014
Thereafter	23,474
Total undiscounted finance lease payments	450,341
Less: Imputed interest	(47,400)
Present value of finance lease liabilities	$ 402,941

XML

LEASES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
LEASES
Operating lease, term of agreements	The Company has various operating and finance lease agreements with terms up to 10 years
Operating lease expense	$ 55,354	$ 54,124
Operating lease weighted-average remaining lease term	5 years 2 months 23 days
Operating lease, weighted average discount rate	6.74%
Finance lease, weighted average remaining lease term	3 years 4 months 2 days
Finance lease, weighted average discount rate	6.74%
Finance lease, interest expense	$ 6,219	3,507
Finance lease, amortization expense	30,710	19,580
Finance lease total cash used	$ 35,596	$ 22,622

XML

COMMITMENTS AND CONTINGENCIES (Details Narrative)	1 Months Ended
	Jun. 26, 2022	Jul. 31, 2021
COMMITMENTS AND CONTINGENCIES
Description of research and development agreement	The cost of the projects amount to EUR 820,000 ($891,504) which is allocated to certain phases. The amount will be due and payable upon completion of the corresponding phases. The Company records the corresponding R&D expense based on the project’s progress, which is actually invoiced by the third party in the relevant period. No such costs were incurred for the 3-month period ended March 31, 2023 or 2022
Description for advisory agreement		the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023

XML

WARRANTS (Details) - Warrants [Member]	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Number of Shares Outstanding, Beginning	$ 4,194,236
Number of Shares Outstanding, Ending	$ 4,194,236
Number of Shares Exercisable | shares	4,194,236
Weighted Average Exercise Price Outstanding, Beginning | $ / shares	$ 8.31
Weighted Average Exercise Price Outstanding, Ending | $ / shares	8.31
Weighted Average Exercise Price Exercisable | $ / shares	$ 8.31
Weighted Average Remaining Contractual Term Outstanding, Beginning	5 years 14 days
Weighted Average Remaining Contractual Term Outstanding, Ending	4 years 9 months 18 days
Weighted Average Remaining Contractual Term Exercisable	4 years 9 months 18 days
Aggregate Intrinsic Value Outstanding, Beginning	$ 2,562,600
Aggregate Intrinsic Value Outstanding, Ending Balance	913,209
Aggregate Intrinsic Value Exercisable	$ 913,209

XML

WARRANTS (Details Narrative) - Warrants [Member]	3 Months Ended
	Mar. 31, 2023 shares
Number of Shares Exercisable	4,194,236
Number of Shares Outstanding, Beginning	4,194,236
Expired dates description	exercisable with 4,180,902 warrants having expiration dates from May 2023 through December 2027 and 13,334 warrants with no expiration date

XML

DISAGGREGATION OF REVENUE (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue	$ 12,349,777	$ 13,071,800
Greece [Member]
Revenue	11,914,231	13,009,038
Cyprus [Member]
Revenue	33,315
UK [Member]
Revenue	402,231	51,426
Croatia [Member]
Revenue	$ 0	$ 11,336

XML

SUBSEQUENT EVENTS (Details Narrative)				1 Months Ended
	May 08, 2023	May 03, 2023 USD ($) ft² $ / shares shares	Apr. 03, 2023 USD ($)	Feb. 28, 2023 USD ($)
Decription of conclusion of stock purchase agreement				(i) the satisfactory completion of due diligence; (ii) delivery of auditors’ financial statements of Cana Holdings as of December 31, 2022; (iii) receipt by the Company of all required approvals, covenants and waivers; (iv) indebtedness of Cana Holdings shall not exceed €1,000,000 ($1,087,200) (exclusive of the Note); (v) payment of the Purchase Price and delivery of the Shares; (vi) no material adverse changes in the business of Cana Holdings; and (vii) customary closing conditions
Principle amount of secured promissory note				$ 4,497,017
Subsequent Events [Member]
RSU purchase price		$ 1,669,760
Purchase price of shares		$ 869,760
Restricted common stock shares | shares		46,377
RSU price per share | $ / shares		$ 17.25
Restricted common stock value		$ 800,000
Payment for acquiring telepath company			$ 150,000
Area of building | ft? | ft²		29,063
Payment for acquire CosmoFarm Pharmaceuticals		$ 1,068,000
Ownership Percentage	100.00%